Negative-pressure wound therapy versus standard dressings for adults with an open lower limb fracture : the WOLLF RCT by Costa, Matthew L. et al.
HEALTH TECHNOLOGY ASSESSMENT
VOLUME 22 ISSUE 73 DEcEMbEr 2018
ISSN 1366-5278
DOI 10.3310/hta22730
Negative-pressure wound therapy versus standard 
dressings for adults with an open lower limb fracture: 
the WOLLF RCT
Matthew L Costa, Juul Achten, Julie Bruce, Sonia Davis, Susie Hennings, 
Keith Willett, Stavros Petrou, Steven Jeffery, Damian Griffin, Ben Parker, 
James Masters, Sarah E Lamb, Elizabeth Tutton and Nick Parsons

Negative-pressure wound therapy versus
standard dressings for adults with an
open lower limb fracture: the WOLLF RCT
Matthew L Costa,1,2,3* Juul Achten,1,3 Julie Bruce,1
Sonia Davis,1 Susie Hennings,1 Keith Willett,3
Stavros Petrou,1 Steven Jeffery,4 Damian Griffin,1,2
Ben Parker,1 James Masters,3 Sarah E Lamb,1,3
Elizabeth Tutton3 and Nick Parsons1
1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
2University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
3Oxford Trauma, Nuffield Department of Orthopaedics, Rheumatology and
Musculoskeletal Sciences, University of Oxford, Oxford, UK
4Selly Oak Hospital, Birmingham, UK
*Corresponding author
Declared competing interests of authors: Matthew L Costa is a member of the general board for the
Health Technology Funding stream. Keith Willett received royalty payments from Zimmer for implant
design outside the submitted work. Sarah E Lamb is a member of the Health Technology Assessment
(HTA) Additional Capacity Funding Board, HTA End of Life Care and Add-on Studies, HTA Prioritisation
Group and HTA Trauma Board.
Disclaimer: This report contains transcripts of interviews conducted in the course of the research and
contains language that may offend some readers.
Published December 2018
DOI: 10.3310/hta22730
This report should be referenced as follows:
Costa ML, Achten J, Bruce J, Davis S, Hennings S, Willett K, et al. Negative-pressure wound
therapy versus standard dressings for adults with an open lower limb fracture: the WOLLF RCT.
Health Technol Assess 2018;22(73).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta
Medica/EMBASE, Science Citation Index Expanded (SciSearch®) and Current Contents®/
Clinical Medicine.

Health Technology Assessment HTA/HTA TAR
ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.513
Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science
Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the
report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they
are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods
(to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research
information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS.
‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation
and long-term care.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute
for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC)
policy decisions.
For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 10/57/20. The contractual start date
was in April 2012. The draft report began editorial review in April 2017 and was accepted for publication in July 2017. The authors have been
wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried
to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document.
However, they do not accept liability for damages or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by
authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme
or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed
by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC,
the HTA programme or the Department of Health and Social Care.
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning
contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of
private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable
acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies
Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
NIHR Journals Library Editors
Professor Ken Stein  Chair of HTA and EME Editorial Board and Professor of Public Health, 
University of Exeter Medical School, UK
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals)
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management 
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont  Scientific Advisor, NETSCC, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, 
University of York, UK 
Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK
Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK
Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK
Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences,  
University of Nottingham, UK
Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact: journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Negative-pressure wound therapy versus standard dressings
for adults with an open lower limb fracture: the WOLLF RCT
Matthew L Costa,1,2,3* Juul Achten,1,3 Julie Bruce,1 Sonia Davis,1
Susie Hennings,1 Keith Willett,3 Stavros Petrou,1 Steven Jeffery,4
Damian Griffin,1,2 Ben Parker,1 James Masters,3 Sarah E Lamb,1,3
Elizabeth Tutton3 and Nick Parsons1
1Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
2University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
3Oxford Trauma, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford, Oxford, UK
4Selly Oak Hospital, Birmingham, UK
*Corresponding author Matthew.Costa@ndorms.ox.ac.uk
Background: Open fractures of the lower limb occur when a broken bone penetrates the skin and is
exposed to the outside environment. These are life-changing injuries. The risk of deep infection may be as
high as 27%. The type of dressing applied after surgical debridement could potentially reduce the risk of
infection in the open-fracture wound.
Objectives: To assess the disability, rate of deep infection, quality of life and resource use in patients with
severe open fracture of the lower limb treated with negative-pressure wound therapy (NPWT) versus
standard wound management after the first surgical debridement of the wound.
Design: A pragmatic, multicentre randomised controlled trial.
Setting: Twenty-four specialist trauma hospitals in the UK Major Trauma Network.
Participants: A total of 460 patients aged ≥ 16 years with a severe open fracture of the lower limb were
recruited from July 2012 through to December 2015. Patients were excluded if they presented more than
72 hours after their injury or were unable to complete questionnaires.
Interventions: Negative-pressure wound therapy (n = 226) where an ‘open-cell’ solid foam or gauze was
placed over the surface of the wound and connected to a suction pump which created a partial vacuum
over the dressing versus standard dressings not involving negative pressure (n = 234).
Main outcome measures: Disability Rating Index (DRI) – a score of 0 (no disability) to 100 (completely
disabled) at 12 months was the primary outcome measure, with a minimal clinically important difference
of 8 points. The secondary outcomes were deep infection, quality of life and resource use collected at 3,
6, 9 and 12 months post randomisaton.
Results: There was no evidence of a difference in the patients’ DRI at 12 months. The mean DRI in the
NPWT group was 45.5 points [standard deviation (SD) 28.0 points] versus 42.4 points (SD 24.2 points) in the
standard dressing group, giving a difference of –3.9 points (95% confidence interval –8.9 to 1.2 points) in
favour of standard dressings (p = 0.132). There was no difference in HRQoL and no difference in the number
of surgical site infections or other complications at any point in the 12 months after surgery. NPWT did not
reduce the cost of treatment and it was associated with a low probability of cost-effectiveness.
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Limitations: Owing to the emergency nature of the interventions, we anticipated that some patients
who were randomised into the trial would subsequently be unable or unwilling to take part. Such
post-randomisation withdrawal of patients could have posed a risk to the external validity of the trial.
However, the great majority of these patients (85%) were found to be ineligible after randomisation.
Therefore, we can be confident that the patients who took part were representative of the population
with severe open fractures of the lower limb.
Conclusions: Contrary to the existing literature and current clinical guidelines, NPWT dressings do not
provide a clinical or an economic benefit for patients with an open fracture of the lower limb.
Future work: Future work should investigate alternative strategies to reduce the incidence of infection
and improve outcomes for patients with an open fracture of the lower limb. Two specific areas of
potentially great benefit are (1) the use of topical antibiotic preparations in the open-fracture wound and
(2) the role of orthopaedic implants with antimicrobial coatings when fixing the associated fracture.
Trial registration: Current Controlled Trials ISRCTN33756652 and UKCRN Portfolio ID 11783.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 73.
See the NIHR Journals Library website for further project information.
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Plain English summary
An ‘open fracture’ occurs when a broken bone is exposed to the outside world through a breach inthe skin. Open fractures often happen after high-energy trauma such as car crashes, but can also be
caused by sports injuries and even simple falls. In an open fracture, the broken bone is at increased risk of
infection due to contamination. Infection rates as high has 27% have been reported.
One factor that may affect the risk of infection is the type of dressing applied after the surgery. In this trial,
we compared standard wound dressings with a new treatment called negative-pressure wound therapy
(NPWT). NPWT is a special type of dressing whereby gentle suction is applied to the surface of the wound.
This removes excess fluid and may reduce the risk of contamination.
A total of 460 patients, from 24 specialist trauma hospitals in England, agreed to take part and were
assigned at random to receive either a standard wound dressing or NPWT after surgery. We then reviewed
the recovery of the patients for 1 year after their injury. We asked the patients to rate the disability they
suffered. We also collected information about the patients’ quality of life (QoL), details of any wound
infections and the cost of their treatment.
What did the trial find?
There was no evidence of a difference in the Disability Rating Index between those patients treated with
NPWT and those treated with standard wound dressings. There was no difference in the rate of wound
complications, including infections, nor any difference in health-related QoL during the first year. NPWT did
not reduce the cost of treatment.
In conclusion, contrary to previous reports and current surgical guidelines, NPWT does not provide a clinical
nor economic benefit for patients with an open fracture of the leg.
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Scientific summary
Background
Fractures of the lower limb are common injuries in civilian and military populations. Most fractures are
‘closed’, that is, the skin overlying the fracture is intact. However, if the fracture is ‘open’ then the broken
bone is exposed to contamination and the risk of infection is greatly increased. In severe, high-energy open
fractures of the lower limb, infection rates of 27% are still reported, even in specialist trauma centres. The
initial management of open fractures involves the surgical removal of damaged tissue and contamination
(debridement) under anaesthetic and the administration of antibiotics. The fracture is usually immobilised
with some form of internal or external fixation and a dressing is applied to the surface of the wound.
Traditionally, a sealed, non-adhesive layer is applied to the exposed area to protect the open fracture from
further contamination. The wound is covered in this way until a reassessment and further debridement are
performed in the operating theatre 48–72 hours later. This method has been used throughout the NHS
and in military practice for many years.
Negative-pressure wound therapy (NPWT) is an alternative form of dressing which may be applied to
open-fracture wounds. This device creates a vacuum that removes blood and exudate that may collect
in the wound and pose an infection risk. The vacuum may also remove bacteria from the wound and
encourage the formation of ‘granulation’ (healing) tissue. However, NPWT dressings and the vacuum
machines are considerably more expensive than traditional wound dressings.
Previous trials of NPWT have shown encouraging results, suggesting lower infection rates in other patient
populations. However, before this trial, there was only one randomised controlled trial (RCT) comparing
standard wound dressing with NPWT for patients with open fractures of the lower limb (Stannard JP,
Volgas DA, Stewart R, McGwin G Jr, Alonso JE. Negative pressure wound therapy after severe open
fractures: a prospective randomized study. J Orthop Trauma 2009;23:552–7). That trial demonstrated a
lower rate of infection in patients treated with NPWT but included only 59 patients at a single trauma
centre. Despite the lack of strong evidence, clinical guidelines around the world rapidly incorporated the
use of NPWT for open-fracture wounds.
The aim of this pragmatic, multicentre RCT was to compare standard wound dressings with NPWT for
adults with an open fracture of the lower limb.
Methods
Study design
The study was conducted in two phases. Phase I assessed the feasibility of running a large-scale
multicentre RCT in the challenging environment of trauma care. The feasibility study was undertaken in
five trauma centres in England over a 6-month period. Qualitative interviews were conducted with
20 patients, while two multidisciplinary focus groups were held with staff to inform recruitment and
consent procedures. Phase II consisted of the main RCT, in which participants were recruited from
24 specialist trauma hospitals in the UK Major Trauma Network.
Patients
Eligible patients were aged ≥ 16 years and had an open fracture of the lower limb assessed as Gustilo
and Anderson (G&A) grade 2 or 3. Patients had to present to the trial hospital within 72 hours of their
injury, including those who were transferred from other hospitals. Patients were excluded if they had
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contraindications to anaesthesia or were unable to adhere to trial procedures or complete questionnaires,
for example patients with permanent cognitive impairment.
Interventions
Usual-care group
Usual care for open fractures is a standard dressing comprising a non-adhesive layer applied directly to the
wound covered by a sealed dressing or bandage. The standard dressing did not use ‘negative pressure’.
The exact details of the materials used were left to the discretion of the treating surgeon as per routine
care. Details of each dressing applied in the trial were recorded and classified according to British National
Formulary classification.
Intervention group: negative-pressure wound therapy
The NPWT dressing used an ‘open-cell’ solid foam or gauze which was laid onto the wound followed by
an adherent, sealed dressing. A sealed tube was connected from the dressing to a pump which created a
partial vacuum over the wound. The basic features of the NPWT are universal, but the exact details of the
dressing and pressure (mmHg) were left to the discretion of the treating health-care team. Details of
dressings used were recorded in trial documentation.
Outcomes
The primary outcome was the Disability Rating Index (DRI) score, a validated scale which assessed patients’
rating of their own disability in the 12 months after randomisation. The DRI provides a 100-point score,
where 0 represents normal function and 100 represents complete disability.
The secondary outcomes were health-related quality of life (HRQoL), deep surgical site infection (SSI),
other postoperative complications and resource use. Infection outcomes and complications were assessed
by independent research staff. A photographic assessment of wound healing was made at 6 weeks.
Radiographic images were collected at 6 weeks and 12 months. Patient-reported outcomes (DRI;
EuroQol-5 Dimensions, three-level version; and Short Form questionnaire-12 items), self-reported
complications and health-care resource use were collected by questionnaire at baseline, 3, 6, 9 and
12 months after randomisation.
Care pathway
In the UK Major Trauma Network, most patients with an open fracture of the lower limb are transported
directly to a specialist trauma hospital (a major trauma centre or a trauma unit with orthoplastic surgeons
on site) for definitive care. Patients presenting to a non-specialist hospital are usually transferred within
72 hours of their injury. Usual care for patients admitted with an open fracture of the lower limb involves
surgery on the next available trauma operating list. All patients received a general or regional anaesthetic.
The wound associated with the fracture was ‘debrided’ (surgical removal of damaged tissue and
contamination) in the operating theatre and the fracture treated with either internal or external fixation.
At the end of the initial operation, if the wound could not be closed primarily (direct suture of the wound
edges), patients were randomised and allocated to either standard dressing or NPWT.
After treatment allocation, both groups of patients then followed the normal postoperative management
pathway for patients with an open fracture of the lower limb. This usually involved a second operation
at 48–72 hours, at which time a further wound assessment and debridement were performed and the
wound closed either primarily or by soft-tissue reconstruction as necessary. In some cases, it is not safe
to perform definitive closure of the wound within 72 hours. For example, some patients with a serious
head injury in association with their open fracture of the lower limb cannot tolerate a long anaesthetic
and surgical procedure such as a ‘free-flap’ reconstruction. If the wound could not be closed definitively,
a further dressing was applied to the open-fracture wound after the second debridement. Any further
wound dressing followed the allocated treatment until definitive closure/cover of the wound was achieved.
SCIENTIFIC SUMMARY
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Randomisation and allocation sequence generation
Randomisation was based on a computer-generated randomisation algorithm held and controlled by York
Clinical Trials Unit. The unit of randomisation was the individual patient on a 1 : 1 basis and then stratified
by trial centre and G&A grade. When a patient entered the trial, non-identifiable details were logged on
the secure, encrypted, web-based system. Information included patient initials, date of birth, gender and
eligibility checks.
Participants were assigned to their treatment allocation intraoperatively at the end of initial surgery, but
before any wound dressing was applied.
Blinding
It was not possible to blind trial participants to treatment allocation as wound dressings were clearly
visible. In addition, the treating surgeons could not be blind to the intervention, but the surgical and
health-care team were not involved in trial assessments. Patient-reported outcomes were collected by
postal questionnaire and returned directly to the central trial office (Warwick Clinical Trials Unit). Wound
photographs were taken by research staff at the 6-week follow-up clinic. Wound images were reviewed
independently by two experienced assessors blind to treatment allocation.
Statistical analysis
The main analysis investigated differences in the primary outcome measure, the DRI score at 1 year after
injury, between the two treatment groups (standard wound dressings and NPWT) on an intention-to-treat
(ITT) basis. Early and mid-term status was assessed and reported at 3, 6 and 9 months.
Health economic analysis
An economic evaluation was conducted from the recommended NHS and Personal Social Services
perspective. An incremental cost-effectiveness analysis was performed, expressed in terms of incremental
cost per quality-adjusted life-years (QALYs) gained. A bivariate regression of costs and QALYs, with
multiple imputation of missing data, was conducted with the view to estimating the incremental cost per
QALY gained associated with NPWT dressings. Sensitivity analyses were undertaken to assess the impact of
uncertainty surrounding aspects of the economic evaluation, while prespecified subgroup analyses were
conducted to explore the effects of heterogeneity in the trial population.
Results
Patients
A total of 625 patients were randomised into the trial between July 2012 and December 2015. Of these,
460 patients were willing and able to provide informed consent.
Primary outcome
There was no evidence of a difference in the DRI at 12 months between those patients treated with NPWT
and those treated with standard wound dressings. The mean DRI in the NPWT group was 45.5 points
[standard deviation (SD) 28.0 points] versus 42.4 points (SD 24.2 points) in the standard dressing group,
giving a difference of –3.9 points [95% confidence interval (CI) –8.9 to 1.2 points] in favour of standard
dressings (p = 0.132). As the minimal clinically important difference for the DRI is 8 points, we conclude
that it is extremely unlikely that NPWT dressings confer a clinically important difference in DRI scores for
patients with an open fracture of the lower limb. Similarly, there was no evidence of a difference in DRI
score at 3, 6 or 9 months.
The secondary per-protocol (per treatment) analysis of the DRI did not differ from the primary ITT analysis,
the difference between groups being –4.0 points (95% CI –9.1 to 1.0 points) in favour of the standard
dressings (p = 0.119). This was as expected because the number of patients who did not receive the
treatment allocated within the trial was small.
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxiii
Secondary outcomes
The main conclusion of the trial is supported by the analyses of the secondary outcome measures. There
was no evidence of a difference in the HRQoL scores between the treatment groups at any point in the
12 months following the injury. The mean EuroQoL-5 Dimensions (EQ-5D) score in the NPWT group was
0.55 (SD 0.33) versus 0.56 (SD 0.32) in the standard dressing group, giving a difference of 0.01 (95% CI
–0.06 to 0.07) in favour of the standard dressing (p = 0.823).
There was no difference in the number of deep SSIs between the treatment groups. In total, 35 out of the
460 participants (7.6%) had an indication of a deep SSI: 16 (7.1%) in the NPWT group and 19 (8.1%) in
the standard dressing group, giving an estimated odds ratio of 1.18 (95% CI 0.59 to 2.37) in favour of
NPWT (p = 0.638).
In terms of the economic evaluation, the base-case analysis used multiply imputed data and produced
an incremental cost-effectiveness ratio of £267,910 per QALY gained, reflecting, on average,
substantially higher costs and only marginally higher QALYs in the NPWT group. The probability that
NPWT is cost-effective in this patient population did not exceed 27% regardless of the value of the
cost-effectiveness threshold.
Discussion
This trial provides no evidence of a difference in the DRI between those patients treated with NPWT and
those treated with standard wound dressings following an open fracture of the lower limb. Contrary
to the existing evidence, there was no difference in the rate of deep SSI. Nor was there any evidence of a
difference in HRQoL at any point in the first 12 months after the injury. NPWT did not reduce the cost of
treatment and was associated with a low probability of cost-effectiveness.
In conclusion, contrary to the existing literature and current surgical guidelines, NPWT does not provide a
clinical or economic benefit for patients with an open fracture of the lower limb.
Trial registration
This trial is registered as Current Controlled Trials ISRCTN33756652 and UKCRN Portfolio ID 11783.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Fractures of the lower limb are extremely common injuries in both the civilian and military populations. The
majority of these injuries are ‘closed’, that is, the skin around the fracture is intact. In such cases, the risk
of infection is low; however, if the fracture is ‘open’, such that the barrier provided by the skin is breached,
then the broken bone is exposed to contamination from the environment. In open fractures, the risk of
infection is greatly increased.1
Wounds associated with open fractures of the lower limb are graded by severity, as part of routine clinical
practice, using the classification of Gustilo and Anderson2 (G&A). Grade 1 injuries are small clean wounds
(< 1 cm in length), grade 2 injuries involve larger wounds (> 1 cm in length) but without extensive
soft-tissue damage, and grade 3 injuries are wounds of > 1 cm in length with extensive soft-tissue damage
(Table 1). In addition, Gustilo and Anderson2 described a special type of grade 3 injury that involved
damage to a major blood vessel that required surgical repair. The greater the extent of the injury to the
soft tissues around the broken bone, the greater the risk of infection. In severe, high-energy fractures of
the lower limb, infection rates of 27% have been reported,3 even in specialist trauma centres.
If complications, such as deep surgical site infection (SSI) occur, treatment frequently continues for
years after the open fracture. There is a huge health-care cost associated with such injuries (US study:4
US$163,000 if the limb can be salvaged and > US$500,000 if amputation is required) and this is a fraction
of the subsequent personal and societal cost. In the UK civilian population, the risk of an open long-bone
fracture is approximately 11.5 per 100,000 per year,5 but this is much higher in the military population and
the severity of the injuries is frequently greater.6
The initial management of open fractures of the lower limb in an emergency department involves the removal
of gross contamination, the application of a sealed dressing and the administration of antibiotics, as described
in the joint British Orthopaedic Association and British Association of Plastic, Reconstructive and Aesthetic
Surgeons ‘BOAST’ publication The Management of Severe Open Lower Limb Fractures (www.boa.ac.uk/
wp-content/uploads/2014/12/BOAST-4.pdf; accessed 9 October 2017)7 and the National Institute for Health
and Care Excellence (NICE) complex fracture guidelines 2016 (www.nice.org.uk/guidance/ng37; accessed
9 October 2017).8 Many patients admitted to local hospitals are transferred immediately to specialist
facilities, such as a major trauma centre (MTC). However, the key component of the management pathway
is the surgical ‘debridement’ (removal of all contaminated tissue and washout of the open fracture under
anaesthetic). Once the wound is clean, the fracture is usually immobilised with some form of internal or
external fixation and a dressing is applied at the end of surgery.
TABLE 1 Gustilo and Anderson open fracture classification system
Fracture
type Description
Grade 1 An open fracture with a wound of < 1 cm in length and clean
Grade 2 An open fracture with a laceration of > 1 cm in length without extensive soft-tissue damage, flaps or
avulsions
Grade 3 An open segmental fracture, an open fracture with extensive soft-tissue damage or a traumatic amputation.
Special categories in grade 3 are gunshot injuries, any open fracture caused by a farm injury and any open
fracture with accompanying vascular injury requiring repair
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Traditionally, if the wound cannot be closed primarily, a sealed, non-adhesive layer is applied to the surface
of the wound to protect the open fracture from further contamination. The wound is covered in this way
until a reassessment and further debridement is performed in the operating theatre, usually within
48–72 hours after the initial injury. This method has been used throughout the NHS and in military practice
for many years.
This study concerns the type of dressing that is applied to the wound at the end of the operation.
Negative-pressure wound therapy (NPWT) is an alternative form of dressing that may be applied to open
fractures. In this treatment, an ‘open-cell’ foam or gauze is cut to size and laid onto the wound, followed
by a sealed dressing. A hole is made in the dressing overlying the foam or gauze and a sealed tube is used
to connect the dressing to a pump, which creates a partial vacuum over the wound. This NPWT removes
blood and exudate from the area of the wound, and may also remove any residual bacteria, encouraging
‘granulation’ (healing) tissue.9 Recent laboratory studies have also suggested that NPWT may stimulate the
release of ’cytokines’ that encourage new blood vessel formation.10 These NPWT dressings are widely used
for other surgical wounds after elective surgery and are increasingly used throughout the NHS. However,
NPWT is considerably more expensive than traditional wound dressings for the dressing and the associated
machinery that generates the partial vacuum.
Negative-pressure wound therapy has shown encouraging results in clinical trials related to diabetic foot
wounds11 and abdominal wounds.12 A systematic review13 of the literature before the Wound management
of Open Lower Limb Fractures (WOLLF) study showed only one randomised controlled trial14 (RCT)
comparing standard wound dressing with NPWT for patients with open fractures of the lower limb. This
trial14 demonstrated a reduction in the rate of wound infection in the group of patients treated with NPWT
[5.4% vs. 20%; relative risk (RR) 0.199, 95% CI 0.05 to 0.87]. However, this was a small trial (59 patients,
63 fractures) at a single centre and was funded by a commercial company which produces a NPWT system.
There were no similar trials registered on the international trials database.
Relevance of project
Despite the limited supporting evidence, the 2009 UK BOAST7 and 2016 NICE guidelines8 for the management
of open fractures of the lower limb included a recommendation for the use of NPWT. A consensus paper,
published by the International Expert Panel on NPWT,13 also recommended that, when the use of primary
closure is not possible, NPWT needs to be considered in the management of wounds associated with open
fractures, but acknowledged that the evidence base to support this statement was very limited.
There was a pressing need to evaluate this relatively expensive technology given the increasing use in
clinical practice without a strong supporting evidence base. This multicentre, pragmatic RCT was
conducted to compare NPWT with standard dressings for patients with wounds associated with open
fractures of the lower limb.
Objectives
The study was conducted in two phases with objectives for each.
Feasibility study
1. To conduct a qualitative assessment of (a) patients’ experience of sustaining fracture of the lower limb;
(b) patients’ experience of being enrolled into a clinical trial, giving or declining consent for the trial;
and (c) the acceptability of the trial procedures to patients and staff.
INTRODUCTION
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2. To determine the number of eligible, recruited and withdrawn patients in five trauma centres over the
course of 6 months. In addition, to determine whether or not any trial participants lacked capacity to
give consent 6 weeks post injury.
Main study
The primary objective for the main RCT was to:
1. estimate differences between the treatment groups in the Disability Rating Index (DRI) at 12 months
after open fracture.
The secondary objectives were to:
1. estimate the rate of ‘deep infection’ (deep SSI) of the limb at 30 days after open fracture
2. estimate differences in health-related quality of life (HRQoL) [Short Form questionnaire-12 items (SF-12)
and EuroQol-5 Dimensions, three-level version (EQ-5D-3L)] up to 12 months after open fracture
3. determine the number and nature of complications and further surgical interventions related to the
injury during the first 12 months after open fracture
4. investigate, using appropriate statistical and economic analysis methods, health-care resource use and
thereby the cost-effectiveness of NPWT versus standard dressing for wounds associated with open
fractures of the lower limb.
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Chapter 2 Methods
Trial design
This was a multicentre pragmatic RCT, recruiting patients with an open lower limb fracture. Patients were
randomly assigned to receive either a standard wound dressing or NPWT after lower limb surgery.
Setting
The trial was conducted in 24 NHS hospitals across the UK. Eighteen were designated MTCs and six were
large trauma units.
Participants
Inclusion criteria
Patients were eligible for the trial if they:
l were aged ≥ 16 years
l presented (or were transferred) to a trial hospital within 72 hours of injury
l had sustained an open fracture of the lower limb assessed as G&A grade 2 or 3. The treating surgeon
determined the G&A grade at the end of surgical debridement as per routine operative practice.
We anticipated that only a very small number of patients would present after 72 hours, but that, in such
cases, it was likely that open-fracture wounds would already be infected.
Exclusion criteria
Patients were excluded from the trial if:
l there were any contraindications to anaesthesia such that the patient was unfit for surgery
l there was evidence that the patient was unable to adhere to trial procedures or complete
questionnaires, such as permanent cognitive impairment. In a small proportion of patients, this
exclusion criterion could be determined only after randomisation and emergency surgery had taken
place. These patients were withdrawn from the study and no patient-identifiable data were retained.
Screening procedures
Patients with an open fracture of the lower limb are admitted to the hospital from the emergency
department. All patients were screened in the emergency department or the trauma wards for eligibility
by a trained research associate. Screening logs from each centre were used to determine the number
of eligible patients and reasons for exclusions. Patients who declined to take part were offered the
opportunity to discuss reasons for this with a member of the research team.
Recruitment challenges
The key challenge to recruitment was the procedure for obtaining the patients’ informed consent.
The nature of these injuries meant that the majority of patients were operated on immediately or were
allocated to the next available trauma operating list. Some patients were unconscious or had reduced
levels of consciousness, and the great majority were given strong opiate-based analgesia. Therefore, many
of the patients lacked capacity to provide informed consent before their surgery. The feasibility phase of
the WOLLF study was designed to address this issue, as well as to estimate the rate of recruitment.
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Consent
Conducting research in the emergency setting is regulated by the Mental Capacity Act (MCA) 2005.15
As patients were likely to lack capacity, as described above, and because of the urgent nature of the
treatment limiting access to, and appropriate discussion with, personal consultees, we acted in accordance
with section 32, subsection 9b of the MCA for following a process approved by the Research Ethics
Committee (REC).
Patients consented preoperatively
Patients who were able to give informed consent preoperatively were approached and recruited by a
member of the research team.
Patients consented postoperatively
Patients who were unconscious or lacking ability to process information were recruited to the study under
consultee agreement. Patient consent was not obtained prior to surgery, but a consultee was approached
to provide agreement for entry to the trial. The consultee was a next of kin, when available, or a
medically trained clinician independent of the trial. At the first appropriate time when the patient had
regained capacity, the research associate provided all the study information. The patients were given the
opportunity to ask questions and discuss the study with their family and friends. They were then asked
to provide written consent for continuation in the study. Participants recruited and randomised under
consultee agreement were withdrawn from the trial if they were unable to give informed consent within
6 weeks of randomisation. Any other participant randomised to treatment could withdraw at any time.
Randomisation
A computer-generated random allocation sequence was generated and controlled by York Clinical Trials
Unit. The unit of randomisation was the individual patient on a 1 : 1 basis, stratified by trial centre and
G&A grade. When a patient entered the trial, non-identifiable details were logged on the secure,
encrypted, web-based randomisation system and then the allocation was generated. Information included
patient initials, date of birth, gender and eligibility checks. The trial and clinical teams were informed of the
unique trial number (TNO) for each participant; this TNO was used on all subsequent trial documentation.
Allocation of treatment
Trial participants were assigned to their treatment allocation intraoperatively at the end of initial surgery,
but before a wound dressing was applied. All operating theatres included a computer with internet access.
Therefore, a secure, 24-hour, web-based randomisation system was used to generate treatment allocation.
Blinding
As the wound dressings were clearly identifiable, it was not possible to blind trial participants or clinical
teams to treatment allocation. However, outcome assessment was undertaken by trained research
associates (nurses or research physiotherapists) independent of the clinical care team. For patient-reported
outcomes [disability, pain, quality of life (QoL), resource use, other complications], trial participants
completed follow-up questionnaires themselves and these were returned directly to the central trial office.
Interventions
Usual-care group
Participants allocated to usual care had a standard dressing applied to the open wound. This comprised a
non-adhesive layer applied directly to the wound covered by a sealed dressing or bandage. The standard
dressing did not use ‘negative pressure’. The exact details of the materials used were left to the discretion
of the treating surgeon as per routine care. Details of each dressing applied in the trial were recorded and
classified according to British National Formulary (BNF) classification.
METHODS
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Negative-pressure wound therapy
The NPWT dressing used an ‘open-cell’ solid foam or gauze which was laid onto the wound followed
by an adherent dressing. A sealed tube was connected from the dressing to a pump which created a
partial vacuum over the wound. The basic features of the NPWT are universal, but the exact details of
the dressing and pressure (mmHg) were left to the discretion of the treating health-care team as per
routine care. Details of dressings used were recorded in trial documentation.
Post-randomisation withdrawals
Lack of consent
Participants recruited and randomised under consultee agreement were withdrawn from the trial within
6 weeks of randomisation if they were unable to give informed consent by that time.
Participant withdrawal
Participants could decline to take part in the trial at any time. There were different levels of withdrawal:
1. withdrawal from the trial with approval for use of all trial data
2. withdrawal from the trial with approval for use of partial trial data (e.g. clinical records, radiographs
only or questionnaires only)
3. withdrawal from the trial rescinding approval for access to trial and clinical data.
Participant care pathway
All of the participants followed routine clinical pathways, other than the allocation of the wound dressing
at the end of the initial surgical debridement of the open-fracture wound.
All patients received a general or regional anaesthetic. Antibiotic prophylaxis and prophylaxis for venous
thromboembolism was used as per routine protocol at each centre. The wound associated with the fracture
was ‘debrided’ (surgically decontaminated and cleaned) in the operating theatre and the fracture was treated
with either internal or external fixation. At the end of the initial operation, if the open-fracture wound could
not be closed primarily, patients were randomised and allocated to either standard dressing or NPWT.
Both groups of patients then followed the normal postoperative management of patients with an open
fracture of the lower limb. This usually involved a ‘second-look’ operation between 48 and 72 hours, at
which time a further debridement was performed and the wound closed with sutures or a soft-tissue
reconstruction as necessary. Depending on the specific injury and depending on the treating surgeon’s
normal practice, the wound may have been redressed again pending further surgery. Any further wound
dressing followed the allocated treatment until definitive closure/cover of the wound was achieved.
Postoperative rehabilitation was left to the discretion of the treating surgeon and clinical team, depending
on the patient’s injuries and usual clinical practice at that centre.
Primary outcome
The primary outcome for the trial was the DRI at 12 months after randomisation. The DRI is a
self-administered, 12-item visual analogue disability scale questionnaire that is transformed to a
100-point score, where 0 represents normal function and 100 represents complete disability.16
If more than six items were missing, the DRI was considered to be invalid and was marked as missing;
3 out of the 377 participants (0.8%) with a DRI at 12 months did not provide responses to sufficient items
to enable a valid score to be calculated. This outcome measure was chosen because it addressed gross
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function in the lower limbs, rather than specific joints or body segments. Therefore, it allowed for the
different fractures and different injury patterns sustained by the trial participants.
The default method of data capture at baseline (pre injury) was a face-to-face meeting. On later occasions,
the default method of data capture was via postal correspondence.
Secondary outcomes
The secondary outcomes were HRQoL, deep SSI, other postoperative complications and resource use.
Patient-reported outcomes, including the DRI, HRQoL measures, criteria for SSI and other complications,
and health-care resource use, were collected by questionnaire at baseline, 3, 6, 9 and 12 months after
randomisation. Baseline assessments were made primarily to allow study participants to retrospectively
assess their pre-injury status. Definitions for outcomes and procedures for data collection are described below.
Health-related quality of life
Health-related QoL was captured using the following measures.
l EuroQoL-5 Dimensions (EQ-5D): a validated measure of HRQoL, consisting of a five-dimension health
status classification system and a separate visual analogue scale (VAS).17 Responses to the health status
classification system were converted into multiattribute utility (MAU) scores using a published utility
algorithm, anchored at 1 (perfect health) and 0 (death).18 These MAU scores were combined with survival
data to generate quality-adjusted life-year (QALY) profiles for the economic evaluation. In addition, health
status was also assessed using the EQ-5D VAS, which required participants to assess their own health
from the worst imaginable (0) to the best imaginable (100). These assessments were made by study
participants pre injury (retrospectively),19 immediately post injury and at 3, 6, 9 and 12 months post injury.
l SF-12: a validated and widely used health-related QoL measure.17 The UK factor score coefficients20 were
used to give physical component scores (PCSs) and mental component scores (MCSs). Each permutation
of response to the SF-12 was converted into a Short Form questionnaire 6-Dimensions (SF-6D) health
utility score using a published utility algorithm.21 These data were also combined with survival data to
generate QALY profiles for a sensitivity analysis within the economic evaluation. HRQoL using the SF-12
was assessed at pre-injury baseline (retrospectively recalled) and at 3, 6, 9 and 12 months post injury.
Surgical site infection and wound healing
The Centers for Disease Control and Prevention (CDC) definitions of SSIs were used (Box 1 and see
Appendices 10 and 11). The CDC definition for superficial and deep SSIs is at 30 days following surgery
(randomisation). Wounds were assessed and medical records reviewed at discharge, or at the first outpatient
appointment after discharge from hospital if the patient was discharged before 30 days. Patients discharged
before 30 days had their first follow-up appointment between 30 days and 6 weeks after surgery as part of
normal clinical practice in the UK. Wounds were directly observed and infection characteristics were recorded
by research staff. The CDC criteria23 for deep SSI also include any deep infection occurring within 1 year if
an implant has been left in place. Therefore, we also recorded deep infection presenting within 12 months
of the injury: any wound infection that required continuing medical or surgical intervention after 30 days,
including infections leading to amputation, was considered a deep SSI.
Wound photographs
Wound photographs were taken at 6 weeks. A Samsung ES9 digital camera with flash (Samsung
Electronics Limited, Surrey, UK) was given to each centre. Staff were trained to adhere to a standard
wound protocol to ensure that images were of adequate quality (e.g. instructions for lighting). Nurses
were instructed to remove wound dressings from the open-fracture wound and place a 15-cm paper ruler
next to the wound for scaling. This paper ruler included the participant TNO. All images were password
protected and returned to the trial co-ordinating centre. Photographs were reviewed blind to treatment
allocation by two experienced wound healing specialists. Disagreement was resolved by a third reviewer.
METHODS
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Other postoperative complications
All complications and further surgical interventions related to the open-fracture wound or treatment of the
wound were recorded using multiple approaches. Complications were documented at routine follow-up
appointments, were self-reported by patients or were notified as adverse events (AEs) or serious adverse
events (SAEs) (see Approval for main trial).
All participants were invited for clinical review and a radiograph at 12 months, as per routine practice after
this type of injury. If a participant had not returned a 12-month postal questionnaire, this was completed
in clinic.
Radiographic images (radiographs)
Radiographic images were taken at 6 weeks and 12 months post surgery as part of routine follow-up
for this group of patients. Standard anteroposterior and lateral radiographs were taken at each centre.
Copies of original radiographs were stored on a secure compact disc and returned to the central trial
office. The radiographs were reviewed by an independent surgeon who was blinded to the treatment
allocation. As part of the assessment of complications, each set of radiographic images was assessed for
failure of fixation (yes or no). For long-bone fractures, the sagittal and coronal angulation were measured
for the index fixation; sagittal angulation > 10° and coronal angulation > 5° were considered to be
clinically important. At 12 months, each set of radiographs was also assessed for bony union (bridging
cortical bone across three cortices).
Health-care and social care resource use
Resource use was measured for the purposes of the health economic evaluation. Unit cost data were
obtained from national databases such as the BNF24 and Personal Social Services Research Unit (PSSRU)’s
Unit Costs of Health and Social Care 2012.25 When these were not available, the unit cost was estimated in
BOX 1 Centers for Disease Control and Prevention definition for deep SSI22
Deep incisional surgical site infection
Must meet the following criteria:
Infection occurs within 30 days after the operative procedure if no implant is left in place or within 1 year if an
implant is in place and the infection appears to be related to the operative procedure.
AND
Involves deep soft tissues of the incision (e.g. fascial and muscle layers).
AND
Patient has at least one of the following:
l Purulent drainage from the deep incision but not organ/space component of surgical site.
l A deep incision that spontaneously dehisces or is deliberately opened by a surgeon and is culture-positive
or not cultured when the patient has at least one of the following signs or symptoms: fever (> 38 °C), or
localised pain or tenderness. A culture-negative finding does not meet this criterion.
l An abscess or other evidence of infection involving the deep incision is found on direct examination, during
reoperation or by histopathologic or radiological examination.
l Diagnosis of a deep incisional SSI by a surgeon or attending physician.
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consultation with the University Hospitals Coventry and Warwickshire (UHCW) NHS Trust finance
department. The cost–consequences following hospital discharge, including NHS costs and patients’
out-of-pocket expenses, were estimated using questions included within a questionnaire sent to participants
at 3, 6, 9 and 12 months post randomisation. Patient self-reported information on service use has previously
been shown to be accurate in terms of the intensity of use of different services.26
Data management: postal questionnaires
All questionnaires were sent from and returned to the Warwick Clinical Trials Unit (WCTU), managed by
data clerks. If no questionnaire was received within 2 weeks, a reminder questionnaire was sent. When
there was no response to reminders, participants were contacted by telephone and invited to answer
questions on core outcomes (DRI and EQ-5D). A small proportion of participants were invited to complete
the 12-month questionnaire during their routine clinic follow-up appointment 1 year post surgery.
We used techniques common in long-term cohort studies to ensure minimum loss to follow-up such as
collection of multiple contact addresses, telephone numbers, mobile telephone numbers and e-mail
addresses. Considerable efforts were made by the trial team to maintain contact with participants
throughout the trial, including regular participant newsletters.
Approval for main trial
On completion of the 6-month feasibility study, results were reviewed by the Trial Steering Committee
(TSC). The target recruitment rate was achieved across five trauma centres (one patient per month per
centre) indicating that it was feasible to proceed. In brief, findings from the qualitative interviews
suggested that patients were willing to consent and they understood the rationale for the study.
Therefore, no changes to the protocol or recruitment targets were made. Following the TSC report, the
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme granted
approval for progression to the main phase of the trial.
Adverse event management
An AE is defined as any untoward medical occurrence in a clinical trial participant that does not necessarily
have a causal relationship with the treatment. All AEs were listed on the appropriate case report form for
routine return to the central trial office.
A SAE is defined as any untoward and unexpected medical occurrence that:
l results in death
l is life-threatening
l requires hospitalisation or prolongation of existing inpatient hospitalisation
l results in persistent or significant disability or incapacity
l is a congenital anomaly or birth defect
or any other important medical condition that, although not included in the above, may require medical or
surgical intervention to prevent one of the outcomes listed.
All SAEs were entered onto a SAE reporting form and faxed to the dedicated fax system at WCTU within
24 hours of the investigator becoming aware of them. Once received, causality and expectedness were
confirmed by the chief investigator. SAEs that were deemed to be unexpected and related to the trial were
METHODS
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notified to the REC within 15 days. All such events were reported to the TSC and Data Monitoring
Committee (DMC) at regular meetings.
Serious adverse events that were expected as part of the surgical interventions and that did not require
reporting to the main REC were complications of anaesthesia or surgery (wound infection, bleeding or
damage to adjacent structures such as nerves, tendons and blood vessels; delayed unions/non-unions;
delayed wound healing; further surgery to remove/replace metal work; and thromboembolic events).
All participants experiencing SAEs were followed up as per protocol (PP) until the end of the trial.
Risks and benefits
The risks associated with this trial were predominantly those related to the injury and surgery, for example
postoperative infection and bleeding and damage to adjacent structures such as nerves, blood vessels and
tendons. Participants in both groups underwent surgery and were potentially at risk from any/all of these
complications. Allocation of the trial intervention took place at the end of the initial surgery so that there
was no difference between the groups in terms of surgical or anaesthetic risk. Both standard dressings
and NPWT have been used widely in the civilian and military settings, and there were no specific risks
anticipated with the use of either type of wound management, which was the focus of this trial.
Statistical analysis
Sample size
The minimal clinically important difference (MCID) for the primary outcome measure (DRI) is 8 points.
At an individual patient level, a difference of 8 points represented the ability to climb stairs or run with
‘some difficulty’ versus with ‘great difficulty’. At a population level, 8 points represented the difference
between a ‘healthy patient’ and a ‘patient with a minor disability’.
In Table 2, the figure of 412 participants represents a conservative scenario, based on a standard deviation
(SD) of 25 participants and 90% power to detect the selected MCID. Allowing a margin of 10% loss
during follow-up, including the small number of patients who die in the first year following their injury,
gave a total sample size of 460 patients. Therefore, 230 patients consented to each intervention arm would
provide 90% power to detect a difference of 8 points in DRI at 12 months at the 5% significance level.
Analysis plan
Feasibility study
At the end of the feasibility phase, the overall mean recruitment at the five selected centres for this phase
of the study was estimated (with a 95% CI) and compared with the target rate of one patient per month
per centre. The estimated recruitment rate and the overall rate of withdrawn patients in the feasibility
phase informed the design and the decision to proceed to the main RCT.
TABLE 2 Sample size for varying power and standard deviation
SD
Power
80% 90%
15 112 150 participants
20 198 264 participants
25 308 412 participants
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Main randomised controlled trial
Standard statistical summaries (e.g. medians and ranges or means and variances dependent on the
distribution of the outcome) and graphical plots showing correlations were presented for the primary
outcome measure and all secondary outcome measures. Baseline data were summarised to check
comparability between treatment arms and to highlight any characteristic differences between those
individuals in the study, those ineligible and those eligible but withholding consent.
The main analysis investigated differences in the primary outcome measure, the DRI score at 1 year after
injury, between the two treatment groups (standard dressings and NPWT) on an intention-to-treat (ITT)
basis. In addition, early functional status was assessed and reported at 3, 6 and 9 months. Differences
between groups were assessed based on a normal approximation for the DRI score at 12 months post
injury and at interim occasions. Tests were two-sided and considered to provide evidence for a significant
difference if p-values were < 0.05 (5% significance level).
Although generally we had no reason to expect that clustering effects would be important for this study,
in reality the data were hierarchical in nature, with patients naturally clustered into groups by the recruiting
centre. Therefore, we accounted for this by generalising the conventional linear (fixed-effects) regression
approach to a mixed-effects modelling approach, in which patients were naturally grouped by recruiting
centres (random effects). This model formally incorporated terms that allowed for possible heterogeneity
in responses for patients owing to the recruiting centre, in addition to the fixed effects of the treatment
groups, G&A grade and other patient characteristics that proved to be important moderators of the
treatment effect, such as age and gender.
It seemed likely that some data would not be available owing to voluntary withdrawal of patients, lack of
completion of individual data items or general loss to follow-up. When possible, the reasons for data
‘missingness’ were ascertained and reported. Although missing data were not expected to be a problem
for this study, the nature and pattern of the missingness were carefully considered including, in particular,
whether or not data were treated as missing completely at random. If judged appropriate, missing data
were imputed, using the multiple imputation facilities available in R (The R Foundation for Statistical
Computing, Vienna, Austria). The resulting imputed data sets were analysed and reported, together with
appropriate sensitivity analyses. Any imputation methods used for scores and other derived variables were
carefully considered and justified. Reasons for ineligibility, non-compliance, withdrawal or other protocol
violations were stated and any pattern observed was summarised. More formal analysis, for example using
logistic regression with ’protocol violation’ as a response, was also considered, when appropriate, to aid
interpretation. About 1–2% of patients were expected to die during follow-up; therefore, this is unlikely to
be a serious cause of bias. However, we conducted a secondary analysis taking account of the competing
risk of death, using methods described by Varadhan et al.27
A detailed statistical analysis plan (SAP) was agreed with the DMC. Any subsequent amendments to this
initial SAP were clearly stated and justified. Interim analyses were performed only when directed by the
DMC. The routine statistical analysis was carried out using R.
Secondary analyses were undertaken using the above strategy for approximately normally distributed
outcome measures SF-12 and EQ-5D. For dichotomous outcome variables, such as indicators of deep
infection and other complications related to the trial interventions, mixed-effects logistic regression analysis
was undertaken with results presented as odds ratios (ORs) [and 95% confidence intervals (CIs)] between
the trial groups. In addition, temporal patterns of any complications were presented graphically and, if
appropriate, a time-to-event analysis (Kaplan–Meier survival analysis) was used to assess the overall risk
and risk within individual classes of complications.
METHODS
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Health economic analysis plan
An economic evaluation was integrated into the trial design. The economic evaluation was conducted from
the recommended NHS and Personal Social Services (PSS) perspective.28 Data were collected on the health
and social service resources used in the treatment of each trial participant during the period between
randomisation and 12 months post randomisation. Trial data collection forms recorded the duration of
each form of hospital care, surgical procedures, adjunctive interventions, medication profiles, and tests and
procedures. Observational research was required to detail additional staff and material inputs associated
with clinical complications. At 3, 6, 9 and 12 months post randomisation, trial participants were asked to
complete economic questionnaires profiling hospital (inpatient and outpatient) and community health
and social care resource use and, for the purposes of sensitivity analysis, out-of-pocket expenditures and
costs associated with lost productivity. Current UK unit costs were applied to each resource item to value
total resource use in each arm of the trial. Per diem costs for hospital care, delineated by level or intensity
of care, were largely derived from national reference cost schedules. The unit costs of clinical events
that were unique to this trial were derived from the hospital accounts of the trial participating centres,
although primary research that used established accounting methods was also required.29 The unit costs
of community health and social services were largely derived from national sources. Trial participants were
asked to complete the EQ-5D-3L17 and SF-1230 measures at baseline and at 3, 6, 9 and 12 months post
randomisation. Responses to the EQ-5D-3L and SF-12 were converted into health utility scores using
established algorithms.18,21
An incremental cost-effectiveness analysis, expressed in terms of incremental cost per QALY gained, was
performed. Results were presented using incremental cost-effectiveness ratios (ICERs) and cost-effectiveness
acceptability curves (CEACs) generated via non-parametric bootstrapping. This accommodated sampling
(or stochastic) uncertainty and varying levels of willingness to pay for an additional QALY. A series of
sensitivity analyses were undertaken to explore the implications of parameter uncertainty on the ICERs.
In addition, CEACs were constructed using the net benefits approach.
Ethics approval and monitoring
Standard NHS cover for negligent harm was in place. There was no cover for non-negligent harm.
Ethics committee approval
The WOLLF study was approved by the Coventry REC on 6 February 2012 (REC reference 10/57/20) and by
the research and development department of each participating centre. The trial protocol31 was published
in the BMJ Open.
Trial Management Group
The day-to-day trial management was the responsibility of the trial co-ordinator, based at WCTU, and
supported by administrative staff. The Trial Management Group (TMG) met monthly to assess overall trial
progress. It was also the responsibility of the trial co-ordinator to train the research associates at each of
the trial centres.
Trial Steering Committee
A TSC was appointed by the NIHR HTA programme and was responsible for oversight, monitoring and
supervising trial progress. The TSC consisted of four independent experts, a lay member and the chief
investigator. Members of the TSC are listed in Acknowledgements.
Data Monitoring Committee
The DMC was also appointed by the NIHR HTA programme and was tasked with monitoring ethics, safety
and data integrity. The trial statistician provided data and analyses requested by the DMC at each meeting.
Members of the DMC are listed in Acknowledgements.
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Patient and public involvement
Prior to the submission of the grant application for the WOLLF study, an informal survey was conducted at
a large university hospital trust to establish the opinion of patients and their carers with regard to research
in orthopaedic trauma. We established that patients place great importance on research comparing
different types of interventions in the area of trauma surgery. Furthermore, they have demonstrated that
they are willing to take part in such trials.
Throughout the trial, a patient with direct experience of sustaining an open lower limb fracture and the
subsequent recovery path reviewed all patient documents prior to submission to the sponsor and the ethics
committee. Furthermore, advice was sought from this lay collaborator during management meetings when
issues were discussed directly related to patient engagement and commitment.
Independent lay representation was present on the TSC. Members of the Trauma Patient and Public
Involvement Group also reviewed the progress of the WOLLF study at the annual NIHR Trauma
Trials Meetings.
METHODS
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Chapter 3 Qualitative study
Background
This study explores the experiences of patients in acute care who have an open fracture of the lower limb
and their experience of being in a trial. Research that examines the experience of having an open fracture
of the lower limb is limited, particularly in the acute phase of recovery. Some studies explore recovery at a
variety of time points post hospitalisation. For example, in order to develop an outcome tool, Trickett et al.32
interviewed nine participants 1.2–2.8 years post injury. They identified the serious impact of injury on
participants’ daily life as they struggled to recover in terms of a range of different types of pain including
stiffness and discomfort, reduced mobility and flexibility, the impact of temperature on their body, frustration
and fear, anxiety around their appearance, concerns about getting back to work, a fear of falling, reduced
finances and the impact of injury on family and friends. Using a grounded theory approach, Shauver et al.33
sought to explore the relationship between high satisfaction levels and poor outcomes. Semistructured
interviews (n = 20) were undertaken 2.3–12 years post injury. Satisfaction despite poor outcomes was
explained by approaches to coping, problem-solving practical difficulties and using cognitive restructuring to
identify positive aspects of experience. Personal growth was present as participants developed alternative
careers to accommodate their injury.
Other studies that include lower limb injury provide useful insights into patient experience. Griffiths
and Jordan34 used diaries and semistructured interviews (n = 9) 5–8 weeks post surgery. Three themes
of (1) dealing with uncertainty, (2) seeking control and (3) returning to normality were identified. The
participants experienced high levels of pain, had difficulty controlling pain and found dependency on
others problematic in their attempt to return to normality. Participants studied by Forsberg et al.35 were
interviewed (n = 9) from 1 to 12 months after injury and identified feelings of frustration, helplessness and
vulnerability as they struggled to feel in control and safe as they regained their autonomy. Like the participants
in the Griffiths and Jordan study,34 they sought to control their pain but also felt vulnerable while waiting
for, and going to, the operating theatre for surgery; security was gained from supportive staff. Studies
of ankle fracture support these aspects of experience. McPhail et al.36 interviewed 12 participants aged
< 60 years at 6 weeks to > 2 years post injury and six staff members. They identified ongoing swelling and
pain, frustration and depression, an inability to return to normal activities and to wear usual footwear, and
a reduction in social life and reduced finances. The emotional vulnerability of older people (aged > 60 years)
with an unstable ankle fracture was identified by Keene et al.37 Unstructured interviews (n = 36) at
6–10 weeks post treatment identified the emotion work participants undertook as they processed being
injured and feeling older and renegotiated interdependency with their partners as they coped with non-
weight bearing. Rethinking taken-for-granted activities and finding ways of keeping busy was key for their
physical and mental well-being. Struggling to move was hampered by comorbidities, lack of skill in using
walking aids, pain, swelling and lack of confidence. Support from family and friends was crucial to the
maintenance of well-being during this period.
Understanding how participants make sense of trauma trials in an emergency situation when their ability
to make decisions may be impaired by pain, medication and emergency treatments is part of the feasibility
phase of the trial. In other research studies,37–39 trust in the clinical team and altruism have been identified
as reasons to take part in a trial. Often, understanding of trial methodology, such as randomisation, can be
limited, which has led to a belief that staff have provided the best treatment for them, often termed
‘therapeutic misconception’.38,39 The acceptability of randomisation or equipoise when clinical treatment is
required is called into question by trial and lay participants40,41 and can threaten participants’ feelings of
trust in the clinician.40 Patients may also make decisions based on a limited understanding of the risks and
disadvantages of being in a trial42 and how the trial benefits them personally.39,43
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Our current understanding of patient experience of taking part in orthopaedic trauma trials is limited.
In a study of ankle injury management,37 in which participants often had at least 24 hours to consider
entering the study, they developed a strong preference for surgery or the non-surgical intervention and
were disappointed when they did not get the treatment they desired. Sometimes the experience of family
and friends supported their preference, also found by Canvin and Jacoby.38 However, when interviewed at
6 weeks, they felt that they had received the right treatment for them.37 This suggests that a process of
acceptance developed over time as participants made sense of their treatment as the best course of action
for them. This may be an extension of therapeutic misconception, a term used to describe the inability of
patients to distinguish between trial participation and normal clinical care or a way of living with their
allocated treatment. This study also identified the importance of experiential knowing at the time of
consenting and how participants felt they could not know the interventions as they had no prior experience
of them. The timing of consent and assessing individuals’ capacity to make an informed decision is
problematic in studies of emergency orthopaedic trauma. From a systematic review of a range of studies,
Gobat et al.44 concluded that researchers face a conflict between providing an opportunity for patients to
take part in a trial and being viewed as immoral by causing high levels of patient distress, related to patients’
ability to absorb sufficient information, and the additional distress of family members. Third-party consent
was generally considered acceptable but there were concerns in high-risk studies and a suggestion that the
burden of consent should be shared between several people. Further evidence is required in relation to
this study and in particular the use of presumed consent, using personal and nominated consultees, with
informed written consent provided for continuation in the study when the participants were well enough to
make a decision.
As outlined above, it is not easy for patients to make a full recovery from open fracture of the lower
limb, and psychological, physical and social consequences limit many from returning to a pre-injury state.
Research involving patients with a range of lower limb injuries adds depth in relation to the impact of such
injuries on patients’ emotions, the need for control over pain management and the effects on daily life and
relationships. Studies are variable in the quality of their reporting of methodology and rigour, and in some
studies samples are small. The theoretical perspectives and timing of the interviews are also variable, and it
is difficult to determine how experiences change over time and what may influence change. There is
currently a gap in the literature regarding patient experience in the early phase of injury while in acute care.
There is also limited evidence regarding the experience of taking part in an orthopaedic trauma trial during
the early phase of treatment and recovery. An understanding of this phase will help lay the foundation for
improving care for this group of patients and lead to better outcomes of care in the future. This study intends
to add to the body of knowledge on patient experience of injury and being in a trial while in hospital.
Methods
The study is underpinned by phenomenology drawing on the work of Heidegger.45 This is a philosophical
approach that focuses on ‘being in the world’ and what it is like to be in the world or ‘dasein’. Research
focuses on the meanings inherent in everyday life, including aspects that may be taken for granted.
Madjar and Walton46 suggest using a ‘listening gaze’ to focus on the unknown in order to gain a deeper
understanding of the person within his or her life world. The central tenets of phenomenology convey
‘being’ within the social, historical context of the person, and include temporality and a sense of space,
both spatially but also in relation to aspects of ‘concern for’ the other.45 The research process therefore is
framed by a focus on what life is like for an individual and the taken for granted meanings inherent in
their everyday world. Interviews are often the method of choice; through descriptions of what it is like,
notions of being, context, time and space can be examined.
In this study, unstructured interviews were undertaken while participants were in acute care. The interview
focused on their experience of being injured. This was followed by prompts such as ‘tell me more about
that’, ‘how did you feel?’, ‘what did you think at that time?’ and ‘how did that differ from?’. The intention
was to give participants the opportunity to describe what it was like to be injured from their perspective,
QUALITATIVE STUDY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
and to explore the issues, concerns and taken-for-granted aspects that were part of their everyday
experience. In addition, one focus group with five clinical and research staff, including doctors and nurses,
focused on what it was like to recruit patients to the trial.
A purposive sample of 20 patients of different ages, genders and breadth of experience was recruited;
participants had been hospitalised for treatment for open fracture of the lower limb and had consented
to be part of the WOLLF study.31 All patients had fractures, G&A grade 2 (n = 4) or grade 3 (n = 16),
often alongside other injuries; two participants had an extended period in critical care. Injuries had been
sustained through motorbike/car collisions and activities at work or in the home. They were aged
20–82 years (mean 40 years, median 38 years). Time since first surgical intervention (within 72 hours of
injury) ranged from 5 to 35 days (mean 12 days, median 11 days). Interview length ranged from 25 to
86 minutes (mean 54 minutes, median 58 minutes). In addition, one focus group was undertaken
(46 minutes) with five interdisciplinary staff to ascertain their experience of undertaking the study.
Interviews took place between July 2012 and July 2013. The researcher approached those who gave
permission and discussed the study with them. They received an information sheet and had at least
24 hours to consider participation before signing a consent form. NHS research ethics approval was
granted. Interviews took place in a ward environment because the nature of participants’ injuries
necessitated them being confined to the ward area. Interviews in busy clinical environments are
problematic as maintaining privacy and dignity can be challenging. This was discussed with participants,
who were given control over when to stop the interview; visiting times were avoided and the researcher
left the area during clinical visits and mealtimes. The participants were comfortable with the interview
environment and not concerned when interruptions occurred.
Interviews were recorded (digital–audio) and transcribed verbatim. Analysis was undertaken by drawing
together codes that conveyed inherent meaning within the descriptions to form categories and themes
while being aware of similarities and differences within the meanings.47 For example, descriptions
underpinning codes reflecting death, saviours, miracles and being lucky were drawn together within
the category ‘being alive’, which best reflected the meaning underlying the codes. This was then drawn
into the theme ‘being emotionally fragile,’ as emotions reflected the broader theme underlying each of
these categories. Reflection on the process drew on notions of the hermeneutic circle,48 considering each
meaning in relation to each other and the emerging whole. NVivo 10 (QSR International, Warrington, UK)
was used to help manage the data. The same process was undertaken for the focus group.
Rigour was demonstrated through the notions of trustworthiness.49 The researcher was immersed in the
data for a prolonged period of time and used verbatim quotes. A range of experiences were presented,
reflecting the breadth of data to enhance transferability and resonance with the reader. Auditability was
demonstrated through identification of the research process. Intersubjectivity of the researcher with the
data was examined throughout by reflection on data collection and the process of analysis with peers and
in field notes. The previous experience of the researcher (ET) of researching concepts such as comfort,
hope and other areas of injury was part of this reflective process.
The findings
The findings identify the overall theme of embodied vulnerability, in which the impact of the injury goes
beyond the physical body to have an impact on all aspects of the individual’s self and their life.
Embodied vulnerability in this study was defined as a response to injury in which participants experienced a
new way of being in the world expressed through their emotionally fragile, visibly wounded, constrained
and painful body. They suffered and endured their recovery in hospital in the context of uncertainty and,
when ready, they reimagined how their life would be at home and at work.
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In this group of previously generally healthy, independent people with busy lives, there were high levels of
emotional and physical distress as a result of sudden injury. The experience was extremely challenging,
requiring dependency on others and a high degree of personal resilience. The participants vulnerability
was expressed through four themes depicted in Figure 1: (1) being emotionally fragile, with categories of
being alive, being close to losing a leg, being a person with strong emotions and being aware of others;
(2) being injured, with categories of being a person with wounds, being constrained and being in pain;
(3) living with injury, with categories of being at home and being at work; and (4) being compromised,
with categories of being dependent on others, being trusting, being grateful, and being without
prior experience.
Theme 1: being emotionally fragile
Being emotionally fragile reflects the feelings required to make sense of the event, live with continued
uncertainty and process their own strong emotions and those of others. It was expressed through being
alive, being close to losing a leg, being a person with strong emotions and being aware of others.
Category: being alive
Being alive conveyed the dramatic, life-threatening nature of this injury, often caused by high-impact road
traffic events, many involving motorbikes, or industrial incidents. Many of the participants felt that they
could have died and the last their families would see of them was in a ‘box’ (participant 10). The shocking
nature of the near-death event created a sense of being saved and, for some, a sense of spirituality, a ‘sort
of a miracle’ (participant 3), with professionals regarded as saviours. Being grateful that they had received
such good care went alongside being lucky, which was linked to what could have happened and how the
situation could have been so much worse:
I’ve just got to go with what happens really but at the same time I’ve still got to harp back to the fact
that in the first place I was lucky. I could easily have died in that incident so you’ve got to think about
relative situations really haven’t you and the injury that I eventually sustained . . .
Participant 5
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FIGURE 1 Conceptual framework: embodied vulnerability – relationships between themes.
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Being alive, being saved and being lucky were notions that participants reflected on when talking about
their recovery and planning their life in the future.
Category: being close to losing a leg
Participants were horrified and shocked, when, at some point in their recovery, they felt, or were told, that
losing their leg had been, or remained, a possibility. The ease with which this could happen, and the
inherent uncertainty about whether or not it would, created a high degree of anxiety:
Emotionally it’s been a real shock and quite a rollercoaster . . . and to be told that if they didn’t get it
right I could lose my leg which was a bit of a shock and just to realise how easy it is to do something
so serious.
Participant 16
Interviewees felt a mixture of relief and hope in relation to the potential loss of a leg. It was not something
they had envisaged before the accident and they hoped it would never happen. Relief that they had kept
their leg so far was mixed with apprehension regarding the uncertain progression of their recovery and the
potential threat of its loss in the future.
Category: being a person with strong emotions
The participants’ stories conveyed an emotional fragility that pervaded every aspect of their lives. Some
had not felt this degree of fragility before; others had, but only in relation to extreme events, such as the
death of a loved one. All interviewees expressed strong emotions, and sometimes these spilled out as
‘meltdowns’, when they cried and felt they were unable to cope. A few participants in this study preferred
not to talk about their injury as the feelings engendered were too strong. Some struggled with these more
than others and, at times, it felt like a rollercoaster as the slow realisation of the seriousness of the impact
of injury on themselves, their families and their lives unfolded. They were unprepared for the emotional hit
of the accident; in addition, the repeated surgical interventions, despite knowing they were in safe hands,
made participants feel vulnerable, a feeling they were not used to in their busy successful lives:
. . . initially I think I found it quite difficult and to be emotional. It’s just not something for me at all. It
would take a lot for me to bring my emotion out, it would take a significant thing in my life and I’ve
probably only experienced it twice, so yes quite a lot to deal with, I found it quite strange but I think
we’re getting there.
Participant 9
The injury event was shocking and overwhelming; many participants relived the event through talking; for
others, it was too upsetting. Some processed the fear and anxiety through regular dreams and nightmares:
I have nightmares about not being able to walk ever again or my children will walk in with my leg in
their hands and stupid stuff like that.
Participant 19
The long, slow process of repeatedly requiring further surgery and coping with the impact of injury in a
hospital setting reduced the participants’ capacity to emotionally cope with their recovery:
. . . it wasn’t until I got right down to the anaesthetics room that the penny dropped and then I was
like a big girl’s blouse because I didn’t have the wife there or anybody there just two strangers and
I felt lonely and vulnerable and basically my life is in their hands.
Participant 3
Strong emotions, such as anxiety, fear and low mood, were expressed in relation to sleep patterns, the
next surgical step, the anaesthetic and being in hospital. As the extent of care required and the impact on
their lives came to the fore, emotional resilience was required to endure the interventions, but participants
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often lacked emotional capacity and felt ‘like flipping, and going absolutely off my head . . . going
absolutely schizo’ (participant 14). Psychologically, it was hard work with frustration setting in after the
initial relief at being in the right place with the right care. The strength of emotions was a surprise for
participants, but something they learnt to manage in a public place. However, on occasions, it was
directed at staff or spilled out when insurance personnel or police asked about the accident. They also
suppressed the emotional consequences of their injury for the sake of family and friends.
Category: being aware of others
The participants were not only processing their own emotions but were also facilitating family and friends’
responses who were also experiencing strong emotions. For example, a group of friends came in singing
with cards and balloons but were stunned when they saw the degree of injury sustained:
I realised they were shocked and that was quite shocking to me, and they realised the grief and
looked back and just joked about it.
Participant 2
There was some degree of suppression of their own emotions with the intention of maintaining normality
and instilling a sense of hope that recovery was progressing:
Inside I really am as tough as old boots. I was more upset when I saw my wife upset and the effect it
had had on her. I don’t think I really realised just how close I did come but as I said, I am still here and
it didn’t happen, it’s just part of life . . . I put on a brave face so the wife can start to relax and start
being normal again, that’s the most important thing to me for the kids to stop worrying, Dad’s on the
mend and it’s all going to be good. There is light at the end of the tunnel.
Participant 3
The younger participants found Facebook (Facebook, Inc., Menlo Park, CA, USA; www.facebook.com)
and the social contact with a wide range of friends incredibly supportive and a good way of maintaining
contact with everyday life, family and friends; however, the nature of the interactions and type of support
was not explored in this study.
Theme 2: being injured
Being injured was an emotional and physical shock for all participants and they struggled to manage their
bodies through the categories of being a person with wounds, being constrained and being in pain.
Category: being a person with wounds
The wound itself and the state of the injured leg created a real sense of panic and shock. Interviewees were
reluctant to see the actual wound and had to be ready to do so. They had to prepare: ‘giving it time and
psych myself up’ (participant 1). The visual look of the wounds often left participants feeling shocked and sick:
It was off and I looked down and thought oh my God they’ve obviously got to cut my leg off because
it just looked horrendous . . .
Participant 2
Participants were concerned about how they would live with the resulting wound. They were surprised by
staff responses when they described their wound as brilliant, beautiful or healing well. Preparation of
participants for seeing their wound was varied; good preparation was beneficial:
I saw it [the wound] for the first time yesterday, which was a bit weird, but if I hadn’t seen the
pictures in the book I wouldn’t have known what to expect at all and it would have been horrible and
it probably would have made me feel a bit sick . . . I’m glad again that I was shown the pictures so I
knew what to expect . . .
Participant 11
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There was a sense of being damaged and concern about what others would think:
I was worried that she wouldn’t find me attractive and she’s so pretty and so perfect and I thought
‘what is she going to think of me now?’.
Participant 2
Some became accustomed to their wounds and, on some level, accepted them and took a cognitive
interest in their healing and progression:
Yes, last couple of days, side by side (both legs undressed and visible), a bit overwhelming but also a
big sigh of relief because they are on the mend, well definitely very far into the mend. Compared to
what they were like. Everything seems to be alright with them, the plastics are happy with them . . .
I was just intrigued to be honest. I took photos to send to the family. It’s not pretty to look at but to
me looking at it, it makes me feel happy to be honest because my legs are still there. It is not pretty to
look at but it is what my legs are like now.
Participant 19
For certain participants, at some point in their recovery, there was a feeling of detachment from their
body; they needed time to assimilate what was happening or were unable to cope with the implications
and so temporarily disconnected from the situation:
The only time I actually felt detachment was when Jim first mentioned the possibility, the extreme
possibility, of amputation. When another surgeon came in and mentioned it again I almost felt like
I was in heaven and just detached slightly. I was listening to him and thought blimey I’ve completely
disconnected from this, that’s when I feel detachment when that gets raised, I’m not consciously,
it’s not a decision to detach, but it just seems to happen because it’s something that even though
I’m aware of it I don’t really want to have to consider it right now.
Participant 15
Readiness to see a wound and preparedness are key elements in being a person with wounds; inclusion of
family and friends is important in this process where they can offer support for the emotional impact of
having a wound with a focus on the natural bodily responses and how they change over time.
Category: being constrained
The participants felt they were constrained by their body’s inability to perform in its normal way. The
majority were outdoor, active people who had physically busy lifestyles. Being constrained by their body was
boring and frustrating. Instead of being taken for granted, their body now required surveillance and they
observed their body, noting the swelling and changes in bruising and watched for signs of healing. They
expressed their shock at how limited they were in terms of what they could do. Their bodies were lacking in
strength and constrained in their ability to function which affected what they did and how they felt:
Yes, the strength in my legs is so reduced it’s quite incredible and so you can imagine a few more weeks
like this and it’s going to take a while to get my strength back, it’s your core strength. If I transfer from
this to a wheelchair I’m absolutely exhausted and you’ve just got no trunk strength or virtually none.
Participant 2
Many participants had lost the use of both legs and had other injuries that left them constrained to the
bed, resulting in frustration, boredom and stress as they tried to cope with the daily discomforts and
waited for their body to heal:
The largest frustration has been the scaphoid fracture in my right wrist which is just another thing to
go with the left leg.
Participant 13
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Hospital life was frustrating, particularly being on bed rest. Once they could physically move, there was a
sense of surprise that they were unable to move naturally, had to plan everything and required help.
Participants had to learn how to cope with prolonged periods of bed rest and immobility, deal with the
frustrations of limited mobility, accept the pace of recovery dictated by the healing process and move their
bodies within the limits of their injuries. There was a heightened sense of surveillance in relation to
monitoring their body for signs of recovery but also a mix of frustration and acceptance combined with
relief when they could finally move about.
Category: being in pain
Participants experienced extreme pain at some point that they found difficult to control and expressed
strong emotions that they would not normally express. Many had support from the pain relief team with
some success. Others struggled to find pain relief that suited them, to get timely access to pain relief, to
balance activities around pain relief and to control their emotions as a result of pain. Pain was a constant
source of concern and was worse early on in the recovery process. Interviewees who had patient-controlled
analgesia were fairly happy with their pain control once they had worked out how to use it, but timely
access to oral medication was difficult. For some, the pain varied in nature but was persistent, wearing
down their ability to cope:
Yes there are days that the pain is bad and there have been days where I can’t bear the pain.
I’ve been asking for painkillers and I’ve curled up . . . to try and deal with the pain. It does have its
days of coming and going, the pain. I had pain when I woke up just now, and now it’s gone into
an ache, which is sometimes worse because obviously an ache you can’t do anything about. It’s
aching now and that’s why I keep fidgeting . . . It’s not always just pain, it’s like itching where it’s
healing and I can’t itch it, which is annoying. There’s aching, itching, pain, throbbing, there’s a
burning pain like when you’ve got sunburn, it feels like that on my legs where they took the skin
grafts from.
Participant 19
Trying to be ‘big and strong’ was a difficult facade to maintain in the face of persistent acute pain;
resilience was lowered by pain to a point at which participants expressed distress:
Yes, it has made me cry a few times and I’m not really the sort of person to cry but obviously where
I’m so stressed out in here and in so much pain it’s bound to come to it.
Participant 14
Overall, pain was a source of concern to all participants at some point in their recovery. This was
complicated by the variety of sources of pain, access to medication and a general reluctance of patients to
take medication. The group appeared to suffer considerably, which reduced their energy to cope and
often led to expression of strong emotions in public that were not normal for them. Thus, being a person
in pain was an inherent part of the injury experience and affected their ability to process their emotions
and actively manage their recovery.
Theme 3: living with injury
Living with injury evolved as they found mental space to rethink or reimagine how they might live their life
at home and at work in the future and was conveyed through the categories of being at home and being
at work. This thinking was done within the context of a high level of uncertainty.
Category: being at home
The participants felt that the future was unknown and uncertain but that they were lucky to have a future.
The need to get home was overwhelming, but as they progressed through the recovery process it was
something they felt was more tangible and they could ‘visualise’ (participant 19) what it would be like to
go home. Emotionally, they were anxious and daunted about going home which was sometimes expressed
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in nightmares. Cognitively working through how it would be at home and how they would manage
physically was mixed with concern about how their families would cope. Managing false hope and having
realistic expectations of what being at home would be like were of concern. Returning to their hobbies
was also a preoccupation, with some planning ways to continue them and others processing the loss of
their ability to undertake their hobby:
It’s really hard and it sickens me the thought of losing my bikes but it’s a small sacrifice. If I want to
live another 30 years on this planet and I want to walk these beautiful girls down the aisle, then it’s a
small price to pay.
Participant 3
Planning a return to home was largely about thinking it through, supporting activities at home to make
living at home doable for the family and planning how they might cope. There was sadness at the loss
of the life they had before and a degree of uncertainty about how things would work out but also a
determination to get home and cope with the changes in their lives.
Category: being at work
Part of getting back to normal was getting back to work. This proved to be a slippery concept that was
difficult to visualise owing to the uncertainty of recovery from trauma and degree of functional recovery
expected. Any information on this aspect was gratefully received, but participants felt that clarity about
timescales was unlikely owing to the complex nature of their injury and individual recovery paths.
Participants with physical jobs had difficulty imagining what they would do. Some had casual contracts
with no other skills and were thinking about what they could do to earn a living, some had plans and
others were unsure how they would manage. Uncertainty over their ability to function as before was a
source of concern:
Yes but I’m not too worried about getting back on a horse or anything like that or the nerves and it’s
whether I can physically do it. Mentally I will be fine, there’s no question about that but physically
I don’t know . . . we’ll see whether it’s time to pack up and get a new trade. I don’t know but it’s
a possibility.
Participant 8
For some interviewees, the accident had provided an opportunity to re-evaluate their lives. Getting back to
work was seen as part of a return to normality and necessary for financial security but they were uncertain
about their ability to function and make it happen. Those with physical jobs were aware that their ability
to work as before was unlikely but could not see an alternative at this stage.
Theme 4: being compromised
The decision to go into the trial was based on being compromised, defined as being dependent on others
owing to the acute/emergency nature of the injury and a high degree of trust invested in the clinical team.
Being grateful included feelings of altruism and the need to give something back, supported by prior
research knowledge and the minimal burden of the research process. Being without prior experience of
the two treatments led to a state of not knowing about the interventions; however, experience of the two
treatments or information from others clearly identifed a technological preference for NPWT.
Category: being dependent on others
There were challenges in relation to the acute circumstances of the injury, the high degree of trust in the
clinical team and the lack of prior experience of the two treatments. The decision to go into the trial was
made at a time of great stress, ‘I don’t think I was in any fit state to make any decisions’ (participant 6),
and there was acceptance that ‘somebody had to make a decision on your behalf’ (participant 2);
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however, some were able to make sense of the trial and, based on the fact that both interventions were
commonly used and not invasive, were happy to go into the trial:
I was informed about it on the first day and I can half remember being informed about it because
I was on gas and air and morphine, tramadol, I was on all sorts of stuff the first day, but yes I can
remember being asked about it. I can remember agreeing to it then but not quite with it and then
they mentioned it afterwards and yes I can’t really see it having that much effect on me.
Participant 11
Verbal consent before going to the operating theatre sometimes helped them make sense of the trial
when they were later asked to provide written consent:
They asked me beforehand and I can remember giving verbal consent so the written consent
afterwards didn’t bother me at all.
Participant 11
The nature of the trial was unproblematic for participants but the principle of being asked to take part was
important for some participants. Some preferred, if at all possible, to be asked about the trial before the
surgery – ‘I would rather that they woke me up and asked me given the choice’ (participant 15) – but, in
light of their poor state and lack of concern about the nature of the dressings, were not concerned about
the study itself. There was a general acceptance that, in some areas of life, there is no choice. Some
participants, despite knowing they were not in a fit state to be asked, considered being a ‘guinea pig’ as a
way of making sense of their participation, while others did not mind and still others felt rather ‘shocked’
(participant 8) at being asked to consent after surgical intervention, but balanced this against any potential
harm and their ability to get better in the longer term. There was some confusion or lack of memory in
relation to the trial, but generally doctors were seen to ‘know best’ (participant 20):
To be honest I was hurt, but they’re doctors and they know what they’re doing so I didn’t really mind
because they know best. I can’t really tell them that that’s not right, you can’t let the computer
choose for me you should have asked me first, it was right for me. I’m not really angry, I’m quite
happy about it.
Participant 20
For others, consenting after surgery was not a problem and they would have made the same decision
(participant 19). They found it helpful that they could withdraw at any time and that the study was low
impact in relation to their time and the effect on their life:
It genuinely didn’t bother me about that and I felt free at any point to say no.
Participant 16
One person chose not to take part in the trial, but this was on the basis of paperwork only. In principle,
there were no concerns about the trial itself:
To be honest the only thing I said to her about doing paperwork was that I would never get round to
doing it, it’s just like homework at school, I never did do it and I had it in my head that I never would
do it. Paperwork is not one of my strong points, that’s why I didn’t do it.
Participant 14
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The staff focus group supported the above findings, with staff having experience of both those who
wished to be informed in the emergency department even though they were not able to formally consent
and those who deferred to the doctors owing to their condition:
I think they probably think of the broken bone and that being fixed is probably the important thing,
they don’t appreciate fully the open nature of the fracture is more likely to affect their outcome.
I think it’s hard and invariably these patients have had a good dose of morphine plus or minus
ketamine or whatever else.
Focus group, staff participant 5
In addition, they identified those who felt that the surgeon should decide on the dressing, rejecting
randomisation as described by Robinson et al.41 They noted that patients thought the burden was minimal
and liked having extra contact with known staff. There was some discomfort approaching patients who
had experienced major injury or death of a loved one, as the study felt insignificant in the light of the
patient’s circumstances. They noted that patients who gave consent to continue in the trial often indicated
that they felt the paperwork was not really necessary:
I think some of them think what’s the fuss, it’s happened so why are you wanting me to sign a piece
of paper, what’s the big deal and then especially if they’re seen after they’ve had their flap for them
to try and remember what they had prior to that, it’s moved on in their pathway of what’s happened.
Focus group, staff participant 2
In general, the staff felt they were in equipoise and had no concerns about entering patients into the trial
but had a heightened awareness of patients’ dependence on them in the early phase of treatment
and recovery.
Category: being trusting
Owing to the severe nature of the injury and intervention required there was an enormous degree of trust
in the clinical team: ‘they thought I would be OK for it, so I didn’t have any qualms about it’ (participant 16).
Many felt that they were not in a position to make a decision because of their general state and that the
medical team knew more and were in a better position to know what was best for them:
I’m stood here to tell the tale and I’m just glad of that and taking part in any trials or vacuum pumps
[NPWT] as such, the decisions were made for me as I wasn’t in a fit state of mind to do that at the
time. To be honest, even if I was I would have agreed to it anyway. If they had said to me they had
got this and that I would have said to them straight, what do you think? I would have passed the
buck back, which was the best one . . .
Participant 3
The degree of trust on occasions worried the staff, who felt:
I think there’s too much going on and, like Donald said, they’re just willing to do anything.
Focus group, staff participant 3
Knowing what is best for them suggests a degree of therapeutic misconception on behalf of the patient
in relation to understanding randomisation, but this was not necessarily the case. There was a need to
trust in the team and know that they can ‘bring me out the other side, as long as that happens I’m happy
regardless of how they do it’ (participant 5). A need to believe in the team and see a future in which
they would recover was of greater importance than the type of dressing they received. Within this was
acknowledgement of the knowledge differential between themselves and the team in relation to wound
healing: ‘they know what they’re doing and it’s obviously better that they’re doing it and I’m not’
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(participant 14); ‘I know nothing about these dressings’ (participant 6). However, those who received
advice from medical family members showed a distinct preference for the NPWT: ‘I have to say I would
probably have been happier if they had randomised me to the vac [NPWT] system’ (participant 6). The staff
focus group noted that having a full description of the NPWT in the information sheet might lead to an
expectation that it was a new and better treatment.
Category: being grateful
The decision to go into the trial was facilitated by a degree of altrusim, prior research knowledge and the
low burden of the research process. There was a sense of privilege at being asked to be in a trial and a
need to give something back as a way of being grateful for the care they received: ‘I have done my bit’
(partcipant 9). It would also be ‘selfish’ (partcipant 10) not to help when they could ‘make it easier for
others’ (partcipant 19), particularly to the biker community (partcipant 11):
I am here, I’m a captive audience and what else have I got to do.
Partcipant 9
Having an appreciation of research and being a ‘quite keen supporter of science’ (participant 15), ‘the fact
that I appreciate research and I would always sign up for something like that if I was asked to, so it didn’t
bother me’ (participant 16), ‘I’m aware of the necessity for trials’ (participant 6) facilitated a decision to join
the trial. The trial processes were also of minimal burden and participants recognised this as no cost to
themselves and of limited effort:
At the end of the day I know it’s just information that you need to gather to get what you need.
It’s free, it doesn’t cost anything does it.
Participant 5
Category: being without prior experience
In making the decision to participate in the trial, participants felt that they did not really understand or
know the two interventions because they had not experienced them before. For some, a visual image of
what the other intervention was like would help:
I don’t know because I don’t know what the sucking thing is or what it’s like. I probably wouldn’t
have minded. I probably would have just accepted that this is what they’re doing for the best. Because
I’ve never had one of the suction dressings before I don’t know what it’s like so I can’t really compare
it. I can’t really comment on it. I’m just happy that they’ve done what they’ve done.
Participant 17
There was a technological preference for the NPWT gained from those with family in medical positions,
interactions with the clinical team and from personal experience. The staff focus group indicated that the
majority of staff were in equipoise regarding the use of NPWT; however, if, as occurred occasionally, a
preference was stated, the patient was entered in a trial. Patients considered the NPWT to be ‘another
piece of clever technology’ (participant 3) that provided security and was visible [‘you can see something
there, less pressure on the foot’ (participant 7)] and ‘reduced the smell’ (participant 19). It was felt to be a
good option and had ‘helped’ them. They wanted other people to know about the benefits of the NPWT
(participant 19). The NPWT dressing was good because it sucked up the ‘goo’ (participant 2), removed
‘nasty fluid’ (participant 20), took the ‘bad stuff’ (participant 19) away that would otherwise be sitting
there ‘festering’ (participant 2) and was felt to be particularly important if the wound was dirty [‘loads of
dirt and building stuff went in my legs’ (participant 20)]. Based on personal experience there was a desire
to have NPWT should they ever require one again:
I would say I would have that again. I would ask them to use that one instead of the normal one.
Participant 20
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The dressing was considered to have an active element ‘propelling your recovery’ (participant 19) and
‘increasing blood flow’ (participant 15). It was also considered a ‘clean space’, ‘sealed’, ‘impervious’
(participant 15) and a protective advantage as dirt could not enter the wound:
. . . I’d be happy if, say, the kids came in and got a bit of mud over it, I feel that it’s protective, it is
because there’s plastic over it there isn’t much that could get into it unless it’s cut but with a normal
bandage dressing it means having to change the whole bandage but the vac dressing [NPWT] you just
wipe down.
Participant 19
The combination of actively taking fluid away and being enclosed enabled participants to experience a
psychological advantage and a feeling of reassurance:
Rather than bandages soaking up all the goo that was coming off to see it being mechanically
extracted for me was as engineer more reassuring than just stood there. I wouldn’t like to think that
my leg could lay in a puddle of goo when it could be freshly vacuumed, so in a way I found that
reassuring. That was good enough for me so there were no issues there.
Participant 2
The decision to go into the trial was made against a background of a high degree of technological
intervention required at this stage of their care so ‘having another tube wouldn’t have really bothered me
at all’ (participant 11). But there were challenges around the NPWT, particularly in relation to movement.
Tubes could get caught up when patients were sleeping, and carrying the dressing pack when walking
with a frame or crutches created issues with balance and concern about falling. Some were concerned
about moving in case they damaged anything: ‘you are very scared to move’ (participant 15). Some would
have preferred not to see the fluid flowing though the tube (participant 3). Dressing changes could cause
excruciating pain as a result of removal of hairs along with the dressing and extremely sensitive skin which
stung after removal:
The actual time came when they were removing the dressing that was definitely the most painful
moment . . . it really was quite painful . . . they got it off eventually, it made me sweat a little bit and
I was pulling on the covers of the bed and squeezing it that tight that they’re still probably trying to
get the creases out now with the iron.
Participant 2
Participants with the standard dressing were accepting of it. There was a feeling that the dressing was
‘just there’ and that, as long as they were not ‘in pain’ (participant 10) and the nurses kept the wound
clean [‘as long as I see it being cleaned properly’ (participant 1)], they were happy with it. Reflections on
whether or not the dressings actually worked reflected the lack of knowing until the wounds healed or an
infection occurred:
I suppose having fractured it in the house there’s not going to be an awful lot of bad contamination,
it’s probably a lower risk than if I had fractured it at football but I don’t know until it heals up perfectly
well and I don’t get infected do I?
Participant 6
Being compromised by the nature of the injury meant that participants were dependent on the clinical
team to get them through acute recovery towards their lives outside hospital. They trusted the team and
invested their hopes in the ability of the team. Being grateful for the care they received and feelings of
altruism facilitated their decision to go into the trial. The type of dressing they received was considered a
small aspect of their care and they were generally happy for the team to put them in the trial with presumed
consent. However, some preferred to be informed and remembered the conversation later on when
approached for their written consent to continue in the trial. Participants also felt that their decision-making
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was compromised as they did not have prior experience of the two treatments; however, those with
experience of the NPWT clearly demonstrated a preference for this.
Overall summary
The core concept of embodied vulnerability conveyed the enormity of the impact of injury for this group;
the experience of hospitalisation, while feeling grateful for being saved and lucky that it was not worse,
was an emotional rollercoaster. They experienced strong emotions, often to a degree they had not felt
before, severe pain, shock and fear in relation to their injured body. There was a physical and emotional
fragility which, despite inner strength and determination, meant that they had few reserves to fall back
on when they encountered a new threat to their body. Repeated surgery, severe pain, anxiety and fear
lowered their ability to contain their emotions and led to what they described as meltdowns. Injury had
changed their lives and they reframed their future in the context of uncertainty in relation to their return
to normal function, their home lives, their hobbies and their work. Taking part in the trial was within the
context of being compromised by the acute event, placing their trust in the clinical team and a feeling of
being grateful for their care. A lack of experience of the two interventions limited their decision-making
ability but, once they had experience of the interventions, a technological preference was identified.
Discussion
The discussion explores embodied vulnerability through the four themes: (1) being emotionally fragile,
(2) being injured, (3) living with injury and (4) being compromised.
Being emotionally fragile
Being emotionally fragile can be explained through notions of an ‘emotionally fragile body’: making sense
of the event and injury, learning to live with uncertainty and processing strong emotions were part
of recovery.
Making sense of the event
Feeling close to death after a traumatic event is common in trauma patients50 and evident in people
who have experienced a vehicle collision,51 many of whom repeatedly relive the event. In this study,
interviewees talked about the event in great detail. Some had met the crew who transported them to
hospital, which helped them to make sense of what had happened and the resulting nature of the injury.
Making sense of their experience, filling missing gaps in their memory, sorting out what is real/unreal and
finding familiar things is evident in others who have been critically ill.52 Ogilvie et al.53 note how survivors
of a life-threatening injury are helped to make sense of the injury by their families, who make connections
between their past, present and future life. In situations when loss leads to prolonged grief, Maccallum
and Bryant54 suggest that memories need to become integrated with autobiographical information to
enable contextualisation in order to facilitate recovery. Feeling lucky to be saved provides a certain degree
of comfort from the harsh reality of the consequences of the event: an outlook that is viewed by others
as cognitive restructuring.33 Talking about the event, and the feelings engendered, asking questions and
listening to others’ experiences may help them make sense of what has happened and incorporate it into
their life story.
Living with uncertainty
Living with uncertainty was part of the emotional work inherent in being emotionally fragile. The future for
participants felt largely unknown owing to the unfolding nature of clinical interventions combined with
anxiety regarding possible loss of a limb. Learning to live with uncertainty is a core concept evident in
many conditions.55,56 Morse and Penrod57 suggest that uncertainty is present when the outcome is clear
but the route to achieve it is not. In this study, there was uncertainty regarding healing, further treatment
and return of function; the hoped-for outcome of a return to normal was not necessarily achievable.
Aspirational hope was expressed in participants’ desire to ride their motorbikes again or to walk their
daughters down the aisle: hopes which can be sustaining during recovery.58 Although some took control
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to limit uncertainty such as smoking cessation, the participants had to learn to live with continued
uncertainty about the future. Living in the present, a ‘wait and see’ approach and focusing on small
obtainable goals has been noted as helpful in early recovery from trauma.59 Later on in recovery, the sense
of uncertainty through closeness to injury and death can be experienced as heightened awareness of
potential danger60 and changing activities to minimise danger.51 Strategies to help participants to process
anxiety and fear created by injury and continued treatment such as counselling or coaching may help them
make sense of uncertainty within the context of their life.
Processing strong emotions
The injury event, hospitalisation and treatment resulted in an emotional rollercoaster, as noted in other
research.35,50 Participants experienced strong emotions, often a new experience for them, and their ability to
contain their emotions was impaired. Seeing their family/friends demonstrably upset was also particularly
hard. Morse et al.61 suggests that emotions spill out when people move from a state of enduring or
emotional containment towards a more emotionally expressive state of suffering. Containment of emotions
is identified by Lawlor62 as ‘the ways in which emotion is experienced or avoided, managed or denied, kept
in or passed on, so that its effects are either mitigated or amplified’. In this study, participants demonstrated
a determination to mitigate the enormity of their emotional response in order to protect their family and
friends, to maintain a sense of normality for them. Parallels can be drawn with work in a burns unit, in which
‘the trauma bubble’ describes containment of emotions that threaten the self; acting as a form of insulation
that can lead to isolation from others.63 Clifton,64 from his auto ethnography of spinal cord injury, argues that
expressing grief is an important part of processing loss and that feelings of ‘sadness, anger and melancholy’
are part of the process towards acceptance of injury. Interviewees with high levels of stress and anxiety up to
23 months after injury identified ongoing strong emotions of frustration, fear, despair and thoughts of
death. They also felt that emotional recovery was not highly valued within trauma services.60 The experience
of overwhelming strong emotions as a result of injury suggests that emotional suffering needs a higher
profile alongside physical suffering and an exploration of interventions that might be helpful for this group.
Being injured
Being injured highlighted the difficulty of being a person with wounds and of the visibly wounded body on
the sense of self, living in a constrained way with the need for full intimate bodily help, and enduring and
managing being in pain.
Sense of self
Interviewees experienced their bodies as changed beyond recognition and they had no immediate
resources of comfort from which to draw. From experiences of having a stoma, Thorpe et al.65 presents
this as a ‘loss of embodied wholeness’, when a part of the body becomes separated from the subjective
self. This was evident when legs were referred to in the third person or they felt detached from their body.
Morse66 and Morse and Mitcham67 note how patients with burns disembody damaged parts of their body
to maintain control of their sense of self. Often staff used a similar approach referring to removal of ‘the
leg’, presenting it as separate from the person. In our study, the participants referred to their wounds as
revolting, disrupting their ability to walk and care for themselves, similar to the ‘awareness of a disrupted
lived body’ in Thorpe et al.65 Using the model of altered body image presented by Price,68 there was a
gap between the body reality and the body ideal, how individuals would like their bodies to be, and a
disruption in body presentation to others. This exposed them to notions of disfigurement and stigma,
and there was concern about how the world would react to them as damaged people and as potential
wheelchair users. In a study of burns, by Johnson et al.,69 participants developed a sense of self-acceptance
in relation to their changed ‘physical otherness’. In our study, family members’ and friends’ responses to
patients’ wounds was important, and interviewees did not want loved ones to feel as horrified as they did
on seeing their wounds. Gullick et al.63 highlight the vicarious suffering of family and friends, also termed
‘compathy’ by Morse and Mitcham.67 Preparation through instruction and feelings of readiness to see their
wounds were important. In time, and with exposure to the wound, participants began to assimilate the
wound as part of themselves, but this was not easy. Support was required to help them and their families
process their emotions and enable them to understand their wounds and the likely process of healing.
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Living in a constrained way
Living in a constrained way was a form of embodied endurance as identified by Keene et al.37 in patients
with an unstable ankle fracture who were non-weight bearing. Participants’ geographical space had
shrunk to the bed/chair and room in a hospital ward. The resulting frustrations of living with a ‘constrained
body’ had to be endured, a state recognised by Morse and Penrod57 alongside suffering, uncertainty and
hope. Their injured body had become a source of constraint, disrupting their way of being in the world
and they had to rethink the simplest of activities as in the non-spontaneous body identified by Kvigne and
Kirkevold.70 If they were able to move, they were reliant on crutches, walking frames and support from
others, evident in the extended body.70
Dependence on others for their comfort, privacy and dignity was frustrating and participants struggled
with bedpans, plastic mattresses and a variety of hospital appliances. While finding technology reassuring,
they were also frustrated by it, a dissonance noted by Stayt et al.71 Dependence on others for intimate
bodily activities, termed the dependent body by Kvigne and Kirkevold,70 was also frustrating, and
there was relief when they could get to the toilet. The indignity created by hospital life is noted by
other patients.72 Dependency in early recovery can put a strain on relationships and can continue in
longer-term recovery.73 The pace of life for participants was slower than normal, and there was an increased
watchfulness for bodily changes that may or may not indicate healing. Increased bodily surveillance is evident
in other injuries37 and the importance of being watchful in self-management of musculoskeletal disorders has
been recognised.74 Frustrations with living in a constrained way were expressed by participants but largely
endured, and emotions contained as a means of getting on with daily hospital life.
Being in pain
Being in pain was something that all participants struggled with at some point during their hospitalisation.
The energy required to endure ongoing pain reduced their ability to handle their daily life and contributed
to their emotional fragility. Pain is recognised as part of the experience of injury and surgery75 and is
difficult to manage. Other studies of lower limb injury identify pain as a key problem.32,34,35 Studies
specifically including open fracture of the lower limb34 identify getting through the pain and seeking
control as two key experiences. Pain management was an overriding concern, and patients struggled to
live with the pain and manage the side effects of medication. The resilience required to manage a ‘painful
body’ can be considerable; Gullick et al.63 note the all-consuming nature of embodied pain whereby it is
difficult to carry out other functions. The emotional impact is also evident in pelvic pain, the experience of
which can be an ‘overwhelming emotional rollercoaster’.76 For participants in this study, being in pain was
an inherent part of being injured, and considerable energy was required to manage and learn to live with
the pain. The embodied nature of pain was expressed through the interrelationship of pain with emotions,
their ability to function, uncertainty and hopes for the future. Opportunities for better clinical management
of pain may ease the burden of being in pain and facilitate their ability to manage their recovery.
Living with injury
Living with injury incorporated a way of envisaging the future: both being at home and being at work.
Being at home
Interviewees expressed a high level of optimism and determination to go home alongside the ideal of
returning to normal, as found in other studies in trauma.59 A degree of readiness, based on feelings of
wellness/mental energy, was required before they could think of home. There was sadness at what they
had lost but also a feeling of being lucky that they had a future. Planning for the future was an embodied
process that required emotion work and involved reimagining how life would be for them and their family.
This was undertaken with a high degree of uncertainty about their recovery and what the future would be
like. Rethinking and reimagining may provide some form of control over the future. Ogilvie et al.53 suggest
that this may be helpful when the future is unknown in terms of recovery. There was an awareness that
they might have false hope about what they may achieve, particularly in relation to their hobbies such as
riding a motorbike. But these hopes conveyed a sense of aspiration and could be a source of motivation
for recovery, as in other specialties.58 Richmond et al.73 identified the long-lasting impact of injury that
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required energy and resilience in order to move on in daily life. Continued disability and dependency
in their study could both reduce or increase opportunities in life. In this study, the participants were
developing a sense of preparedness for the transition to home but could not fully imagine what it would
be like until they had experienced it.
Being at work
Rethinking and reimagining continued in relation to returning to work, which felt like a much longer-term
goal. There was a strong sense of uncertainty, linked to ability to recover and return to normal function.
Many of those in manual jobs felt that it was unlikely that they could return to the same job; others
imagined how they could reconfigure their work to facilitate their return. Johnson et al.69 note how patients
with burns rethink how they will manage at work and struggled when medical staff did not understand
their fear or anxiety. They experienced a slow return to normal, with a gradual increase in the number of
good days; however, normal was tangibly different from their pre-injury normal. Some injured participants
questioned their role in society and needed to find meaning in their very existence.53 In this study, there was
evidence for some of a re-evaluation of life plans and opportunity to make a new path in their working life.
At this stage of recovery, what it was like to be at work was unknown and hard to imagine.
Being compromised
The findings identify that making a decision to take part in a trauma trial takes place within the context of
participants’ broader experience of recovery. Participants experienced being in the trial within the context
of being compromised and being dependent on others to facilitate their recovery. The type of wound
dressing was a small part of a much larger life-changing experience. This may be similar to the finding that
women chose to take part in oncology drug trials because of their cancer treatment goals rather than
because of information they received about the trial.77 Therapeutic misconception37,38,40 was present on
occasions, with some participants trusting the clinicians to provide the right treatment for them. However,
the nature of their trust was also based on their belief that the team had saved them and that they were
lucky to be alive; they focused on a longer-term hope that the clinical team would be able to lead them to
recovery, not noted in other studies. There was some evidence that information about the study before
surgery, despite being compromised, was useful for participants and could facilitate a feeling of being
involved and having a say in their care. The principles of inclusionary consent in which individuals can
actively take part despite their current limitations as identified in dementia care78 may, therefore, have
utility in emergency orthopaedic trauma studies.
Participants’ rationale for taking part or continuing with the study was gratitude for the care they
received, which included some element of altruism also found in other studies.38,39,43,79 Some subgroups
of patients felt that they were helping their peer-group as well as society more generally, for example
the motorcycle community, whose fractures are often open. The limited burden of follow-up activities
on participants was also important.38,39 In relation to understanding the trial, not having experience of the
two dressings added to participants’ belief that they were not really in a position to judge the utility of
the dressings and, hence, they trusted that staff would not support a trial that would cause them harm.
Experiential knowledge was also important to participants in the ankle injury management study.37
However, once the NPWT had been experienced, there was a strong technological preference for the
dressing as it was considered cleaner and had a visible, dynamic component of suction, which removed
exudate away from the wound. Participants reported that they wanted this intervention if they ever had a
wound again, suggesting that experience was important to how they make sense of an intervention.
Limitations
The sample was purposive in relation to gender, age, severity of injury and a range of experience;
however, it was not ethnically diverse. The study was undertaken in hospital where privacy and dignity
were negotiated but could not be ensured. A more private setting may have facilitated deeper explorations
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of the concepts; however, the participants were keen to talk and often asked if another meeting was
possible. A longitudinal study would help to highlight the change in concepts over time.
Conclusions
This study, the first exploring lower limb injury in acute care, adds to current evidence through the
identification of the concept of embodied vulnerability as a result of lower limb injury, which conveys the
vast amount of emotional and physical work undertaken by participants while in hospital. It demonstrated
that patients, although comfortable with others leading on informed consent, wished to be involved to the
extent of their abilities at the time. The focus of the study in this case was of minimal concern but they did
have a strong preference for NPWT once they had experience of this dressing. Lack of experience of the
interventions was an important factor and influenced how they understood the study. Trust in the team
went beyond therapeutic misconception but was linked to longer-term hopes of recovery. The study
highlights how previous taken-for-granted ways of being in the world were changed and new ways of
being, incorporating their injury, were sought. Participants were actively processing the impact of injury
and treatment and staff have a vital role to play in supporting this activity through the early recovery
phase. Supportive activities may include emotion-focused activities related to emotional fragility enabling
them to make sense of the event, live with uncertainty, process strong emotions, integrate their injury with
their sense of self, develop resilience for managing pain and envisage the future. Potential for further
support at this stage will require exploration in light of patient-important outcomes along the recovery
continuum. Implications for practice are to create a heightened awareness of emotional work and a
requirement for skills to support this work, resources to provide time for specific supportive work such as
coaching, innovative ways of facilitating better active management of pain, and creative ways of helping
participants envisage the future to ease their transition to a home/work environment.
Summary
l Both treatment groups, those receiving standard dressings and those receiving NPWT, require support,
when possible, to ease their experience of vulnerability caused by traumatic injury. That support should
focus on (1) participants’ emotional fragility, closeness to death and/or loss of a limb and helping them
to process strong emotions while containing their emotions for the benefit of other people; (2) the
state of being injured and participants’ changed sense of self as they became a person with wounds,
are constrained by their broken body and live with pain; and (3) living with injury and reimagining how
it will be at home and at work in the future.
l Both treatment groups wanted to be involved within the limits of their ability in this emergency
orthopaedic trauma trial. They were comfortable with other people providing informed consent
because of their own physical/emotional state and the treatment of the wound being of comparative
low importance at that time.
l Both groups had an overall faith in the team regarding their longer-term recovery and hopes for the
future and trusted that they would not put them in a study that caused them harm.
l Both groups felt that they did not really know the interventions as they had no experience of them but
those who had NPWT developed a strong technological preference for this treatment.
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Chapter 4 Results
Screening
Patient screening for potential study participants started in July 2012, with n = 2434 patients screened.
For 1809 patients, the local research associate provided the reason for ineligibility (Table 3).
Rates of primary closure increased during the course of the WOLLF study, from 34.5% in 2012 to 56.6%
in 2015. Figure 2 shows changes in primary closure during study recruitment. The increase in the rate of
primary closure was statistically significant; a Poisson regression model for counts provided a regression
coefficient for the recruitment year term of 1.2 (95% CI 1.1 to 1.3; p < 0.001). The relative rate of increase
in primary closures was approximately 20% per year.
TABLE 3 Reasons for ineligibility by recruitment year
Reason
Year
Total %2012 2013 2014 2015
Aged < 16 years 2 14 12 12 40 2.2
Presented/transferred to trial hospital > 72 hours after injury 7 25 35 26 93 5.1
Fracture G&A grade 1 11 65 87 73 236 13.0
Patient unable to adhere to trial procedures 4 23 80 50 157 8.7
Amputation 3 3 18 13 37 2.0
Primary closure 19 139 316 401 875 48.4
Other/unknown 8 52 79 71 210 11.6
Missed 0 16 36 34 86 4.8
Randomisation temporarily suspended 0 12 2 0 14 0.8
Surgeon decision 1 5 22 21 49 2.7
Surgeon preference: NPWT 0 0 1 0 1 0.1
Surgeon preference: standard dressing 0 0 3 0 3 0.2
Polytrauma or unlikely to survive 0 1 0 5 6 0.3
No pump available 0 0 0 2 2 0.1
Total 55 355 691 708 1809 100
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Recruitment
Overall recruitment and recruitment by centre
A total of 625 patients were recruited and randomised into the study. Of these, 460 were consented.
Recruitment started in July 2012 and was completed in December 2015. Recruitment took place at 24 centres:
1. Royal London Hospital
2. Poole Hospital
3. Aintree University Hospital
4. Leeds General Infirmary
5. Addenbrookes Hospital, Cambridge
6. University Hospital Southampton
7. Northern General Hospital Sheffield
8. Queen Alexandra Hospital
9. Royal Berkshire Hospital
10. Kings College Hospital
11. University Hospital of North Staffordshire
12. Plymouth Hospitals
13. University Hospital Coventry and Warwickshire
14. Norfolk and Norwich University Hospital
15. Queen Elizabeth Hospital, Birmingham
16. Royal Victoria Infirmary
17. Royal Derby Hospital
18. John Radcliffe Hospital
19. Frenchay Hospital
20. Hull Royal Infirmary
21. University Hospital Leicester
22. Nottingham University Hospital
23. Royal Sussex County Hospital, Brighton
24. Morriston Hospital Swansea.
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FIGURE 2 Rates of primary closure from 2012 to 2015 in screened population. Observed rates (circles) with 95% CIs,
fitted line (solid line) and 95% CI on fit (dashed line).
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For those patients who lacked capacity to consent prospectively, consent for continuation in the trial
was made at the first appropriate time point in the postoperative period. Therefore, a proportion of
randomised patients did not consent to be in the study. Table 4 shows that a total of 625 patients were
recruited and randomised, with 460 consenting to take part in the study and 165 not consenting.
The planned overall required recruitment rate for the WOLLF study was approximately 0.75 patients per
centre per month, based on 460 patients recruited and consented over 36 months at 24 centres.
Overall recruitment across centres was 0.7 patients per month. This was lower than the planned rate, based
on the original recruitment period, therefore the trial recruitment period was extended by 3 months to the
end of 2015 to reach the target of 460. Full details of recruitment by centre are shown in Appendix 1
(see Table 34).
Population characteristics
The breakdown of the recruited population (n = 625) by age group (< 40 and ≥ 40 years), gender and
treatment group is shown in Table 5.
The majority (444/625; 71.0%) of patients recruited to the trial were male. There was also a clear
difference in age structure between genders. Figure 3 shows age distributions by gender.
The figures show the relative size of male and female population recruited to the study and also the
differing age structure between genders. Males were predominantly younger [median age 39 years;
interquartile range (IQR) 26–52 years] and females were older (median age 61 years; IQR 44–79 years).
This is probably due to differences in the mechanism of injury between genders (see Table 10).
TABLE 4 The WOLLF study recruitment and consent
Treatment group
Consented
TotalNo Yes
NPWT 85 226 311
Standard 80 234 314
Total 165 460 625
TABLE 5 Recruitment by treatment group, age group and gender
Gender Age group (years)
Treatment group, n (%)
TotalNPWT Standard
Male < 40 123 (55) 102 (45) 225
≥ 40 115 (53) 104 (47) 219
Female < 40 16 (47) 18 (53) 34
≥ 40 57 (39) 90 (61) 147
Total 311 314 625
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Consented participants and interventions
Consented and non-consented participants
Figure 4 shows the study CONSORT (Consolidated Standards of Reporting Trials) plot. Of the 625 participants
recruited into the study, 460 consented to take part. The pattern and number of pre-consent withdrawals
were well balanced between intervention groups (NPWT group, n= 85; standard dressing group, n= 80).
Only a small proportion of those randomised decided subsequently not to consent to take part in the
study [NPWT group, n = 14 (4.5%); standard dressing group, n= 15 (4.8%)]. The main reason for
post-randomisation (pre-consent) withdrawal was primary closure of the index wound during surgery
(NPWT group, n = 20; standard dressing group, n = 18). This made the patients ineligible for entry into
the study.
Table 6 presents the characteristics of those consented and those not consented.
A chi-squared test indicated that the proportion of females was significantly (p = 0.037) higher in the
non-consented population than in the consented population: 34.5% (57/165) versus 25.7% (118/460).
The difference in median age between the consented and non-consented population was 5 years (43 years
for consented; 48 years for non-consented). Analysis indicated that this difference did not quite reach
statistical significance (Mann–Whitney U-test; p = 0.056). Therefore, we conclude that patients who
declined to consent, who were not able to consent or who were ineligible for inclusion in the study after
initial recruitment were generally older and more likely to be female than those who consented to take
part (see Figure 3, distribution of patient age by gender).
604020
0
20
40
60
Fr
eq
u
en
cy
80
(a)
100
120
80 100
Age (years)
604020
0
20
40
60
Fr
eq
u
en
cy
80
(b)
100
120
80 100
Age (years)
FIGURE 3 Age distribution by 10-year age bands for (a) males and (b) females. Solid lines show smoothed distributions.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
36
Randomised
(n = 625)
Consented
(n = 460)
NPWT
(n = 311)
Standard
(n = 314)
Allocated (ITT):
NPWT
(n = 226)
Allocated (ITT):
Standard
(n = 234)
Received (PP):
NPWT (n = 211) 
Received (PP):
Standard (n = 226)
• Standard, n = 15
Withdrawn (n = 85) 
• Declined to consent (n = 14)
   • Not happy being part of research, n = 9
   • Does not want to complete
      questionnaires, n = 3
   • Other, n = 2
• Unable to adhere to trial procedures (n = 17)
• Permanent cognitive impairment (n = 3)
• Unable to consent before 6-week FU (n = 12)
• Other (free text) (n = 39)
   • Amputation, n = 1
   • Death, n = 8
   • Primary closure, n = 20
   • Randomised in error, n = 5
   • Transferred, n = 2
   • No reason, n = 3
Withdrawn (n = 19) 
• Withdrew consent (n = 7)
   • Not happy being part of research, n = 5
   • Does not want to complete
      questionnaires, n = 1
   • Other, n = 1
• Unable to adhere to trial procedures (n = 5)
• Other (free text) (n = 7)
   • Death, n = 6
   • No reason, n = 1
Withdrawn (n = 80) 
• Declined to consent (n = 15)
   • Not happy being part of research, n = 6
   • Does not want to complete
      questionnaires, n = 3
   • Other, n = 6
• Unable to adhere to trial procedures (n = 15)
• Permanent cognitive impairment (n = 9)
• Unable to consent before 6-week FU (n = 5)
• Other (free text) (n = 36)
   • Amputation, n = 1
   • Death, n = 6
   • Primary closure, n = 18
   • Randomised in error, n = 8
   • Transferred, n = 2
   • No reason, n = 1
Withdrawn (n = 14) 
• Withdrew consent (n = 9)
   • Not happy being part of research, n = 6
   • Does not want to complete
      questionnaires, n = 2
   • Other, n = 1
• Unable to adhere to trial procedures (n = 0)
• Other (free text) (n = 5)
   • Death, n = 4
   • No reason, n = 1
• NPWT, n = 8
FU (DRI):
• Baseline, n = 220
• 3 months, n = 166
• 6 months, n = 154
• 9 months, n = 153
• 12 months, n = 179
FU (DRI):
• Baseline, n = 230
• 3 months, n = 189
• 6 months, n = 176
• 9 months, n = 162
• 12 months, n = 195
FIGURE 4 The WOLLF study CONSORT plot. FU, follow-up.
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Interventions
Table 7 shows the details of operative procedures by study intervention arm. There were no important
differences in the length of the operation, surgeon experience, intraoperative problems or additional
injuries between the intervention groups.
Treatment allocation
There were 23 deviations (crossovers) from the allocated treatment (NPWT group, n = 15; standard
dressing group, n = 8). Unavailability of equipment accounted for two crossovers in the NPWT group
and one in the standard dressing group. In nine cases in the NPWT group, the surgeon chose to use a
different dressing, and, in three cases in the standard dressing group, the surgeon chose to use NPWT.
There were four cases in each group in which the allocated dressing was not communicated to the
operating team.
The details of the types of dressing used for the standard and NPWT interventions are shown in Table 8.
There were 241 standard dressing procedures in total (226 in the standard dressing arm of the study and
15 in the NPWT arm). The median number of dressing changes was 1 for the standard dressing arm
(IQR 0–2). There were 219 NPWT procedures in total (211 in the NPWT arm of the study and eight in the
standard dressing arm). The median number of dressing changes for the NPWT arm was 1 (IQR 0–2).
Baseline characteristics
Unless stated otherwise, all analyses reported here are on an ITT basis, that is, by allocated treatment.
TABLE 6 Study participant characteristics at randomisation: consented and non-consented
Characteristic
Treatment group
Consented (N= 460) Non-consented (N= 165)
NPWT (n= 226) Standard (n= 234) Total NPWT (n= 83) Standard (n= 82) Total
Consent type, n (%)
Hospital data 1 (0.4) 2 (0.9) 3 – – – – –
Prospective 19 (8.4) 24 (10.3) 43 – – – – –
Retrospective 206 (91.2) 208 (88.9) 414 – – – – –
Gender, n (%)
Female 48 (21.2) 70 (29.9) 118 27 (32.5) 30 (36.6) 57
Male 178 (78.8) 164 (70.1) 342 56 (67.5) 52 (63.4) 108
G&A grade,a n (%)
2 34 (15.0) 30 (12.8) 64 12 (14.5) 17 (20.7) 29
3 171 (75.7) 180 (76.9) 351 62 (74.7) 59 (72.0) 121
3C 21 (9.3) 24 (10.3) 45 9 (10.8) 6 (7.3) 15
Age group (years), n (%)
< 40 102 (45.1) 99 (42.3) 201 36 (43.4) 29 (35.4) 65
≥ 40 124 (54.9) 135 (57.7) 259 47 (56.6) 53 (64.6) 100
Age (years), median (IQR) 42 (29–61) 43 (26–57) 50 (28–65) 48 (29–68)
a A G&A grade 3C is any open fracture with accompanying vascular injury requiring repair.
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TABLE 7 Operative procedure details. Percentages are based on full population size. If they do not sum to 100%,
it indicates that some values are missing
Characteristic
Treatment group
TotalNPWT (N= 226) Standard (N= 234)
First operative procedures
Lead surgeon grade, n (%)
Consultant 148 (65.5) 165 (70.5) 313
Associate specialist 10 (4.4) 11 (4.7) 21
Specialist trainee 56 (24.8) 49 (20.9) 105
Other 9 (4.0) 7 (3.0) 16
Number of surgeons, median (IQR) 2 (1–2) 2 (1–2)
Operation time in minutes, median (IQR) 126 (90–182) 120 (86–183)
Side, n (%)
Left 118 (52.2) 111 (47.4) 229
Right 108 (47.8) 123 (52.6) 231
Bone, n (%)
Femur 16 (7.1) 26 (11.1) 42
Patella 3 (1.3) 2 (0.9) 5
Fibula/tibia 187 (82.7) 192 (82.1) 379
Foot 20 (8.8) 13 (5.6) 33
Type of fixation, n (%)
Nail 49 (21.7) 56 (23.9) 105
Plate and screws 38 (16.8) 32 (13.7) 70
Wires/tension band wires 7 (3.1) 3 (1.3) 10
External fixator-half-pin 107 (47.3) 111 (47.4) 218
External fixator-fine-wire 3 (1.3) 11 (4.7) 14
Other 21 (9.3) 21 (9.0) 42
Intraoperative problems, n (%)
No 212 (93.8) 213 (91) 425
Yes 14 (6.2) 21 (9) 35
Nerve injury
No 222 (98.2) 234 (100) 456
Yes 4 (1.8) 0 (0) 4
Vascular injury
No 222 (98.2) 228 (97.4) 450
Yes 4 (1.8) 6 (2.6) 10
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TABLE 7 Operative procedure details. Percentages are based on full population size. If they do not sum to 100%,
it indicates that some values are missing (continued )
Characteristic
Treatment group
TotalNPWT (N= 226) Standard (N= 234)
Tendon injury
No 221 (97.8) 228 (97.4) 449
Yes 5 (2.2) 6 (2.6) 11
Extension of fracture
No 225 (99.6) 231 (98.7) 456
Yes 1 (0.4) 3 (1.3) 4
Other problems
No 220 (97.3) 227 (97) 447
Yes 6 (2.7) 7 (3) 13
Surgeon satisfaction with debridement, n (%)
No 1 (0.4) 3 (1.3) 4
Yes 201 (88.9) 210 (89.7) 411
Surgeon satisfaction with dressing, n (%)
No 6 (2.7) 4 (1.7) 10
Yes 195 (86.3) 208 (88.9) 403
Other surgery at time of wound debridement, n (%)
No 148 (65.5) 149 (63.7) 297
Yes 78 (34.5) 85 (36.3) 163
Other operative procedures
Head, n (%)
No 215 (95.1) 231 (98.7) 446
Yes 11 (4.9) 3 (1.3) 14
Chest, n (%)
No 223 (98.7) 231 (98.7) 454
Yes 3 (1.3) 3 (1.3) 6
Abdomen, n (%)
No 219 (96.9) 230 (98.3) 449
Yes 7 (3.1) 4 (1.7) 11
Pelvis, n (%)
No 217 (96) 226 (96.6) 443
Yes 9 (4) 8 (3.4) 17
Spine, n (%)
No 222 (98.2) 231 (98.7) 453
Yes 4 (1.8) 3 (1.3) 7
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TABLE 7 Operative procedure details. Percentages are based on full population size. If they do not sum to 100%,
it indicates that some values are missing (continued )
Characteristic
Treatment group
TotalNPWT (N= 226) Standard (N= 234)
Upper limb, n (%)
No 203 (89.8) 209 (89.3) 412
Yes 23 (10.2) 25 (10.7) 48
Ipsilateral limb, n (%)
No 193 (85.4) 189 (80.8) 382
Yes 33 (14.6) 45 (19.2) 78
Ipsilateral limb fracture, n (%)
Open 13 (5.8) 18 (7.7) 31
Closed 13 (5.8) 21 (9.0) 34
Contralateral limb, n (%)
No 201 (88.9) 203 (86.8) 404
Yes 25 (11.1) 31 (13.2) 56
Contralateral limb fracture, n (%)
Open 6 (2.7) 10 (4.3) 16
Closed 13 (5.8) 15 (6.4) 28
Treatment of other open injuries, n (%)
Standard 13 (5.8) 18 (7.7) 31
NPWT 7 (3.1) 3 (1.3) 10
Primary closure 10 (4.4) 12 (5.1) 22
Flap graft 1 (0.4) 1 (0.4) 2
Other 0 (0.0) 1 (0.4) 1
No other open injuries 195 (86.3) 199 (85.0) 394
Prophylactic antibiotics, n (%)
No 5 (2.2) 3 (1.3) 8
Yes 200 (88.5) 209 (89.3) 409
Lead surgeon experience: number of open fractures, n (%)
< 5 2 (0.9) 3 (1.3) 5
5–10 7 (3.1) 11 (4.7) 18
10–20 16 (7.1) 13 (5.6) 29
> 20 195 (86.3) 197 (84.2) 392
Lead surgeon experience: number of NPWT dressings, n (%)
< 5 10 (4.4) 9 (3.8) 19
5–10 7 (3.1) 16 (6.8) 23
10–20 29 (12.8) 28 (12) 57
> 20 171 (75.7) 167 (71.4) 338
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Baseline participant characteristics
Table 9 shows the baseline patient characteristics for the 460 participants recruited and consented into the
WOLLF study.
Table 10 shows details of the mechanism of injury and the participants’ previous medical history.
Operative procedures
Table 11 reports the methods used for fixation (temporary and definitive) and wound closure in
planned operations.
There was no evidence to suggest that methods of closure or fixation differed between treatment groups
(see p-values in Table 11).
TABLE 8 Details of procedures by allocated intervention (NPWT, N = 219; standard, N= 241)
Procedure
Treatment group
TotalNPWT (N= 211) Standard (N= 8)
Number of dressing packs used, median (IQR) 1 (1–1) 1 (1–1) –
Pump pressure 125 mmHg, n (%)
No 35 (16.6) 3 (37.5) 38
Yes 156 (73.9) 3 (37.5) 159
Unknown 20 (9.5) 2 (25.0) 22
Pressure in mmHg, median (IQR) 125 (125–125) 100 (100–110) –
Number of days pump on, median (IQR) 3 (2–5) 5 (3–5) –
NPWT operation, n (%)
Continuous 163 (77.3) 2 (25.0) 165
Intermittent 13 (6.2) 1 (12.5) 14
Unknown 35 (16.6) 5 (62.5) 40
Irrigation, n (%)
No 181 (85.8) 4 (50.0) 185
Yes 7 (3.3) 1 (12.5) 8
Unknown 23 (10.9) 3 (37.5) 26
Irrigation and antibiotics, n (%)
No 2 (28.6) 1 (100) 3
Yes 3 (42.9) 0 (0.0) 3
Unknown 2 (28.6) 0 (0.0) 2
NPWT (N= 15) Standard (N= 226) Total
Antiseptic gauze, wool crepe bandage, n (%) 7 (46.7) 99 (43.8) 106
Bead pouch, n (%) 0 (0) 62 (27.4) 62
Other antibiotic-impregnated dressing, n (%) 0 (0) 5 (2.2) 5
Gauze, wool or crepe bandage, n (%) 2 (13.3) 57 (25.2) 59
Other, n (%) 0 (0) 1 (0.4) 1
Unknown, n (%) 6 (40) 2 (0.9) 8
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TABLE 9 The WOLLF study participants: baseline descriptive characteristics
Characteristic
Treatment group
TotalNPWT (N= 226) Standard (N= 234)
Gender, n (%)
Female 48 (21.2) 70 (29.9) 118
Male 178 (78.8) 164 (70.1) 342
Diabetes mellitus, n (%)
No 208 (92.0) 218 (93.2) 426
Yes 14 (6.2) 13 (5.6) 27
Age (years), median (IQR) 42 (29–61) 43 (26–57)
Height (cm), median (IQR) 175 (170–182) 175 (165–180)
Weight (kg), median (IQR) 79.4 (69.9–90.0) 78.5 (68.5–90.0)
Smoker, n (%)
No 149 (65.9) 151 (64.5) 300
Yes 70 (31) 79 (33.8) 149
If yes, how many smoked per day, median (IQR) 11 (9–20) 15 (10–20)
If yes, how many years, median (IQR) 15 (10–21) 15 (7–25)
Training, n (%)
None 76 (33.6) 84 (35.9) 160
Work-based training 51 (22.6) 44 (18.8) 95
Non-degree qualification 62 (27.4) 65 (27.8) 127
College/university degree 26 (11.5) 36 (15.4) 62
Employment, n (%)
Full-time employed 105 (46.5) 106 (45.3) 211
Part-time employed 9 (4.0) 14 (6.0) 23
Self-employed 25 (11.1) 31 (13.2) 56
Retired/inactive 44 (19.5) 44 (18.8) 88
Unpaid work 2 (0.9) 0 (0.0) 2
Unemployed 28 (12.4) 25 (10.7) 53
Full-time student 6 (2.7) 9 (3.8) 15
Alcohol per normal week (units), n (%)
0–7 130 (57.5) 141 (60.3) 271
8–14 33 (14.6) 46 (19.7) 79
15–21 28 (12.4) 17 (7.3) 45
> 21 27 (11.9) 24 (10.3) 51
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TABLE 9 The WOLLF study participants: baseline descriptive characteristics (continued )
Characteristic
Treatment group
TotalNPWT (N= 226) Standard (N= 234)
Marital status, n (%)
Single 84 (37.2) 80 (34.2) 164
Separated 5 (2.2) 8 (3.4) 13
Married/civil partner 63 (27.9) 87 (37.2) 150
Living with a partner 42 (18.6) 38 (16.2) 80
Divorced 13 (5.8) 10 (4.3) 23
Widowed 15 (6.6) 9 (3.8) 24
Ethnic group, n (%)
White 207 (91.6) 215 (91.9) 422
Black Caribbean 2 (0.9) 2 (0.9) 4
Black African 3 (1.3) 1 (0.4) 4
Black other 0 (0) 0 (0) 0
Indian 4 (1.8) 2 (0.9) 6
Pakistani 1 (0.4) 2 (0.9) 3
Bangladeshi 1 (0.4) 2 (0.9) 3
Chinese 0 (0) 0 (0) 0
Other 3 (1.3) 7 (3) 10
TABLE 10 The WOLLF study participants: mechanism of injury and previous medical history
Characteristic
Treatment group, n (%)
TotalNPWT (N= 226) Standard (N= 234)
Mechanism of injury
Low-energy fall 34 (15) 39 (16.7) 73
High-energy fall 34 (15) 25 (10.7) 59
Road traffic accident 125 (55.3) 139 (59.4) 264
Crush injury 17 (7.5) 19 (8.1) 36
Contact sports injury 3 (1.3) 1 (0.4) 4
Other 13 (5.8) 9 (3.8) 22
Hospital transfer
No 164 (72.6) 166 (70.9) 330
Yes 58 (25.7) 65 (27.8) 123
Other injury
No 168 (74.3) 158 (67.5) 326
Yes 58 (25.7) 76 (32.5) 134
Head
Yes 14 (6.2) 11 (4.7) 25
RESULTS
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TABLE 10 The WOLLF study participants: mechanism of injury and previous medical history (continued )
Characteristic
Treatment group, n (%)
TotalNPWT (N= 226) Standard (N= 234)
Chest
Yes 24 (10.6) 22 (9.4) 46
Abdomen
Yes 3 (1.3) 12 (5.1) 15
Pelvis
Yes 8 (3.5) 15 (6.4) 23
Spine
Yes 21 (9.3) 22 (9.4) 43
Upper limb
Yes 17 (7.5) 32 (13.7) 49
Ipsilateral limb
Yes 6 (2.7) 16 (6.8) 22
Ipsilateral limb fracture
Open 3 (1.3) 4 (1.7) 7
Closed 3 (1.3) 8 (3.4) 11
Contralateral limb
Yes 4 (1.8) 14 (6) 18
Contralateral limb fracture
Open 0 (0) 1 (0.4) 1
Closed 3 (1.3) 8 (3.4) 11
Previous problem with injured limb
No 163 (72.1) 175 (74.8) 338
Yes 63 (27.9) 59 (25.2) 122
Fracture
Yes 16 (7.1) 25 (10.7) 41
Ligament/tendon/nerve
Yes 12 (5.3) 9 (3.8) 21
Arthritis
Yes 13 (5.8) 8 (3.4) 21
Other
Yes 25 (11.1) 23 (9.8) 48
Regular analgesia before injury
No 193 (85.4) 201 (85.9) 394
Yes 28 (12.4) 27 (11.5) 55
Other medication before injury
No 126 (55.8) 133 (56.8) 259
Yes 84 (37.2) 94 (40.2) 178
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Primary outcome
The primary outcome measure for the WOLLF study was the DRI at 12 months post injury. Baseline DRI,
based on retrospective recall of pre-injury health, was also assessed, as was early disability at 3, 6 and
9 months. Table 12 shows the observed means and SDs for DRI and Figure 5 shows the full data
distributions and trends in the mean scores.
TABLE 11 Methods used for fixation and wound closure, by treatment group
Method
Treatment group
Total p-valuea
NPWT
(n= 226) %
Standard
(n= 234) %
Fixation
Temporary fixation: external 81 35.8 93 39.7 174 0.443
Temporary fixation: POP 1 0.4 1 0.4 2 1.000a
Definitive fixation: ORIF 88 38.9 92 39.3 180 1.000
Definitive fixation: IM nail 88 38.9 103 44.0 191 0.312
Definitive fixation: K-wire TBW 8 3.5 3 1.3 11 0.201
Definitive fixation: external circular frame 19 8.4 33 14.1 52 0.075
Definitive fixation: external half pin 17 7.5 12 5.1 29 0.387
Definitive fixation: external NOS 8 3.5 3 1.3 11 0.201
Definitive fixation: other 10 4.4 5 2.1 15 0.263
Segmental defect Masquelet first stage 4 1.8 6 2.6 10 0.752a
Segmental defect bone transport first stage 0 0.0 3 1.3 3 0.249a
Amputation 2 0.9 1 0.4 3 0.618a
Wound closure
Primary closure 37 16.4 47 20.1 84 0.363
Local flap 22 9.7 23 9.8 45 1.000
Free flap 90 39.8 82 35.0 172 0.336
Local flap and SSG 11 4.9 10 4.3 21 0.935
Skin graft 45 19.9 49 20.9 94 0.875
IM nail, intramedullary nail; NOS, not otherwise specified; ORIF, open reduction and internal fixation; POP, plaster of Paris;
SSG, split skin graft; TBW, tension band wire.
a Results of chi-squared test or Fisher’s exact test for those indicated.
TABLE 12 Means and SDs of DRI scores, by treatment arm
Treatment group
Time point, DRI scores
Pre injury Post injury 3 months 6 months 9 months 12 months
NPWT
n 220 – 166 154 153 179
Mean (points) 12.1 – 64.3 53.2 49.2 45.5
SD (points) 22.6 _ 22.3 23.8 25.9 28.0
Standard
n 231 – 188 175 161 195
Mean (points) 12.6 – 65.6 50.3 45.4 42.4
SD (points) 24.3 – 20.1 24.1 25.2 24.2
RESULTS
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The rates and method of data collection (face to face, postal, telephone or e-mail) are described in
Appendix 2 (see Table 35). The method of data collection was very similar between the groups.
Analysis of primary outcome
The primary outcome for the WOLLF study is DRI at 12 months post injury. DRI scores recover in the
postoperative period in both groups, but function is still worse than before the injury.
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FIGURE 5 Pre-injury baseline, 3, 6, 9 and 12 months. (a) Box plots of DRI scores and (b) trends in means (with 95% CIs).
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Table 12 shows the means and SDs by treatment group. A mixed-effects linear regression model is used to
estimate treatment differences (and 95% CIs). The full (planned) model incorporated terms that allowed for
possible heterogeneity in responses for patients owing to the recruiting centre (random effect), in addition to
the fixed effects of the wound grade (G&A grade), gender (male or female), patient age (< 40 years and
≥ 40 years), pre-injury DRI and the intervention groups (NPWT and standard dressing) on an ITT basis.
Table 13 shows the raw and adjusted estimates of treatment effects for DRI at 12 months and earlier
occasions; a negative value is in favour of the standard treatment, as lower DRI scores indicate less
disability. The covariates used to adjust the treatment effect estimates generally showed strong statistical
significance, indicating that the inclusion of these terms improved the overall model fit. For the 12-month
DRI model, a higher pre-injury DRI was associated with a higher 12-month DRI (p < 0.001); 12-month DRI
was higher (i.e. they were more disabled) for participants aged ≥ 40 years than those aged < 40 years
(p < 0.001); and 12-month DRI was higher for those participants with G&A grade of 3, or 3 with vascular
involvement, than for those participants with G&A grade of 2 (p = 0.047).
The adjusted estimate of the treatment effect for the 12-month DRI is –3.9 (95% CI –8.9 to 1.2) in favour of
the standard dressing group; a lower DRI score indicates less disability. The p-value of 0.132 (see Table 13)
indicates that there is no evidence for a statistically significant difference in DRI scores between the treatment
groups at 12 months post injury. The MCID for the DRI is 8 points. Therefore, we must conclude, based on
our estimated CIs that show evidence in favour of the standard dressing group, that it is extremely unlikely
that there is a clinically important difference in DRI scores in favour of the NPWT dressing.
Disability Rating Index at 12 months was positively correlated with earlier DRI scores; the Pearson
correlation coefficient with pre-injury DRI is 0.23, 3-month DRI is 0.53, 6-month DRI is 0.71 and 9-month
DRI is 0.70. The strong associations between 12-month DRI and earlier (3, 6 and 9 months) DRI can be
seen in the similar adjusted treatment effect estimates for these outcomes in Table 13 to those for
12-month DRI. There was no evidence of statistically significant differences in early DRI outcomes between
the NPWT and standard dressing treatment groups.
Secondary analyses of the Disability Rating Index data
There were 23 deviations (crossovers) from the allocated treatment (NPWT group, n = 15; standard, n = 8).
The PP treatment means for the groups, as defined by the actual treatment participants received rather
than the treatment to which they were allocated, were as follows: for NPWT, mean DRI at 12 months
was 45.4 points (SD 27.7 points) and for the standard dressing mean DRI at 12 months was 42.5 points
TABLE 13 Estimated treatment (ITT) effect for DRI
Outcome
Treatment group
Difference (95% CI)
p-value
NPWT Standard
Mean (SD) n Mean (SD) n Rawa Adjustedb
Primary outcome
DRI, 12 months (points) 45.5 (28.0) 179 42.4 (24.2) 195 –3.1 –3.9 (–8.9 to 1.2) 0.132
DRI scores (points) over time
3 months 64.3 (22.3) 166 65.6 (20.1) 188 1.3 0.7 (–3.7 to 5.0) 0.761
6 months 53.2 (23.8) 154 50.3 (24.1) 175 –2.8 –3.5 (–8.4 to 1.5) 0.172
9 months 49.2 (25.9) 153 45.4 (25.2) 161 –3.8 –4.4 (–10.0 to 1.3) 0.128
a Mean of the standard dressing group minus the mean of the NPWT group; a negative value is in favour of the standard
treatment as lower DRI scores indicate less disability.
b Mixed-effects regression based on a complete-case analysis with treatment group, age group, gender, baseline
pre-injury DRI and wound grade as covariates (fixed effects) and recruiting centre as a random effect; p-values are from
analysis of variance F-test and a negative coefficient estimate is in favour of the standard dressing.
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(SD 24.5 points), giving a raw mean difference of –2.9. A mixed-effects regression analysis, adjusting exactly
as for the ITT model (see Table 13), gave an adjusted treatment effect estimate of –4.0 (95% CI –9.1 to 1.0)
in favour of standard dressings with a p-value of 0.119.
Missing data analysis
There were 86 study participants with missing DRI data at the 12-month study end point; 33 participants
withdrew from the study after consenting but prior to the 12-month study end point and so, based on the
available participants, the study end point is 88% (374/427) towards being complete. Three participants
returned 12-month DRI assessments that were classed as missing because more than six of the items were
missing. A summary of missing values, by age group and sex, for DRI at 12 months is shown in Appendix 2
(see Table 36).
Secondary outcomes
Health-related quality of life
Health-related QoL was assessed using the EQ-5D-3L and the SF-12. Table 14 shows the observed means
and SDs and Figures 6–9 show the full data distributions and trends in the mean scores.
Analysis of health-related quality of life
Health-related QoL was measured using the EQ-5D-3L utility score, EQ-5D VAS score, physical health score
(PCS from SF-12) and mental health score (MCS from SF-12) at 12 months post randomisation. There appears
to be, from a visual inspection of Figures 6–9, very little evidence of a treatment group difference in these
outcomes. Scores for all outcome measures other than MCS improve significantly in the postoperative period
in both groups, indicating improved physical health, but participants never recover to pre-injury levels. Mental
health score, as measured by MCS, does not vary much in the 12 months following injury, but is always
marginally lower than pre-injury levels.
Table 15 shows raw and adjusted estimates of treatment effects for QoL measures across all time points.
There is no evidence to support statistically significant differences between treatment groups for any of
these measures, at any time point in the first year after injury.
There is no evidence that missingness patterns differed between treatment groups. Of the 86 study
participants who did not provide DRI score data at 12 months, 47 were in the NPWT group and 39 were in
the standard dressing group. Only nine study participants who provided consent had no post-baseline DRI
data: six in the NPWT group and three in the standard dressing group.
Logistic regression, with missing data coded as 1 and complete data as 0, indicated that none of age
group, gender, wound grade or treatment allocation was predictive of DRI missingness at 12 months;
p-values from chi-squared tests for age group, gender, wound grade and treatment group in the logistic
regression model were 0.723, 0.306, 0.787 and 0.318, respectively Given that these variables are the most
likely to affect missingness patterns and they show no statistically significant association with missingness,
it seems reasonable to assume that data are missing at random (MAR).
Imputing the missing data and rerunning the analysis on fully complete data provides a useful sensitivity
analysis. Missing data were imputed using the MICE (multiple imputation by chained equations) package in
R and pooled estimates of model parameters based on 50 data imputations, and were obtained for the
mixed-effects regression models (see Table 13). The pooled estimate of the treatment group effect for DRI
at 12 months was –4.5 (95% CI –4.2 to 1.9), with the percentage of the variability attributable to the
uncertainty caused by the missing data estimated at 12.8%. Equivalent analyses for the early outcomes at
3, 6 and 9 months were 0.2 (95% CI –4.0 to 4.5), –4.0 (95% CI –8.6 to 0.7) and –5.3 (95% CI –10.5 to –0.1),
respectively, with percentages for the variability attributable to the uncertainty caused by the missing data
estimated at 19.8%, 18.9% and 24.7%, respectively.
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TABLE 14 Means and SDs of QoL, by intervention group outcomes
Outcome
Time point
Pre injury Post injury 3 months 6 months 9 months 12 months
NPWT
EQ-5D utility
n 220 210 152 146 144 172
Mean 0.88 0.00 0.34 0.47 0.51 0.55
SD 0.22 0.29 0.33 0.33 0.33 0.33
EQ-5D VAS
n 219 210 151 144 144 174
Mean 82.22 43.47 56.87 62.79 65.56 67.73
SD 18.07 23.53 22.61 23.11 23.41 24.12
SF-12 PCS
n 214 138 132 130 154
Mean 54 21.1 26.6 29.5 32.2
SD 13 11.8 14.4 16.3 17.4
SF-12 MCS
n 214 138 132 130 154
Mean 47.8 43 45.5 43.8 44.7
SD 7.5 8.9 9.0 9.0 8.4
Standard
EQ-5D utility
n 231 226 175 166 154 192
Mean 0.90 0.00 0.34 0.47 0.54 0.56
SD 0.21 0.30 0.32 0.32 0.29 0.32
EQ-5D VAS
n 231 223 175 165 151 190
Mean 82.64 42.56 60.15 63.27 67.32 68.34
SD 17.98 23.7 21.66 22.67 22.68 22.75
SF-12 PCS
n 227 164 156 137 175
Mean 55.3 21.6 26.7 29.7 32.7
SD 11.8 12.4 15.3 16.6 15.5
SF-12 MCS
n 227 164 156 137 175
Mean 47.6 43.4 45.1 45.2 44.3
SD 7.7 9.1 9.8 8.1 8.2
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FIGURE 6 (a) Box plots of EQ-5D-3L utility scores and (b) trends in means (with 95% CIs) pre injury, at post-injury
baseline and at 3, 6, 9 and 12 months post injury.
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FIGURE 7 (a) Box plots of EQ-5D VAS scores and (b) trends in means (with 95% CIs) pre injury, at post-injury
baseline and at 3, 6, 9 and 12 months post injury.
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FIGURE 8 (a) Box plots of SF-12 PCSs and (b) trends in means (with 95% CIs) pre injury, at post-injury baseline and
at 3, 6, 9 and 12 months post injury.
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FIGURE 9 (a) Box plots of SF-12 MCSs and (b) trends in means (with 95% CIs) pre injury, at post-injury baseline and
at 3, 6, 9 and 12 months post injury.
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In summary, the inferences based on the complete data, after imputation, are not markedly different from
those reported from the complete-case analysis in Appendix 2 (see Table 37).
Complications
Complications were recorded from several sources as part of the routine clinical follow-up for all study
participants, through SAEs and directly from participants to the trial team. The routinely reported
complications are summarised in Appendix 12 (see Tables 40–45). However, the complete pattern and
extent of complications was considerably more complex than these routinely reported assessments.
In some cases, it was unclear whether complications were related or unrelated to the index WOLLF study
wound. Therefore, to provide a more comprehensive and comprehensible summary of the full extent of
complications, the totality of data was assessed by a surgeon independent from the trial team and
TABLE 15 Estimated treatment effects for QoL over 12 months post injury
Outcome
Treatment group
Difference (95% CI)
p-value
NPWT Standard
Mean (SD) n Mean (SD) n Rawa Adjustedb
QoL at 12 months
EQ-5D utility 0.55 (0.33) 172 0.56 (0.32) 192 0.02 0.01 (–0.06 to 0.07) 0.823
EQ-5D VAS 67.7 (24.1) 174 68.3 (22.7) 190 0.6 1.0 (–3.6 to 5.7) 0.660
SF-12 PCS 32.2 (17.4) 154 32.7 (15.5) 175 0.5 0.4 (–3.0 to 3.8) 0.817
SF-12 MCS 44.7 (8.4) 154 44.3 (8.2) 175 –0.4 –0.2 (–2.1 to 1.6) 0.797
QoL over time
3 months
EQ-5D utility 0.34 (0.33) 152 0.34 (0.32) 175 0.00 0.00 (–0.07 to 0.07) 0.948
EQ-5D VAS 56.9 (22.6) 151 60.1 (21.7) 175 3.3 3.6 (–1.2 to 8.4) 0.140
SF-12 PCS 21.1 (11.8) 138 21.6 (12.4) 164 0.5 0.4 (–2.3 to 3.2) 0.758
SF-12 MCS 43.0 (8.9) 138 43.4 (9.1) 164 0.4 0.8 (–1.3 to 2.8) 0.465
6 months
EQ-5D utility 0.47 (0.33) 146 0.47 (0.32) 166 0.01 0.01 (–0.06 to 0.08) 0.793
EQ-5D VAS 62.8 (23.1) 144 63.3 (22.7) 165 0.5 1.2 (–3.7 to 6.2) 0.632
SF-12 PCS 26.6 (14.4) 132 26.7 (15.3) 156 0.1 0.5 (–2.8 to 3.9) 0.761
SF-12 MCS 45.5 (9.0) 132 45.1 (9.8) 156 –0.5 –0.4 (–2.6 to 1.8) 0.730
9 months
EQ-5D utility 0.51 (0.33) 144 0.54 (0.29) 154 0.03 0.04 (–0.03 to 0.10) 0.301
EQ-5D VAS 65.6 (23.4) 144 67.3 (22.7) 151 1.8 2.9 (–2.2 to 8.0) 0.267
SF-12 PCS 29.5 (16.3) 130 29.7 (16.6) 137 0.2 1.0 (–2.8 to 4.8) 0.604
SF-12 MCS 43.8 (9.0) 130 45.3 (8.1) 137 1.5 1.8 (–0.3 to 3.9) 0.094
a Mean of the standard dressing group minus the mean of the NPWT group a negative value is in favour of the standard
treatment, a lower EQ-5D, EQ-5D VAS, PCS and MCS scores indicates lower QoL health status, physical health and
mental health, respectively.
b Mixed-effects regression based on a complete-case analysis with treatment group, age group, gender, baseline score
and wound grade as covariates (fixed effects) and recruiting centre as a random effect; p-values are from analysis of
variance F-test.
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categorised into the groupings that are reported in Local complications related to the open fracture or its
treatment and Systemic complications potentially related to the open fracture or its treatment. We present
summaries of trial-related and unrelated complications, and related and unrelated reoperations.
Local complications related to the open fracture or its treatment
Surgical site infections
Deep surgical site infection at 30 days
In total, 35 out of the 460 participants (7.6%) had a deep SSI: 16 (7.1%) in the NPWT group and 19
(8.1%) in the standard dressing group. Mixed-effects logistic regression with treatment group, age group,
gender and wound grade as covariates (fixed effects) and recruiting centre as a random effect showed no
evidence that deep SSI rates differed between treatment groups; estimated OR 1.18 (95% CI 0.59 to
2.37), with p-values from analysis of variance (ANOVA) F-test given by 0.638.
Superficial surgical site infection within 30 days
In total, 68 out of the 460 participants (14.8%) had a superficial SSI: 35 (15.5%) in the NPWT group and
33 (14.1%) in the standard dressing group. Mixed-effects logistic regression with treatment group, age
group, gender and wound grade as covariates (fixed effects) and recruiting centre as a random effect
showed no evidence that superficial SSI rates differed between treatment groups; estimated OR 0.89
(95% CI 0.53 to 1.51), with p-values from ANOVA F-test given by 0.675.
Deep surgical site infection diagnosed after 30 days but before 12 months
In total, 28 out of the 460 participants (6.1%) had persistent or new symptoms of deep SSI after 30 days
(but before 12 months): 12 (5.3%) in the NPWT group and 16 (6.8%) in the standard dressing group.
Mixed-effects logistic regression with treatment group, age group, gender and wound grade as covariates
(fixed effects) and recruiting centre as a random effect showed no evidence that late deep SSI rates
differed between treatment groups; estimated OR 1.39 (95% CI 0.53 to 3.02), with p-values from ANOVA
F-test given by 0.407.
Specific signs/symptoms
Table 16 shows the number of participants with each of the identified signs/symptoms by treatment group
at 30 days. There was no evidence of a difference in individual signs or symptoms.
Assessment of photographic images taken at 6 weeks
Photographic images of the index wound were assessed as ‘healed’ or ‘unhealed’ and ‘infected’ or
‘uninfected’ by two independent clinical assessors blinded to the treatment allocation. Agreement between
the two assessors was quantified using Cohen’s kappa statistic, which measures inter-rater agreement for
categorical items. For ‘wound healed’, there was substantial agreement between assessors (Cohen’s kappa
0.80 with 95% bootstrapped CI 0.73 to 0.86). There was also substantial, but less, agreement between
assessors for ‘wound infected’ (Cohen’s kappa 0.63 with 95% bootstrapped CI 0.52 to 0.72).
Table 17 shows percentage wound healing and signs of infection, based on photographic image data
only, by treatment group.
Adjusted ORs (see Table 17), based on a mixed-effects logistic regression with treatment group, age group,
gender and wound grade as covariates (fixed effects) and recruiting centre as a random effect, show no
evidence from photographic images to support differences in wound healing or infection rates between
treatment groups.
Other complications
Table 18 shows other complications related to the open fracture, by treatment group.
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TABLE 18 Postoperative complications related to the WOLLF study wound/injury
Complication
Treatment group
Total p-valueaNPWT (n= 226) % Standard (n= 234) %
Soft tissue (other) 20 8.8 17 7.3 37 0.650
Neurovascular 5 2.2 8 3.4 13 0.618
Pain 8 3.5 11 4.7 19 0.696
DVT/PE 6 2.7 4 1.7 10 0.538a
Other 0 0.0 3 1.3 3 0.249a
DVT, deep-vein thrombosis; PE, pulmonary embolism.
a Results of chi-squared test or Fisher’s exact test for those indicated.
TABLE 17 Estimated treatment effects for photographic assessments at 6 weeks
Healed/infected
Treatment group
OR (95% CI)
p-value
NPWT Standard
% (n) N % (n) N Rawa Adjustedb
Wound healed 52.0 (91) 175 51.7 (93) 180 0.99 1.0 (0.6 to 1.6) 0.994
Wound infected 15.4 (27) 175 17.2 (31) 180 1.14 1.1 (0.6 to 1.9) 0.798
a An OR value of > 1 indicates a higher % in the standard treatment group.
b Mixed-effects logistic regression based on a complete-case analysis with treatment group, age group, gender and wound
grade as covariates (fixed effects) and recruiting centre as a random effect; p-values are from ANOVA F-test.
TABLE 16 Responses used for assessment of SSI at 30 days
Response
Within 30 days
Treatment group
p-valuea
NPWT (N= 226) Standard (N= 234)
n % n %
Red and inflamed 34 15.0 28 12.0 0.494
Swollen 26 11.5 33 14.1 0.325
Painful/tender 26 11.5 35 15.0 0.165
Fluid leaking 40 17.7 42 18.0 0.712
Fluid (pus) cloudy 16 7.1 15 6.4 0.837
Gaping open 4 1.8 8 3.4 0.255
Surgeon opened 13 5.8 10 4.3 0.670
Fever > 38 °C 22 9.7 16 6.8 0.396
Abscess/infection 7 3.1 8 3.4 0.796
Culture swab taken 40 17.7 28 12.0 0.184
Antibiotics 34 15.0 37 16.4 0.603
a Results of Fisher’s exact tests.
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There was no evidence to suggest that numbers of trial-related complications differed between treatment
groups (see p-values in Table 18).
Further surgery related to the open fracture
Table 19 shows details of the further surgery related to the open fracture in the 12 months after the injury,
by treatment group.
There was no evidence to suggest that the number of related reoperations differed between treatment
groups (see p-values in Table 19). Mixed-effects logistic regression with treatment group, age group,
gender and wound grade as covariates (fixed effects) and recruiting centre as a random effect showed no
evidence that overall revision fixation rates differed between treatment groups (8.0% in the NPWT group
and 6.4% in the standard dressing group; see Table 19); estimated OR 0.78 (95% CI 0.38 to 1.60),
with p-values from ANOVA F-test given by 0.494.
TABLE 19 Further surgery related to the open fracture
Further surgery
Treatment group
Total p-valuea
NPWT
(n= 226) %
Standard
(n= 234) %
Removal external fixation 4 1.8 8 3.4 12 0.414
Removal internal fixation 14 6.2 18 7.7 32 0.654
Revision coverage free flap 4 1.8 5 2.1 9 1.000a
Revision coverage not specified 2 0.9 0 0.0 2 0.241a
Revision coverage local flap + SSG 0 0.0 5 2.1 5 0.061a
Revision coverage primary 1 0.4 0 0.0 1 0.491a
Revision coverage free flap + SSG 2 0.9 1 0.4 3 0.618a
Revision coverage skin graft 9 4.0 4 1.7 13 0.234
Amputation 4 1.8 6 2.6 10 0.752a
Other 0 0.0 3 1.3 3 0.249a
Wound management 19 8.4 21 9.0 40 0.960
Revision fixation: ORIF 9 4.0 4 1.7 13 0.234
Revision fixation: IM nail 6 2.7 4 1.7 10 0.538a
Revision fixation: external fixation circular frame 5 2.2 6 2.6 11 1.000
Revision fixation: POP 0 0.0 2 0.9 2 0.499a
Cement nail 1 0.4 2 0.9 3 1.000a
Reoperation for non-fixation/non-coverage failure 7 3.1 7 3.0 14 1.000
Segmental defect Masquelet 4 1.8 6 2.6 10 0.752a
Local antibiotic therapy 1 0.4 3 1.3 4 0.624a
Bone biopsy 1 0.4 3 1.3 4 0.624a
Segmental defect bone transport 0 0.0 1 0.4 1 1.000a
Other operation 2 0.9 2 0.9 4 1.000a
Bone graft 10 4.4 18 7.7 28 0.204
IM nail, intramedullary nail; ORIF, open reduction and internal fixation; POP, plaster of Paris; SSG, split skin graft.
a Results of chi-squared test or Fisher’s exact test for those indicated.
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Radiographic assessment of complications
Radiographs were assessed at 6 weeks for failure of fixation (yes or no) and the sagittal and coronal
angulation measured for the index fixation. Union (yes or no) was assessed using 12-month radiographs.
Table 20 shows percentages by treatment group.
Adjusted ORs, based on a mixed-effects logistic regression model with treatment group, age group,
gender and wound grade as covariates (fixed effects) and recruiting centre as a random effect, show no
evidence from radiographs to support differences between treatment groups.
Systemic complications potentially related to the open fracture or its treatment
There were 10 participant deaths reported during the study: six in the NPWT group and four in the
standard dressing group. Table 21 shows details of the events.
Kaplan–Meier curves based on cause-specific survival (censoring the unrelated house fire death) are shown
in Figure 10. The number of deaths was small, so a cause-specific analysis was not attempted.
TABLE 20 Estimated treatment effects for radiograph assessments at 6 weeks and 12 months
Assessment
Treatment group
OR (95% CI)
p-value
NPWT Standard
% (n) N % (n) N Rawa Adjustedb
6 weeks
Fixation intact 96.2 (177) 184 96.8 (179) 185 1.18 1.2 (0.4 to 3.6) 0.800
Sagittal angle (> 5°) 23.7 (23) 97 19.6 (18) 92 0.78 0.8 (0.4 to 1.7) 0.580
Coronal angle (> 10°) 7.5 (7) 93 4.4 (4) 91 0.57 0.5 (0.1 to 2.4) 0.397
12 months (discharge)
Union 69.6 (112) 161 71.9 (110) 153 1.12 1.1 (0.7 to 1.9) 0.682
a An OR value of > 1 indicates a higher percentage in the standard treatment group.
b Mixed-effects logistic regression based on a complete-case analysis with treatment group, age group, gender and wound
grade as covariates (fixed effects) and recruiting centre as a random effect; p-values are from ANOVA F-test.
TABLE 21 Participant deaths, cause of death and time (post injury) and likely relatedness to the index fracture
Treatment group Cause of death Time (days)
NPWT Complications after below-knee amputationa 29
Unknownb 46
Respiratory failureb 84
House firec 192
Complications after below-knee amputationa 265
Chronic pulmonary embolismb 332
Standard Acute renal failure and dehydration due to gastrointestinal infectionb 25
Septic shockb 37
Septicaemia and bronchopneumoniab 45
Acute kidney injury and urosepsisb 96
a Related to the open fracture in particular.
b Related to other injuries sustained at the time of the open fracture.
c Unrelated to injury.
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A log-rank test provided no evidence to support a difference in survival between treatment groups;
the chi-squared statistic is 0.1 on 1 degree of freedom and p-value is 0.699.
Unrelated serious adverse events
There was no evidence to suggest that numbers of SAEs differed between treatment groups (see p-values
in Table 22).
In addition, there was no evidence to suggest that numbers of unrelated reoperations differed between
treatment groups (see p-value in Table 23).
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FIGURE 10 Kaplan–Meier survivor curves: plus symbols show censored events in which participants withdrew from
the study before the end of 12 months’ follow-up.
TABLE 22 Adverse events not directly related to the open fracture
Specialty area
Treatment group
Total p-valueaNPWT (n= 226) % Standard (n= 234) %
Surgical 7 3.1 7 3.0 14 1.000
Medical 19 8.4 21 9.0 40 0.960
Trauma 5 2.2 8 3.4 13 0.618
Psychiatric 3 1.3 0 0.0 3 0.118a
Anaesthetic 3 1.3 4 1.7 7 1.000a
a Results of chi-squared test or Fisher’s exact test for those indicated.
TABLE 23 Reoperations unrelated to the trial wound
Operation
Treatment group
Total p-valueaNPWT (n= 226) % Standard (n= 234) %
Any operation 68 30.1 75 32.1 143 0.723
a Results of chi-squared test.
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Chapter 5 Health economic evaluation
Overview
In order to estimate the cost-effectiveness of NPWT compared with standard dressings, a prospective
economic evaluation was conducted alongside the RCT. The primary analysis adopted a NHS and PSS
perspective, as recommended by NICE.28 This analysis excluded costs that fell outside the NHS and PSS
sectors. A secondary analysis conducted from a societal perspective, which included broader societal costs,
was also carried out as part of the sensitivity analyses. The economic evaluation took the form of a cost–utility
analysis, expressed in terms of incremental cost attributable to the NPWT dressing per QALY gained.
There were three main components to the strategy used to estimate incremental costs associated with
NPWT dressings. These were estimation of the costs associated with:
1. the NPWT and standard dressings, as well as costs associated with dressing changes during the period
of initial hospitalisation
2. each participant’s initial hospitalisation as well as any further readmissions related to their WOLLF study
wound, taking account of all procedures carried out during each inpatient admission
3. broader resource use recorded in patient questionnaires completed at 3, 6, 9 and 12 months
post randomisation.
All costs were expressed in Great British pounds and valued at 2014/15 prices. When necessary, costs were
inflated or deflated to 2014/15 prices using the NHS Hospital and Community Health Services Pay and
Prices Index,80 or the October 2016 annual consumer prices index81 to deflate from 2016/17 prices.
Costings of negative-pressure wound therapy and standard dressings
The components of both types of dressing and their standard NHS costs were obtained from the finance
department within the UHCW NHS Trust. The costs of dressing changes were determined from a sample
of trial participants for whom additional details were recorded on dressing changes during the initial
hospital admission. This data were used to calculate the average number and cost of dressing changes
within each trial arm for 38 WOLLF study participants (randomised to NPWT, n = 20; randomised to
standard, n = 18). The NPWT dressing comprised the dressing pack (an average cost for the available sizes
was used), the canister and the pump (a daily rental cost was applied to the period of initial hospitalisation
relevant to the open-fracture wound). The standard dressing comprised Mepitel® (Mölnlycke Health Care,
Gothenburg, Sweden) (a non-adhesive dressing), dressing gauze and a wool and crepe bandage.
Costing of initial hospitalisation and readmissions
Inpatient resource use for many participants within the WOLLF study was complex and featured multiple
procedures and complications as well as multiple readmissions. Given the importance of capturing the costs
associated with complications and further surgeries, all of the trial data related to the initial admission were
collated from the background information, operation notes, 6-week follow-up and SAE forms. This information
was then assessed for each participant individually to determine the procedures carried out. Procedures were
then grouped manually for all participants to determine Healthcare Resource Groups (HRGs) for each initial
admission, using the HRG4+ 2015/16 Reference Costs82 code to group guidance, which could then be related
to costs using the NHS Reference Costs 2014 to 2015 schedule.83 When insufficient information was available
to reliably assess the procedure(s) carried out during the initial inpatient admission, operation notes and/or
discharge letters were requested from trial sites for further clarification.
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In order to assign costs to readmissions, it was necessary first to determine which admissions were related to
the WOLLF study wound, the process of which was based on clinical judgement, using data from the 3-, 6-,
9- and 12-month follow-up forms as well as the SAE forms. This process was analogous to the process that
determined whether AEs were related or unrelated to the open fracture or its treatment. Operation notes
were then requested from sites for all relevant admissions, allowing the procedures carried out during each
readmission to be determined. HRG codes could then be determined for each readmission and related to
NHS Reference Costs. For cases in which there was evidence of a related readmission but the specific
procedure carried out was unknown, a weighted average of the base costs, average length of stay and
excess bed-day cost of the five most common procedures carried out during readmissions were assumed.
Measurement of broader resource use
As well as inpatient resource use related to the initial admission and readmissions, data were also
collected about broader NHS and PSS resource use as well as broader societal resource use for the period
between randomisation and 12 months post randomisation. Trial participants self-completed resource use
questionnaires at 3, 6, 9 and 12 months post randomisation, covering their use of outpatient and day-case
hospital services and community health care, as well as their use of medications, PSSs, and aids and
adaptations (e.g. crutches, walking sticks, grab rails, etc.). The 3-month questionnaire covered the period
following initial hospitalisation to 6 months post randomisation, with subsequent questionnaires covering
the 3 months since the previous questionnaire. Further questionnaires captured wider societal resource
use, with data collected on time off work, over-the-counter medications, aids and adaptations purchased
privately, as well as any additional costs (e.g. travel costs, lost earnings, child care costs and help with
housework) borne by themselves, their partners or their friends and relatives. A copy of the follow-up
questionnaire can be found in Appendix 8.
Value of broader resource use
Resource inputs were valued using a combination of primary research, based on established accounting
methods and data from secondary national tariff sets. Costs were applied to inpatient hospital care
resource use as described in Costing of initial hospitalisation and readmissions. For outpatient hospital care,
costs per contact from the NHS Reference Costs 2014 to 201583 were multiplied by the numbers of
contacts in each department. For community health care and PSS, unit costs were primarily extracted from
the PSSRU Unit Costs of Health and Social Care 201580 compendium. When trial participants provided data
on the average duration of each community health or social care contact, the per-minute unit cost was
applied to these inputs. When unavailable, the mean cost per contact was used. Medication costs were
derived from NHS Prescription Costs Analysis84 data. Data on dose, dose frequency (number of times daily)
and dose duration (number of days used) were used when available. When this information was
unavailable, a combination of clinical input and the mean values of other trial participants using the same
medication was used. Aids and adaptations were valued using a combination of data from the NHS Supply
Chain Catalogue85 as well as other sources. Aids and adaptations that could reasonably be assumed to be
returned to the NHS following use were assumed to last for 5 years with no resale value, and a discount
rate of 3.5% was used to calculate an annuitised cost which was then applied to the period of use during
the trial.86 Time off work was valued using income data from the Office for National Statistics 2014 New
Earnings Survey,87 categorised by age and gender. Unit costs were inflated/deflated to 2014/15 prices
when necessary using the NHS Hospital and Community Health Services Pay and Prices Index80 for health
service resource inputs and the consumer prices index81 for broader resource inputs. No discounting of
costs was applied because cost-effectiveness was determined over a 1-year time horizon.
Calculation of utilities and quality-adjusted life-years
The HRQoL of WOLLF study participants was measured using the EQ-5D-3L collected at baseline (which
provided an immediate assessment of post-injury HRQoL, as well as separate retrospectively recalled pre-injury
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values) and at 3, 6, 9 and 12 months post randomisation.88 The EQ-5D-3L consists of both a descriptive
system and a VAS ranging from 100 (best imaginable health state) to 0 (worst imaginable health state). The
descriptive system defines HRQoL across five dimensions: mobility, self-care, usual activities, pain, and anxiety
or depression. Responses in each dimension take the form of ‘no problems’, ‘some or moderate problems’ or
‘serious or extreme problems’. Responses to each of these five dimensions can then be valued on a health
utility scale from –0.59 to 1, with negative values relating to health states considered worse than death,
0 equivalent to being dead, and 1 being a state of full health. For the purposes of this study, the UK time
trade-off tariff was applied to each set of responses to generate a EQ-5D utility score (preference weight) for
each participant.18 QALYs were calculated as the area under the baseline-adjusted utility curve of EQ-5D-3L
utility scores at (immediate post injury) baseline, 3, 6, 9 and 12 months, using the trapezoidal rule.86 No
discounting of QALYs was applied because cost-effectiveness was determined over a 1-year time horizon.
Within the WOLLF study, the SF-12 score was also collected at baseline (when participants were asked to
retrospectively recall their pre-injury health state) as well at 3, 6, 9 and 12 months post randomisation. The
SF-12 is a generic health measure with 12 questions covering aspects of physical and mental health across
eight dimensions. The UK standard gamble tariff was applied to the responses to the SF-12 in order to
generate SF-6D utility scores, from which QALYs could be recalculated using the trapezoidal rule for the
purposes of a sensitivity analysis.21,89,90
Missing data
Missing data were anticipated to be a problem; 69% of data inputs were incomplete when assessing all
study time points for the base-case analysis. Multiple imputation was therefore used for all analyses except
the complete-case analysis. Multiple imputation produces unbiased estimates of treatment effect when
data are MAR. This assumption was explored using logistic regression on missingness of costs and QALYs
against baseline covariates. Multiple imputation using chained equations with predictive mean matching
was carried out on total QALYs over the entire 1-year follow-up period, total costs in each follow-up
period (baseline to 3 months, 3–6 months, 6–9 months and 9–12 months) and on pre- and post-injury
baseline EQ-5D utility scores.91 Included also within the imputation models were predictive covariates;
these included costs associated with initial hospitalisation and dressing changes, trial site, G&A grade,
gender and age. A total of 69 imputed data sets were generated for the base-case analysis, following the
‘rule of thumb’ suggested in recent methodological guidance.91
Analyses of costs and outcome data
The mean and standard error (SE) of cost values for each cost category at each time point and within each
trial allocation were calculated. Differences between these means were calculated and tested for statistically
significant differences from zero using t-tests. For total costs and for each cost category, non-parametric
bootstrap estimates based on 10,000 replications were calculated for differences in mean costs and their
respective 95% bootstrap CIs also calculated.
The proportion of participants in each arm of the trial providing a suboptimal response at each time point
of follow-up for each EQ-5D-3L dimension were tested for equality using the chi-squared test. The mean
EQ-5D VAS scores and EQ-5D-3L utility scores for each arm of the trial were also tested for equality at
each time point of follow-up using t-tests.
Cost-effectiveness analysis
Bivariate regression using seemingly unrelated regression was used to model total costs and total QALYs
over the 1-year follow-up period. This approach allows for correlation between costs and outcomes and
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estimates the two regression equations jointly, potentially improving the precision of the estimates. By
specifying the treatment group as an indicator within each equation, the incremental costs and QALYs
attributable to NPWT was estimated, while controlling for baseline covariates (age, gender, trial site and
G&A grade). Within the equation for QALYs, baseline EQ-5D utility scores (both pre- and post-injury)
were included to adjust for potential baseline imbalances between the trial allocation groups.92 The
cost-effectiveness result was expressed as an ICER, defined as the incremental cost of NPWT divided by
the incremental QALYs produced by NPWT. The ICER was then compared with cost-effectiveness threshold
values for an additional QALY. The NICE cost-effectiveness threshold for British studies93 ranges between
£20,000 and £30,000 per QALY. In addition, a £15,000 cost-effectiveness threshold was included to
reflect more recent trends in health-care decision-making.94
By bootstrapping the data with replacement and recalculating these incremental costs and QALYs 1000
times, a cost-effectiveness plane was populated with 1000 simulated ICER values. Net monetary benefits
were estimated from the incremental costs and QALYs at each given cost-effectiveness threshold value and
describes the resource gain or loss due to investing in NPWT, given that resources can be used elsewhere
within the NHS at the same cost-effectiveness threshold level. By calculating net monetary benefits for
each of these 1000 simulated ICER values at levels of the cost-effectiveness threshold varying from £0 to
£50,000 per QALY gained, the probability of cost-effectiveness of NPWT (defined as the proportion of
positive net monetary benefits at a given threshold level) was calculated, and plotted as a CEAC.
Sensitivity and subgroup analyses
Several sensitivity analyses were undertaken to explore the effects of alternative perspectives or scenarios
on the cost-effectiveness results. The cost-effectiveness analysis was therefore repeated under the
following assumptions: (1) adopting a wider societal costing perspective (described under Value of broader
resource use), (2) calculating QALYs using the SF-6D instead of the EQ-5D21,89,90 and (3) restricting the
analysis only to complete cases (i.e. those with complete cost and outcome data).
A single prespecified subgroup analysis was also conducted to explore potential heterogeneity in the
incremental cost-effectiveness of NPWT related to whether or not there was evidence of deep infection,
assessed using the CDC SSI algorithm.
Long-term cost-effectiveness model
The trial-based economic evaluation focused on the short- and medium-term costs and consequences of
NPWT dressing in the treatment of adult patients with an open fracture of the lower limb. The study
protocol31 allowed for extrapolation of costs and consequences over a longer time horizon if the trial
demonstrated statistically significant differences in medium-term outcomes. This would have required the
development of a de novo decision-analytic model. Accepted guidelines for good practice in decision-
analytic modelling and the general principles outlined in the NICE ‘reference case’ were to be followed.95,96
Long-term extrapolations of outcomes were to be expressed in terms of QALYs in the event of differences
in medium-term outcomes. Both costs and outcomes accruing beyond the first year post randomisation
were to be discounted using a 3.5% annual discount rate in line with current guidance.28
Results
Study population
A total of 460 participants were consented into the WOLLF study, of whom 226 were randomised to the
NPWT dressing and 234 were randomised to the standard dressing. These participants formed the baseline
study population for the trial-based health economic evaluation. A complete profile of resource use, from a
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NHS and PSS perspective, was collected for 285 participants (62%) at 3 months post randomisation, 277
participants (60%) at 6 months post randomisation, 262 participants (57%) at 9 months post randomisation
and 322 participants (70%) at 12 months post randomisation. A complete profile of EQ-5D data was
collected for 218 participants (47%) and a complete profile of both EQ-5D and resource use values (from
a NHS and PSS perspective), across all time points, was collected for 144 participants (31%). Results of the
primary clinical and health economic outcomes collected are detailed in Table 24. The completeness of the
relevant health economic data items, by follow-up point and by resource category, is detailed in Table 25.
TABLE 24 Health outcomes by follow-up point
Follow-up
point
All
(n)
Treatment group Mean EQ-5D (SE) p-value
difference
in mean
EQ-5D
Mean DRI score,
points (SE) p-value
difference
in mean
DRI
NPWT
(n)
Standard
(n) NPWT Standard NPWT Standard
Baseline:
pre injury
451 220 231 0.881
(0.015)
0.897
(0.014)
0.427 – – –
Baseline:
post injury
436 210 226 0.002
(0.02)
–0.003
(0.02)
0.833 – – –
3 months 325 151 174 0.342
(0.027)
0.346
(0.024)
0.900 64.2 (1.8) 64.9 (1.5) 0.799
6 months 308 143 165 0.468
(0.027)
0.471
(0.025)
0.934 52.5 (2) 50.2 (1.9) 0.414
9 months 294 142 152 0.51
(0.027)
0.533
(0.024)
0.527 48.8 (2.1) 45.4 (2) 0.251
12 months 363 171 192 0.545
(0.025)
0.564
(0.023)
0.582 45.4 (2.1) 42.7 (1.7) 0.338
TABLE 25 Completeness of data by follow-up point
Time point
Treatment group, n (%)
Total (N= 460)NPWT (N= 226) Standard (N= 234)
Health status
Pre-injury baseline EQ-5D 220 (97) 231 (99) 451 (98)
Post-injury baseline EQ-5D 210 (93) 226 (97) 436 (95)
3-month EQ-5D 152 (67) 175 (75) 327 (71)
6-month EQ-5D 146 (65) 166 (71) 312 (68)
9-month EQ-5D 144 (64) 154 (66) 298 (65)
12-month EQ-5D 172 (76) 192 (82) 364 (79)
QALYs complete cases 94 (42) 124 (53) 218 (47)
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TABLE 25 Completeness of data by follow-up point (continued )
Time point
Treatment group, n (%)
Total (N= 460)NPWT (N= 226) Standard (N= 234)
Resource use
3 months
Inpatient care 157 (69) 174 (74) 331 (72)
Outpatient care 148 (65) 164 (70) 312 (68)
Community care 148 (65) 162 (69) 310 (67)
Medications 142 (63) 159 (68) 301 (65)
PSSs 144 (64) 158 (68) 302 (66)
Aids and adaptations 144 (64) 162 (69) 306 (67)
Total costs 136 (60) 149 (64) 285 (62)
6 months
Inpatient care 145 (64) 164 (70) 309 (67)
Outpatient care 142 (63) 157 (67) 299 (65)
Community care 138 (61) 156 (67) 294 (64)
Medications 136 (60) 155 (66) 291 (63)
PSSs 141 (62) 157 (67) 298 (65)
Aids and adaptations 138 (61) 156 (67) 294 (64)
Total costs 128 (57) 149 (64) 277 (60)
9 months
Inpatient care 145 (64) 150 (64) 295 (64)
Outpatient care 140 (62) 143 (61) 283 (62)
Community care 138 (61) 138 (59) 276 (60)
Medications 139 (62) 143 (61) 282 (61)
PSSs 141 (62) 142 (61) 283 (62)
Aids and adaptations 139 (62) 140 (60) 279 (61)
Total costs 129 (57) 133 (57) 262 (57)
12 months
Inpatient care 168 (74) 186 (79) 354 (77)
Outpatient care 162 (72) 180 (77) 342 (74)
Community care 161 (71) 180 (77) 341 (74)
Medications 159 (70) 179 (76) 338 (73)
PSSs 163 (72) 182 (78) 345 (75)
Aids and adaptations 163 (72) 180 (77) 343 (75)
Total costs 152 (67) 170 (73) 322 (70)
Complete cases
EQ-5D and resource use 65 (29) 79 (34) 144 (31)
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Resource use and costs
Initial hospitalisation
The costs associated with each participant’s initial hospitalisation were based on the primary procedure,
which was the most resource-intensive procedure during their hospitalisation. The number of primary
procedures, and their associate lengths of hospital stay, are broken down by trial arm and detailed in
Table 26. The most common primary procedure was microvascular free tissue transfer of flap of muscle
of shoulder (latissimus dorsi), with 130 participants having this as their primary procedure. There was a
statistically significant difference between the two trial arms in the number of participants receiving
primary open reduction of fracture of long bone and extramedullary fixation using plate of hip as their
primary procedure (p = 0.005), with none of the participants receiving NPWT having this as their primary
procedure, compared with eight participants in the standard dressing arm. There were no other differences
in the type of fixation. There were no statistically significant differences in length of stay for each primary
procedure between the two trial arms.
TABLE 26 Primary initial procedures by trial arm
Primary initial procedure name
Number of
procedures:
NPWT
Mean
length of
stay: NPWT
(days)
Number of
procedures:
standard
Mean
length
of stay:
standard
(days)
p-value
difference in
number of
procedures
p-value
difference
in length
of stay
Microvascular free tissue transfer
of flap of muscle of shoulder
(latissimus dorsi)
70 18.5 60 20 0.204 0.512
Primary open reduction of fracture
of bone and external fixation HFQ
of knee
53 22.7 60 18.3 0.585 0.12
Primary open reduction of fracture
of long bone and fixation using
rigid nail NEC of knee
28 17 33 15.2 0.588 0.654
Primary open reduction of fracture
of long bone and extramedullary
fixation using plate NEC of knee
17 15.2 17 15.2 0.916 0.988
Microvascular free tissue transfer
of flap of muscle of hip
18 16.9 14 28.2 0.404 0.148
Primary open reduction of fracture
of long bone and fixation using
rigid nail NEC of hip
5 7.4 9 14.1 0.308 0.094
Primary open reduction of fracture
of bone and external fixation HFQ
of hip
9 18.2 4 23.8 0.141 0.652
Primary open reduction of fracture
of long bone and extramedullary
fixation using plate NEC of hip
0 – 8 31.5 0.005 –
Primary open reduction of fracture
dislocation of joint and internal
fixation NEC of foot
4 7.5 2 12.5 0.387 0.691
Amputation of leg below knee 4 33 2 21 0.387 0.441
Primary open reduction of fracture
of bone and external fixation HFQ
of foot
3 19 2 15.5 0.625 0.442
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TABLE 26 Primary initial procedures by trial arm (continued )
Primary initial procedure name
Number of
procedures:
NPWT
Mean
length of
stay: NPWT
(days)
Number of
procedures:
standard
Mean
length
of stay:
standard
(days)
p-value
difference in
number of
procedures
p-value
difference
in length
of stay
Primary open reduction of
fragment of bone and fixation
using wire system of foot
3 5.7 2 20.5 0.625 0.279
Unspecified split autograft of skin 3 17 1 8 0.299 –
Application of external ring
fixation to bone NEC of knee
0 – 3 30 0.088 –
Revision of microvascular vessel
anastomosis of blood vessel of
lower limb
0 – 3 33 0.088 –
Primary open reduction of
fragment of bone and fixation
using screw of knee
0 – 2 7 0.164 –
Amputation of leg above knee 0 – 2 40.5 0.164 –
Primary open reduction of fracture
of ankle and extramedullary
fixation NEC
1 0 1 9 0.98 –
Amputation of leg through knee 0 – 2 37 0.164 –
Primary open reduction of
fragment of bone and fixation
using wire system of knee
1 14 1 18 0.98 –
Application of skeletal traction to
bone NEC of hip
0 – 1 62 0.325 –
Debridement of soft tissue NEC
of knee
1 15 0 – 0.308 –
Application of external fixation to
bone NEC of knee
0 – 1 1 0.325 –
Unspecified local flap of skin
and muscle
1 12 0 – 0.308 –
Application of external fixation to
bone NEC of foot
0 – 1 4 0.325 –
Debridement of soft tissue NEC of
foot
1 1 0 – 0.308 –
Other specified transplantation of
muscle of hip
1 50 0 – 0.308 –
Primary open reduction of
fragment of bone and fixation
using screw of foot
1 7 0 – 0.308 –
Microvascular free-tissue transfer
of flap of muscle of knee
0 – 1 18 0.325 –
Remanipulation of fracture of
bone and external fixation HFQ
of knee
0 – 1 25 0.325 –
Remanipulation of fragment of
bone and fixation using screw
of knee
0 – 1 2 0.325 –
Primary open reduction of fracture
of long bone and extramedullary
fixation using plate NEC of foot
1 8 0 – 0.308 –
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Costs of negative-pressure wound therapy and standard dressings
The resource components associated with NPWT and standard dressings and their associated costs are
summarised in Table 27. A further component of dressing costs is those costs associated with dressing changes.
In order to estimate these costs, data on dressing changes were collected for 38 participants (randomised to
NPWT, n= 20; randomised to standard dressing, n= 18) and the mean costs associated with dressing changes
as well as the mean number of dressing changes in each group is also summarised in Table 27.
Broader resource use
Table 28 presents resource use for trial participants with complete data (for each resource category and
follow-up point) by trial allocation and study period. The resource use values are presented for each
resource category (inpatient care, outpatient care, community care, medication, PSSs, and aids and
adaptations) and by individual items within each category. Resource use values were combined with unit
costs for each resource item (Table 29) to estimate economic costs for each resource category.
TABLE 26 Primary initial procedures by trial arm (continued )
Primary initial procedure name
Number of
procedures:
NPWT
Mean
length of
stay: NPWT
(days)
Number of
procedures:
standard
Mean
length
of stay:
standard
(days)
p-value
difference in
number of
procedures
p-value
difference
in length
of stay
Primary simple repair of tendon
of foot
1 41 0 – 0.308 –
Total 226 18.5 234 19.5 NA 0.437
HFQ, however further qualified; NA, not applicable; NEC, not elsewhere classified.
TABLE 27 Costs (2014/15 pricesa) associated with dressings and dressing changes
Dressing component Cost (£) Source
NPWT dressing elements
VAC dressing pack 31.67 Sue Wetton, UHCW NHS Trust, 2016,
personal communication
VAC canister 34.87 Sue Wetton, UHCW NHS Trust, 2016,
personal communication
VAC pump (daily rental cost) 17.56 Janet Sensicle, UHCW NHS Trust, 2016,
personal communication
Standard dressing elements
Mepitel 8 cm × 10 cm 3.46 NHS Supply Chain Catalogue 2015/1685
Dressing gauze 0.21 NHS Supply Chain Catalogue 2015/1685
Formflex Natural Sterile Padding Bandage
10 cm × 2.7 m (Lantor, Bridgewater, UK)
0.39 NHS Supply Chain Catalogue 2015/1685
Premier Band Light Support Bandage
10 cm × 4.5 cm (Shermond, Coalville, UK)
0.60 NHS Supply Chain Catalogue 2015/1685
Mean cost per dressing change (NPWT) 22.40
Mean cost per dressing change (standard dressing) 6.12
Mean additional cost of NPWT 16.28
Mean number of dressing changes (NPWT) 2.05
Total additional cost of NPWT dressing changes 33.37
VAC, vacuum-assisted closure.
a When relevant, prices were deflated to 2014/15 prices using the NHS hospital and community health services pay and
prices index.80
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TABLE 28 Resource use values by resource category and follow-up point: complete cases
Resource use type
Time point
3 months 6 months 9 months 12 months
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
Inpatient resource use n= 157 n= 174 n = 145 n= 164 n= 145 n= 150 n= 168 n= 186
Readmissions
related to WOLLF
study wound
0.22 (0.03) 0.22 (0.03) 0.869 0.22 (0.03) 0.26 (0.03) 0.467 0.21 (0.03) 0.17 (0.03) 0.305 0.11 (0.02) 0.11 (0.02) 0.991
Outpatient resource
use
n= 148 n= 164 n = 142 n= 157 n= 140 n= 143 n= 162 n= 180
Orthopaedics 2.36 (0.27) 2.55 (0.21) 0.576 1.97 (0.18) 2.12 (0.22) 0.593 1.16 (0.14) 1.34 (0.15) 0.388 1.05 (0.13) 0.98 (0.12) 0.715
Pathology 0.16 (0.09) 0.20 (0.06) 0.766 0.32 (0.11) 0.21 (0.07) 0.383 0.17 (0.05) 0.15 (0.04) 0.803 0.15 (0.05) 0.14 (0.06) 0.894
Radiology 1.16 (0.16) 1.28 (0.11) 0.552 1.27 (0.16) 1.29 (0.12) 0.898 0.62 (0.10) 0.76 (0.11) 0.368 0.66 (0.11) 0.75 (0.14) 0.608
Physiotherapy
(NHS)
1.85 (0.25) 2.07 (0.32) 0.588 3.72 (0.45) 3.99 (0.62) 0.726 1.64 (0.26) 3.21 (0.72) 0.040 1.05 (0.20) 1.24 (0.23) 0.539
Physiotherapy
(private)
0.33 (0.16) 0.59 (0.24) 0.358 0.84 (0.38) 0.60 (0.20) 0.576 0.41 (0.17) 0.78 (0.28) 0.265 0.34 (0.15) 0.28 (0.11) 0.768
Emergency
department
(injury related)
0.04 (0.02) 0.06 (0.03) 0.596 0.07 (0.06) 0.04 (0.02) 0.668 0.07 (0.03) 0.04 (0.02) 0.364 0.02 (0.02) 0.03 (0.01) 0.874
Other 0.94 (0.33) 1.46 (0.45) 0.347 0.41 (0.17) 0.38 (0.12) 0.900 0.10 (0.04) 0.20 (0.07) 0.226 0.19 (0.09) 0.11 (0.05) 0.393
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Resource use type
Time point
3 months 6 months 9 months 12 months
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
Community care
resource use
n= 148 n= 162 n = 138 n= 156 n= 138 n= 138 n= 161 n= 180
GP surgery 0.48 (0.09) 0.72 (0.16) 0.185 1.37 (0.36) 0.65 (0.13) 0.063 0.72 (0.14) 0.56 (0.13) 0.422 0.42 (0.13) 0.34 (0.06) 0.599
GP home 0.23 (0.06) 0.18 (0.05) 0.531 0.14 (0.05) 0.10 (0.03) 0.579 0.05 (0.03) 0.08 (0.04) 0.572 0.04 (0.03) 0.02 (0.02) 0.525
GP phone 0.43 (0.15) 0.51 (0.09) 0.633 0.28 (0.09) 0.44 (0.11) 0.265 0.25 (0.09) 0.30 (0.08) 0.664 0.11 (0.05) 0.17 (0.05) 0.427
Practice nurse 2.07 (0.49) 1.12 (0.31) 0.099 0.86 (0.28) 0.75 (0.25) 0.758 0.40 (0.18) 0.51 (0.28) 0.727 0.43 (0.26) 0.09 (0.04) 0.190
District nurse 4.74 (0.93) 4.24 (0.63) 0.66 2.75 (1.00) 1.50 (0.39) 0.243 0.54 (0.27) 1.25 (0.45) 0.173 0.38 (0.18) 0.47 (0.22) 0.740
Community
physiotherapist
0.67 (0.21) 0.59 (0.13) 0.736 1.93 (0.75) 1.72 (0.43) 0.808 0.33 (0.12) 0.60 (0.21) 0.260 0.18 (0.10) 0.64 (0.28) 0.125
NHS direct call 0.10 (0.07) 0.07 (0.03) 0.696 0.04 (0.03) 0.03 (0.01) 0.715 0.10 (0.07) 0.02 (0.02) 0.238 0.01 (0.01) 0.07 (0.06) 0.314
Ambulance or
paramedic
0.04 (0.02) 0.06 (0.03) 0.659 0.15 (0.08) 0.04 (0.02) 0.149 0.03 (0.02) 0.00 (0.00) 0.207 0.00 (0.00) 0.00 (0.00) –
Occupational
therapy
0.26 (0.10) 0.27 (0.07) 0.945 0.12 (0.08) 0.17 (0.06) 0.665 0.12 (0.09) 0.05 (0.03) 0.499 0.01 (0.01) 0.02 (0.02) 0.838
Other 0.25 (0.16) 0.32 (0.17) 0.759 0.16 (0.10) 0.16 (0.09) 0.995 0.12 (0.09) 0.02 (0.02) 0.266 0.13 (0.11) 0.01 (0.01) 0.296
PSS resource use n= 144 n= 158 n = 141 n= 157 n= 141 n= 142 n= 163 n= 182
Meals on wheels
(hot)
0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.46 (0.46) 0.319
Laundry 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.10 (0.07) 0.180
Social worker 0.13 (0.09) 0.01 (0.01) 0.178 0.04 (0.04) 0.00 (0.00) 0.319 0.06 (0.06) 0.03 (0.03) 0.652 0.02 (0.02) 0.00 (0.00) 0.207
Care worker 1.52 (0.78) 4.26 (1.74) 0.151 2.44 (1.88) 2.39 (1.34) 0.985 0.71 (0.46) 1.37 (0.85) 0.493 1.41 (0.81) 1.39 (0.97) 0.988
Other 0.08 (0.05) 1.19 (1.07) 0.300 0.02 (0.01) 0.11 (0.11) 0.426 0.00 (0.00) 0.00 (0.00) – 0.00 (0.00) 0.02 (0.02) 0.319
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TABLE 28 Resource use values by resource category and follow-up point: complete cases (continued )
Resource use type
Time point
3 months 6 months 9 months 12 months
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
NPWT
mean (SE)
Standard
mean (SE)
p-value
difference
between
means
Aids and adaptations
resource use
n= 144 n= 162 n = 138 n= 156 n= 139 n= 140 n= 163 n= 180
Crutches 0.83 (0.08) 0.80 (0.08) 0.743 0.38 (0.07) 0.40 (0.06) 0.824 0.23 (0.05) 0.13 (0.04) 0.121 0.16 (0.04) 0.09 (0.03) 0.201
Sticks 0.03 (0.02) 0.08 (0.02) 0.102 0.13 (0.04) 0.21 (0.05) 0.201 0.09 (0.03) 0.14 (0.04) 0.399 0.08 (0.02) 0.12 (0.03) 0.253
Zimmer frames 0.31 (0.05) 0.40 (0.05) 0.217 0.09 (0.03) 0.15 (0.03) 0.172 0.03 (0.01) 0.01 (0.01) 0.407 0.02 (0.01) 0.03 (0.01) 0.563
Grab rails 0.06 (0.04) 0.14 (0.03) 0.088 0.01 (0.01) 0.12 (0.04) 0.008 0.06 (0.03) 0.06 (0.03) 0.856 0.01 (0.01) 0.02 (0.01) 0.280
Dressing aids 0.25 (0.13) 0.20 (0.10) 0.749 0.01 (0.01) 0.04 (0.02) 0.195 0.79 (0.72) 0.14 (0.14) 0.375 0.00 (0.00) 0.03 (0.03) 0.319
Long-handle shoe
horns
0.04 (0.02) 0.04 (0.01) 0.836 0.02 (0.01) 0.03 (0.02) 0.845 0.02 (0.01) 0.01 (0.01) 0.313 0.01 (0.01) 0.00 (0.00) 0.158
Other 0.47 (0.05) 0.52 (0.04) 0.463 0.16 (0.03) 0.22 (0.04) 0.215 0.05 (0.02) 0.10 (0.05) 0.335 0.10 (0.03) 0.04 (0.01) 0.027
NPWT
n (%)
Standard
n (%) All n (%)
NPWT
n (%)
Standard
n (%)
NPWT
n (%)
Standard
n (%)
NPWT
n (%)
Standard
n (%)
Medications resource
use
n= 142 n= 159 n = 136 n= 155 n= 139 n= 143 n= 159 n= 179
Prescription
medication
76 (54) 85 (53) 0.991 49 (36) 74 (48) 0.044 41 (29) 47 (33) 0.541 44 (28) 67 (37) 0.057
GP, general practitioner.
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TABLE 29 Unit costs for resource items (2014/15 pricesa)
Resource item
Unit cost (£)
SourcePer contact Per minute
Outpatient care
Orthopaedics 112.50 NHS Reference Costs 2014 to 201583
Pathology 77.70 NHS Reference Costs 2014 to 201583
Radiology 82.37 NHS Reference Costs 2014 to 201583
Physiotherapy (NHS) 46.00 NHS Reference Costs 2014 to 201583
Physiotherapy (private) 45.54 NHS Reference Costs 2014 to 201583
Emergency department 140.59 NHS Reference Costs 2014 to 201583
Community care
GP visits in surgery 44.46 3.80 Unit Costs of Health and Social Care 201580
GP home visits 43.32 3.80 Unit Costs of Health and Social Care 201580
GP telephone contacts 26.98 3.80 Unit Costs of Health and Social Care 201580
Practice nurse contacts 14.47 0.93 Unit Costs of Health and Social Care 201580
District nurse contacts 38.00 1.12 Unit Costs of Health and Social Care 201580
Community physiotherapy contacts 34.05 0.61 Unit Costs of Health and Social Care 201497
Calls to NHS Direct 20.18 BBC98
Calls for an ambulance or paramedic 99.00 Unit Costs of Health and Social Care 201580
Occupational therapy contacts 77.69 0.61 Unit Costs of Health and Social Care 201497
PSSs
Meals on wheels 6.55 Unit Costs of Health and Social Care 201099
Laundry services 9.78 Elderly Accommodation Counsel100
Social worker contacts 49.28 1.32 Unit Costs of Health and Social Care 201580
Care worker contacts 18.50 0.62 Unit Costs of Health and Social Care 201580
Aids and adaptations
Crutches 5.06 NHS Supply Chain Catalogue 2015/1685
Stick 3.94 NHS Supply Chain Catalogue 2015/1685
Zimmer frame 21.54 Complete Care Shop101
Grab rail 1.61 NHS Supply Chain Catalogue 2015/1685
Dressing aids 5.34 NHS Supply Chain Catalogue 2015/1685
Long-handle shoe horn 1.66 NHS Supply Chain Catalogue 2015/1685
BBC, British Broadcasting Corporation; GP, general practitioner.
a When relevant, prices were inflated/deflated to 2014/15 prices using the NHS hospital and community health services
pay and prices index.
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In terms of inpatient resource use, readmissions related to the WOLLF study wound were broadly similar in
both trial arms, varying between 0.11 readmissions per participant during the 9- to 12-month follow-up
period (in both trial arms) and 0.26 readmissions per participant during the 3- to 6-month follow-up period,
for participants receiving standard dressings. Within outpatient resource use, the department with the
highest average visits per participant was NHS physiotherapy, which peaked at 3.99 visits per participant
during the 3- to 6-month follow-up period for participants receiving standard dressings. In the 6- to 9-month
follow-up period, participants receiving standard dressings made statistically significantly (p = 0.040) more
NHS physiotherapy visits (3.21 compared with 1.64), an effect mirrored for private physiotherapy visits (0.78
compared with 0.41 visits), although the latter difference was not statistically significant. This was followed
by orthopaedics, with 2.55 visits per patient in the 0- to 3-month follow-up period for participants receiving
standard dressings. This fell to 0.98 visits per participant during the 9- to 12-month follow-up period. Within
community care, the district nurse category received the greatest average number of visits per participant,
with 4.74 visits per participant during the 0- to 3-month follow-up period, for participants randomised to
NPWT. Within the aids and adaptations category, statistically significantly (p = 0.008) more grab rails were
utilised on average by the participants in the standard dressing arm during the 3- to 6-month follow-up
period (0.12 grab rails on average, compared with 0.01 for those receiving NPWT).
Prescription medication usage was highest during the first 3 months of the post-randomisation period,
with 53% of all participants using some form of prescription medication. In the 3- to 6-month follow-up
period, this fell to 42% of participants, with statistically significantly (p = 0.044) higher usage for those
participants randomised to standard dressings (48% compared with 36%).
Economic costs
Economic costs for trial participants with complete data at each time point are presented in Table 30
by trial arm, study period and cost category. With the exception of the cost of the initial inpatient stay
(including costs associated with dressings and dressing changes), there were no statistically significant
differences in costs between the trial arms in any cost category. For the initial patient stay, mean costs
were £1223 higher in the NPWT arm (p = 0.030). Over the entire follow-up period, mean (SE) total NHS
and PSS costs, inclusive of the additional cost of the intervention and associated dressing changes, was
£14,079 (£1109) in the NPWT group, compared with £14,002 (£654) in the standard dressing group,
generating a mean cost difference of £77 (bootstrap 95% CI –£2114 to £2925).
Health-related quality-of-life outcomes
Table 31 presents the numbers and proportions of responses to each level of the EQ-5D-3L for each of the
five EQ-5D dimensions, across all follow-up time points, as well as the means and SEs for the EQ-5D VAS
and EQ-5D-3L utility scores for all follow-up time points. Presented also are p-values for the test of equality
of proportions of participants with suboptimal function between the two trial arms, for each EQ-5D
dimension, as well as p-values for the test of equality for the mean EQ-5D VAS and utility scores between
the two trial arms, at each follow-up time point. Participants in the two trial arms were strikingly similar,
with no statistically significant differences in EQ-5D outcomes across any of the tests carried out.
Cost-effectiveness results
Table 32 presents the incremental cost-effectiveness results for the NPWT dressing in the base-case analysis
as well as in each of the sensitivity analyses. The probability that NPWT is cost-effective is also presented,
at cost-effectiveness thresholds of £15,000, £20,000 and £30,000 per QALY gained, as well as the 95%
CIs for net monetary benefit at each of these cost-effectiveness thresholds. All analyses were adjusted for
potential imbalances in baseline covariates of age, gender, G&A grade and trial site. The analysis of QALYs
was adjusted for both pre-injury and post-injury baseline EQ-5D-3L utility scores.92
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TABLE 30 NHS and PSS costs (2014/15 pricesa) by cost category and follow-up point: complete cases
Cost category
Treatment group, mean cost (£) (SE)
Mean
difference p-value Bootstrap 95% CINPWT Standard
Baseline to 3 months (n= 285 complete cases out of 460 total)
Initial inpatient stay 10,324.10 (460.00) 9101.00 (319.10) 1223.10 0.030 210.60 to 2363.80
Inpatient care 717.90 (190.40) 814.50 (170.20) –96.60 0.705 –568.60 to 434.60
Outpatient care 545.90 (54.30) 625.50 (47.30) –79.60 0.271 –216.20 to 70.70
Community care 263.90 (45.00) 280.70 (33.90) –16.80 0.766 –121.00 to 101.00
Medications 25.90 (7.80) 19.30 (3.30) 6.60 0.440 –6.30 to 28.50
PSSs 32.00 (14.80) 85.30 (34.10) –53.30 0.153 –154.80 to 1.80
Aids and adaptations 10.20 (1.60) 13.60 (2.70) –3.40 0.277 –10.80 to 1.80
Total cost 11,919.90 (504.70) 10,939.90 (358.20) 980.00 0.115 –162.50 to 2255.00
3–6 months (n= 277 complete cases out of 460 total)
Inpatient care 724.70 (204.70) 842.60 (167.70) –117.90 0.656 –582.30 to 464.90
Outpatient care 542.80 (51.90) 591.70 (49.70) –48.90 0.496 –193.70 to 96.50
Community care 349.20 (94.10) 174.70 (25.90) 174.50 0.076 36.30 to 459.10
Medications 46.20 (28.10) 23.40 (10.30) 22.80 0.449 –13.90 to 134.80
PSSs 200.60 (164.40) 49.90 (24.90) 150.70 0.367 –34.60 to 857.50
Aids and adaptations 7.70 (2.90) 7.90 (2.60) –0.20 0.965 –7.40 to 7.90
Total cost 1871.10 (311.10) 1690.10 (193.00) 181.00 0.622 –464.70 to 996.00
6–9 months (n= 262 complete cases out of 460 total)
Inpatient care 651.90 (148.00) 461.30 (153.00) 190.60 0.371 –263.50 to 572.70
Outpatient care 290.20 (29.30) 386.80 (47.80) –96.60 0.086 –225.30 to –1.10
Community care 101.30 (21.80) 101.50 (20.80) –0.20 0.994 –58.60 to 58.00
Medications 27.10 (9.40) 12.10 (3.50) 15.00 0.135 0.20 to 42.40
PSSs 37.30 (20.90) 31.70 (19.50) 5.60 0.843 –49.40 to 63.90
Aids and adaptations 1.50 (0.60) 1.30 (0.60) 0.20 0.751 –1.80 to 1.90
Total cost 1109.50 (176.40) 994.60 (182.80) 114.90 0.652 –403.60 to 598.80
9–12 months (n = 322 complete cases out of 460 total)
Inpatient care 440.40 (183.50) 275.10 (79.30) 165.30 0.409 –111.50 to 765.90
Outpatient care 261.70 (33.00) 254.30 (32.90) 7.40 0.873 –87.70 to 95.70
Community care 50.30 (14.20) 66.80 (16.20) –16.50 0.444 –61.70 to 22.50
Medications 16.40 (5.90) 24.60 (10.80) –8.20 0.504 –44.60 to 9.70
PSSs 38.20 (26.50) 35.70 (23.00) 2.50 0.943 –65.80 to 71.60
Aids and adaptations 4.10 (2.10) 4.60 (3.70) –0.50 0.918 –14.70 to 5.10
Total cost 811.20 (204.30) 661.10 (97.20) 150.10 0.508 –176.10 to 815.40
Total NHS and PSS costs, including intervention costs (n= 152 complete cases out of 460 total)
14,078.90 (1108.60) 14,002.10 (653.60) 76.80 0.953 –2114.30 to 2925.40
a When relevant, prices were inflated/deflated to 2014/15 prices using the NHS hospital and community health services
pay and prices index.
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TABLE 31 The EQ-5D descriptive measurements by trial allocation, study period and dimension
Time/allocation
Domain, n (%)
Mobility Self-care Usual activities
Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal
Pre-injury baseline (n= 450)
Intervention
(n= 219)
184 (84) 34 (16) 1 (0.46) 35 (16) 202 (92) 15 (7) 2 (0.91) 17 (8) 195 (89) 22 (10) 2 (0.91) 24 (11)
Control
(n= 231)
202 (87) 29 (13) 0 (0) 29 (13)
0.298a
218 (94) 13 (6) 0 (0) 13 (6) 0.364a 210 (91) 16 (7) 5 (2) 21 (9) 0.509a
Post-injury baseline (n = 432)
Intervention
(n= 209)
3 (1) 50 (24) 156 (75) 206 (99) 27 (13) 117 (56) 65 (31) 182 (87) 3 (1) 34 (16) 172 (82) 206 (99)
Control
(n= 223)
3 (1) 45 (20) 175 (79) 220 (99)
0.936a
22 (10) 139 (62) 62 (28) 201 (90)
0.317a
2 (1) 32 (14) 189 (85) 221 (99)
0.601a
3 months (n= 322)
Intervention
(n= 149)
6 (4) 125 (84) 18 (12) 143 (96) 65 (44) 75 (50) 9 (6) 84 (56) 9 (6) 63 (42) 77 (52) 140 (94)
Control
(n= 173)
6 (3) 146 (84) 21 (12) 167 (97)
0.792a
66 (38) 105 (61) 2 (1) 107 (62)
0.319a
5 (3) 84 (49) 84 (49) 168 (97)
0.167a
6 months (n= 308)
Intervention
(n= 143)
19 (13) 121 (85) 3 (2) 124 (87) 87 (61) 54 (38) 2 (1) 56 (39) 12 (8) 84 (59) 47 (33) 131 (92)
Control
(n= 165)
27 (16) 134 (81) 4 (2) 138 (84)
0.450a
102 (62) 60 (36) 3 (2) 63 (38)
0.860a
21 (13) 94 (57) 50 (30) 144 (87)
0.220a
9 months (n= 294)
Intervention
(n= 143)
30 (21) 108 (76) 5 (4) 113 (79) 90 (63) 46 (32) 7 (5) 53 (37) 22 (15) 87 (61) 34 (24) 121 (85)
Control
(n= 151)
31 (21) 116 (77) 4 (3) 120 (80)
0.924a
95 (63) 54 (36) 2 (1) 56 (37)
0.997a
25 (17) 91 (60) 35 (23) 126 (83)
0.784a
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Time/allocation
Domain, n (%)
Mobility Self-care Usual activities
Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal
12 months (n = 362)
Intervention
(n= 172)
47 (27) 123 (72) 2 (1) 125 (73) 121 (70) 48 (28) 3 (2) 51 (30) 43 (25) 92 (54) 37 (22) 129 (75)
Control
(n= 190)
50 (26) 136 (72) 4 (2) 140 (74)
0.82a
132 (70) 56 (30) 2 (1) 58 (31)
0.856a
39 (21) 120 (63) 31 (16) 151 (80)
0.310a
Time/allocation
Domain, n (%)
EQ-5D VAS score EQ-5D-3L utility scorePain Anxiety/depression
Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Mean (SE) Mean (SE)
Pre-injury baseline (n= 450)
Intervention
(n= 219)
169 (77) 46 (21) 4 (2) 50 (23) 177 (81) 36 (16) 6 (3) 42 (19) 82.2 (1.2) 0.880 (0.015)
Control (n= 231) 192 (83) 34 (15) 5 (2) 39 (17)
0.113a
193 (84) 29 (13) 9 (4) 38 (17)
0.449a
82.6 (1.2) 0.804b 0.897 (0.014) 0.412b
Post-injury baseline (n = 432)
Intervention
(n= 209)
25 (12) 139 (67) 45 (22) 184 (88) 93 (45) 101 (48) 15 (7) 116 (56) 43.4 (1.6) 0.002 (0.020)
Control (n= 223) 25 (11) 155 (70) 43 (19) 198 (89)
0.807a
105 (47) 98 (44) 20 (9) 118 (53)
0.590a
42.6 (1.6) 0.702b –0.001 (0.021) 0.918b
3 months (n= 322)
Intervention
(n= 149)
22 (15) 103 (69) 24 (16) 127 (85) 69 (46) 73 (49) 7 (5) 80 (54) 57.2 (1.9) 0.345 (0.027)
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TABLE 31 The EQ-5D descriptive measurements by trial allocation, study period and dimension (continued )
Time/allocation
Domain, n (%)
EQ-5D VAS score EQ-5D-3L utility scorePain Anxiety/depression
Level 1 Level 2 Level 3 Suboptimal Level 1 Level 2 Level 3 Suboptimal Mean (SE) Mean (SE)
Control (n= 173) 18 (10) 132 (76) 23 (13) 155 (90)
0.237a
70 (41) 91 (53) 12 (7) 103 (60)
0.291a
60.0 (1.8) 0.253b 0.348 (0.026) 0.936b
6 months (n= 308)
Intervention
(n= 143)
19 (13) 107 (75) 17 (12) 124 (87) 61 (43) 69 (48) 13 (9) 82 (57) 62.8 (1.9) 0.468 (0.027)
Control (n= 165) 21 (13) 121 (73) 23 (14) 144 (87)
0.884a
80 (49) 72 (44) 13 (8) 85 (52)
0.306a
63.3 (1.9) 0.850b 0.477 (0.027) 0.809b
9 months (n= 294)
Intervention
(n= 143)
23 (16) 102 (71) 18 (13) 120 (84) 69 (48) 65 (46) 9 (6) 74 (52) 65.5 (2.0) 0.505 (0.028)
Control (n= 151) 22 (15) 119 (79) 10 (7) 129 (85)
0.719a
78 (52) 62 (41) 11 (7) 73 (48)
0.560a
67.3 (1.9) 0.498b 0.531 (0.025) 0.478b
12 months (n = 362)
Intervention
(n= 172)
30 (17) 122 (71) 20 (12) 142 (83) 85 (49) 73 (42) 14 (8) 87 (51) 67.7 (1.9) 0.547 (0.025)
Control (n= 190) 36 (19) 134 (71) 20 (11) 154 (81)
0.711a
105 (55) 72 (38) 13 (7) 85 (45)
0.266a
68.3 (1.7) 0.789b 0.563 (0.024) 0.640b
a p-value for difference between proportions experiencing suboptimal function in each group estimated using chi-squared test.
b p-value for difference between groups using t-test.
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TABLE 32 Cost-effectiveness results
Base-case and
sensitivity analyses
Incremental cost
(£) (95% CI)
Incremental
QALYs (95% CI) ICER (£)
Probability
cost-effectivea
Probability
cost-effectiveb
Probability
cost-effectivec
Net monetary
benefita (£)
(95% CI)
Net monetary
benefitb (£)
(95% CI)
Net monetary
benefitc (£)
(95% CI)
Base-case NHS and
PSS perspective –
imputed costs and
QALYs, covariate
adjusted
678
(–1082 to 2438)
0.002
(–0.054 to 0.059)
267,910 0.233 0.244 0.271 –615
(–2163 to 848)
–606
(–2210 to 938)
–588
(–2320 to 1169)
Societal perspective –
imputed costs and
QALYs, covariate
adjusted
2264
(–1271 to 5800)
0.008
(–0.043 to 0.059)
282,858 0.076 0.081 0.104 –2156
(–5177 to 826)
–2121
(–5197 to 922)
–2051
(–5324 to 1163)
QALYs calculated
using SF-6D –
imputed costs and
QALYs, covariate
adjusted
796
(–925 to 2518)
–0.002
(–0.030 to 0.027)
Dominated 0.119 0.120 0.127 –823
(–2216 to 585)
–833
(–2268 to 595)
–853
(–2347 to 674)
Complete-case
analysis – covariate
adjusted
–452
(–2926 to 2022)
0.022
(–0.041 to 0.086)
Dominant 0.709 0.721 0.736 760
(–1820 to 3401)
862
(–1919 to 3745)
1068
(–2195 to 4694)
Subgroup analysis –
deep infection
3295
(–3680 to 10,269)
–0.036
(–0.243 to 0.171)
Dominated 0.139 0.137 0.142 –3821
(–11,083 to 3414)
–3982
(–11,557 to 3777)
–4304
(–12,455 to 4155)
a Assumes a cost-effectiveness threshold of £15,000 per QALY.
b Assumes a cost-effectiveness threshold of £20,000 per QALY.
c Assumes a cost-effectiveness threshold of £30,000 per QALY.
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Base-case analysis
The base-case analysis used multiply imputed data and produced an ICER of £267,910 per QALY gained,
reflecting higher costs on average and marginally higher QALYs on average in the NPWT arm. The
probability that NPWT was cost-effective was also computed at the cost-effectiveness thresholds referred
to previously but never exceeded 27% (24.4% at the widely used £20,000 per QALY cost-effectiveness
threshold). The base-case analysis indicates that NPWT is highly unlikely to be cost-effective in this patient
population. The cost-effectiveness plane and CEAC for the base-case analysis are displayed in Figure 11.
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FIGURE 11 Base-case analysis. (a) Cost-effectiveness plane; and (b) CEAC.
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Sensitivity analyses
Societal perspective
When taking a broader costing perspective that additionally included costs that fell outside the NHS and
PSS sectors, the ICER increased to £282,858 per QALY gained, largely driven by an increased incremental
cost attributable to NPWT; the probability that NPWT is cost-effective did not exceed 11% (8.1% at a
£20,000 cost-effectiveness threshold). The cost-effectiveness plane and CEAC for the analysis carried out
taking a societal perspective is shown in Figure 12.
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FIGURE 12 Sensitivity analysis adopting a societal perspective. (a) Cost-effectiveness plane; and (b) CEAC.
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Quality-adjusted life-years calculated using the Short Form questionnaire-6 Dimensions
With QALYs calculated using the SF-6D utility measure rather than the EQ-5D-3L, NPWT was strictly
dominated by standard dressings, meaning that NPWT resulted in both higher costs and worse outcomes,
on average. The probability that NPWT is cost-effective did not exceed 13% (12.0% at a £20,000 per QALY
cost-effectiveness threshold). The cost-effectiveness plane and CEAC for the analysis with QALYs calculated
using the SF-6D is shown in Figure 13.
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FIGURE 13 Sensitivity analysis calculating QALYs using SF-6D rather than EQ-5D. (a) Cost-effectiveness plane;
and (b) CEAC.
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Complete-case analysis
The complete-case analysis restricted the analysis to individuals with complete data and resulted in a
qualitative change in the direction of the results, with NPWT becoming dominant in health economic
terms; that is, it generated both lower costs and higher QALYs, on average. The probability that NPWT is
cost-effective was estimated as 71%, 72% and 74% at cost-effectiveness thresholds of £15,000, £20,000
and £30,000 per QALY, respectively. The cost-effectiveness plane and CEAC for the complete-case analysis
are shown in Figure 14. Although there was a clear difference in the results of the base-case analysis using
multiply imputed data and the results of the complete-case analysis, this difference is plausible given the
large number of missing data. For the base-case analysis, complete cases were available for only 31% of
the total cases and logistic regressions on missingness of total QALYs and total costs support the
MAR assumption.
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FIGURE 14 Sensitivity analysis restricted to complete case. (a) Cost-effectiveness plane; and (b) CEAC.
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Subgroup analyses
A post hoc subgroup analysis was also carried out to explore the cost-effectiveness of NPWT in those
participants with a deep infection. NPWT was dominated in this group of participants, generating
increased costs and lower QALYs, on average. The probability of cost-effectiveness did not exceed 15%
and, as such, the results suggest that NPWT is highly unlikely to be cost-effective in this subgroup.
The cost-effectiveness plane and CEAC for the deep infection subgroup is shown in Figure 15.
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FIGURE 15 Deep infection subgroup. (a) Cost-effectiveness plane; and (b) CEAC.
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Chapter 6 Summary and discussion
Qualitative study
The integrated qualitative study (Chapter 3) was very important in the progression of the trial from the
feasibility to the main phase of recruitment. In particular, it informed the process for consent into the trial
in the context of acute trauma, emergency surgery and a potentially limb-threatening injury. There were
two related components to the qualitative work: first, the patient’s experience of having an open fracture
of the lower limb and its subsequent treatment and, second, the patient’s experience of taking part in the
trial under these difficult circumstances.
All of the patients involved in the interviews experienced a strong sense of vulnerability caused by the
traumatic injury. The extent of this emotional as well as physical vulnerability, although recognised in previous
studies, is brought home by the first-hand accounts described in the WOLLF study. There were several clear
themes: (1) emotional fragility, closeness to death and the loss of a limb and the processing of strong
emotions while containing emotions for the benefit of other people; (2) the state of being injured and
experiencing a changed sense of self as participants became a person with wounds, were constrained by their
broken body and lived with pain; and (3) living with injury and reimagining how home and work life will be in
the future. These themes underline the need for support that focuses on these areas: support in both the
acute phase of treatment in the hospital, but also on-going support following discharge into the community.
Despite the very serious nature of the injuries and the requirement for repeat operations and prolonged
periods in hospital, both treatment groups expressed a clear desire to be involved in this clinical trial of
emergency orthopaedic trauma.
With particular regard to the process of consent, the patients were comfortable with other people providing
consultee agreement in lieu of their personal consent, owing to their physical/emotional state in the immediate
period after the injury. Both groups had an overall faith in the team regarding their longer-term recovery and
hopes for the future and trusted that they would not put them in a study that caused them harm. They
expressed a clear view that they would like to be involved, to the limit of their capacity, in the decision-making
process before surgery. However, they were comfortable with the formal written consent process taking place
after surgery, when they had recovered full capacity and could consider all aspects of the trial. Although the
great majority of the patients gave their consent to continue in the study, it was important to them that they
had the option to withdraw at any time.
These findings were important in the trial-specific training that was provided during the main phase of the
WOLLF study. Patients should be included in the decision-making process as much as possible, but formal
written consent could, when appropriate, wait until after the initial surgery. This approach was also
supported by the staff who took part in the associated focus group.
Another important theme, and one which has implications for other trials in emergency surgery, is the
importance of the nature of the intervention under investigation. Both groups of patients felt that they did
not really know the interventions as they had no prior experience of them. This was particularly the case
for the group allocated to the NPWT intervention, although participants in this group generally felt that the
‘new technology’ was likely to be beneficial. This lack of prior knowledge is, of course, the case in most
emergency trials. In terms of this particular intervention, the patients also felt that the type of dressing
applied to the wound was of comparatively low importance at that time, in the context of their injury/
injuries more broadly. This emphasises the importance of tailoring the trial process to the nature of the
intervention. The involvement of patients and the public in the development of trial design, with particular
reference to the consent process, is therefore of great importance.
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Screening
Over 2400 patients were screened during the course of the trial, which is testament to the hard work of the
clinical and research associate teams in the trial centres. As expected, primary closure of the open-fracture
wound – that is, closure of the wound after the first surgical debridement of the open fracture – was by far
the most common reason, accounting for just under half of all patients excluded. Other exclusion criteria
were used much less commonly: injury sustained > 72 hours before presentation at a trial site (5%), G&A
grade 1 injury (13%), patient unable to adhere to trial procedures (8.7%) and primary amputation of the
limb (2%). Reassuringly, in terms of the external validity of the trial, only 3% of patients were excluded
because of ‘surgeon decision’, and only 0.3% of these because of surgical preference for one dressing or
another. Therefore, it is very unlikely that lack of surgical equipoise created a selection bias within the trial.
Interestingly, the rate of primary closure increased during the course of the WOLLF study, from 34.5% in
2012 to 56.6% in 2015 (see Figure 2), and this change of clinical practice was statistically significant
(p < 0.001). Although the WOLLF study was not designed to investigate such a change in clinical practice,
the study does provide an opportunity to quantify this increase in the rate of primary wound closure
following an open fracture of the lower limb; most MTCs in the UK taking part in the trial. The trial
coincided with the most significant change to the system for looking after patients with ‘major trauma’
that the NHS has known, namely the creation of the Major Trauma Networks in England in 2012. In the
Major Trauma Network system, and for the first time in the UK, patients with serious traumatic injuries,
including those with open fractures of the lower limb, bypassed the nearest hospital to be taken to a
designated MTC. The MTC specification included the colocation of orthopaedic trauma surgeons and
plastic surgeons, creating ’orthoplastic’ centres. These centres facilitated joint care between the two
surgical specialties and greatly increased the volume of patients with open fractures seen in each centre,
and hence the experience of the surgical and support teams. Traditional teaching in orthopaedic practice
was that it is ‘dangerous’ to primarily close any wound associated with an open fracture of the lower limb,
because of the high risk of infection.2 A ’second-look’ wound debridement was advocated, usually at
48–72 hours, when any non-viable or contaminated tissue would have ‘declared’ itself and could be
removed. This teaching was, at least in part, based on the fact that each individual surgeon in the 200
acute hospitals in England would see only one or two severe open fractures of the lower limb each year
and, therefore, few surgeons would gain sufficient experience to be entirely confident in their primary
wound debridement to the point at which they would close the open-fracture wound at the first visit to
the operating theatre. With the development of the Major Trauma Network, the surgeons in each of these
22 adult MTCs would individually become much more experienced. This greater experience added to the
fact that joint orthoplastic working enabled shared decision-making and therefore even more confidence
in early radical wound debridement. While it is, to some degree, speculation, it seems likely that this great
experience/confidence led to the increased use of primary wound closure noted during the course of
the trial.
Declined to participate
In total, 625 patients were randomised into the WOLLF study. Of these, 460 were eligible and consented
to participate in the trial. A total of 165 patients did not consent to enter the trial: 85 in the NPWT group
and 80 in the standard dressing group.
The patients who declined to consent, were not able to consent or were ineligible for inclusion in the
study after initial recruitment (see Table 6) were generally older and more likely to be female. One of
the exclusion criteria was that patients were unable to adhere to trial procedures, including filling out
questionnaires, and this was most commonly because of permanent cognitive impairment. This may
explain why the patients who did not consent were older than those who did consent. However, the
number of patients in this category was small, so it seems more likely that older female patients were
either less likely to survive their injuries, or simply less likely to agree to participate.
There were two main reasons for patients being unable to take part in the trial post randomisation.
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First, owing to the emergency nature of the surgery, many patients went straight to the operating theatre
before their eligibility for the trial could be definitively confirmed. For example, some patients were
unconscious or had been anaesthetised before transfer to the hospital, so that, at the time of surgery,
it was not clear whether or not they would be able to ‘adhere to trial procedures’. Therefore, it was
anticipated that a number of patients randomised would subsequently be deemed ineligible to participate
in the trial.
Second, and in keeping with the findings of the integrated qualitative study, we anticipated that a small
number of patients who were not able to consent to enter the trial prospectively, owing to lack of
capacity, would subsequently choose not to take part in the trial.
Regarding the first group, 140 out of the 165 patients who did not consent for the trial were found to be
ineligible in the postoperative period and were therefore not consented to take part. Of these, 75 were in
the NPWT group and 65 in the standard dressing group (see Figure 6). Some of the reasons for ineligibility
were anticipated. These included 28 patients in each group who were deemed ‘unable to adhere to
trial procedures’ or ‘unable to consent before 6 weeks’, most of whom had significant head injuries in
association with their open fracture of the lower limb or were found to have permanent cognitive
impairment which could not be identified preoperatively. In keeping with the major trauma sustained
by patients in this trial, 14 patients died in the postoperative period and were never able to consent.
However, of the ‘other’ reasons (see Figure 6), the great majority were actually related to failure of the
surgical team to follow the trial procedures. Several sites, particularly at the beginning of the trial, chose
to randomise the patients during surgery, rather than waiting until the end of the operation. This was
understandable, as it allowed the operating theatre team to prepare the dressings in advance of the
wound closure. However, the result was that several patients were randomised before a final decision
about the open-fracture wound was taken. A total of 20 patients in the NPWT group and 18 patients in
the standard dressing group went on to have a primary wound closure and were therefore no longer
eligible for the trial. One patient in each group went on to have an amputation as the extent of the injury
became clear during surgery. As this issue was recognised, the sites received further training and the
number of patients randomised before the end of surgery reduced as the trial continued. When possible,
all patients who were randomised into the trial but who were subsequently found to be ineligible were
told about the trial but no other data were collected on these patients.
There is no reason to suspect that these patients, who were randomised but later found to be ineligible,
created a selection bias within the trial.
Of more potential concern were the second group of patients who were eligible and were randomised,
but who later declined to participate. If this group of patients was large, it could draw into question
the external validity of the trial, that is, the ability to generalise the results of the trial to the broader
population of patients with an open fracture of the lower limb. However, in keeping with the findings of
the integrated qualitative study, the great majority of patients were happy to take part. In fact, only 25
potentially eligible patients declined to participate in the WOLLF study: 10 in the NPWT group and 15 in
the standard dressing group. The most common reason for declining was that the patient ‘did not want to
be part of a research project’ or ‘did not want to complete questionnaires’. Overall, 460 out of the 485
(95%) patients who were randomised and eligible for the trial agreed to participate in the WOLLF study.
Therefore, we can be very confident that the patients who took part were representative of the population
with open fractures of the lower limb.
Treatment according to allocation
There were 23 deviations (crossovers) from the allocated treatment: 15 in the NPWT group and eight in
the standard dressing group. Eight of these (four in each group) were because of miscommunication
between the surgical team and the operating theatre staff and three were caused by lack of equipment.
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However, nine cases in the NPWT group and three in the standard dressing group were because of
interoperative surgeon preference, which may reflect a lack of equipoise. However, as this number was a
very small proportion of the total number of patients we did not expect it to affect the results of the trial
(i.e. we did not anticipate a difference between the ITT and secondary per-treatment analysis).
Recruitment by centre
There was considerable variation in the rate of recruitment by centre. The fastest rate of recruitment was in
Bristol MTC, at just under two patients per month. Other units struggled to recruit to the trial. In some cases,
this was caused by the increasing effects of the Major Trauma Network service reconfiguration. For example,
the only centre to withdraw from the trial was Reading after a Network decision that all patients with a
suspected open fracture of the lower limb were to bypass the Royal Berkshire Hospital and go directly to the
regional MTC in Oxford. In general, recruitment in the ‘Trauma Units’ reduced over time as more patients
with an open fracture of the lower limb were diverted to the regional MTCs as they matured. In some
centres, the slow rate of recruitment was largely caused by staffing issues in the local research team.
However, more pertinently, the breakdown of recruited participants by centre and G&A grade showed
good balance between treatments both across and within centres (see Table 6).
Baseline characteristics of the two groups
Overall, the baseline characteristics of the two groups of participants were very well balanced by the
randomisation process.
Patients
The largest group of patients in the WOLLF study were young men, with the most common age group
being in their 20s. This fits with the idea that younger men are more likely to suffer the sort of high-energy
trauma associated with open fractures of the lower limb, the sort of trauma that can cause severe injuries
even in the presence of normal bone quality. Over half of all the open fractures were caused by road
traffic accidents, many of which involved motorcycles.
Only 30% of the open fractures occurred in women. However, in this group, the most common age group
was in their 70s. This suggests that the mechanism of injury is different in women, being more likely to be
low-energy trauma in association with osteoporosis (brittle bones).
Fractures
Over 80% of all of the open fractures in the trial occurred in the tibia. The tibia is subcutaneous for its
entire length from the knee down to the ankle (i.e. there is very little soft tissue covering the tibia so the
bone is more likely to penetrate the overlying skin when it is broken). The next most commonly broken
bone was the femur, closely followed by the bones in the foot.
Just over one-third of the patients in the trial required concomitant surgery for other injuries sustained at
the time of the open fracture. This highlights the fact that the majority of patients sustained high-energy
trauma, during which other areas of the body were also likely to be injured. The most common other
areas requiring surgery were the contralateral lower limb (≈17%) and another part of the ipsilateral limb
(≈12%), followed by upper limb injuries in around 10% of patients. Head (≈3%), spine (≈2%), chest
(≈1%), abdominal (≈2%) and pelvic (≈4%) surgery were much less common.
Surgeons and surgery
Two-thirds of operations were performed by consultant surgeons, with the majority of the other
procedures performed by trainees under the supervision of consultant surgeons. Associate specialist
surgeons performed < 5% of operations in each treatment group. In keeping with the principle of joint
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orthoplastic surgical operating, there was a median of two surgeons involved in each case. On average,
the primary wound debridement and associated surgery took 2 hours. However, as expected given the
wide range of injuries and variable requirement for fixation of the broken bones, there was considerable
variation around this 2-hour average operating time.
Current clinical guidelines8 suggest that definitive fixation of the bone involved in an open fracture should
be performed at the same time as definitive closure of the wound. Therefore, it is no surprise that the
most common form of initial fixation was external fixation, this being the common ‘temporary’ method to
hold the position of the broken bone pending definitive internal fixation at a second sitting when the
wound was closed.
A total of 47% of patients in both groups had ‘half-pin’ external fixation at their initial surgery. Half-pins
were generally used for temporary fixation rather than ‘fine-wire’ external fixators (see Table 7), with the
latter being more commonly used for definitive fixation. Table 11 shows that in the great majority of
patients treated with a half-pin external fixator at the initial surgery this was later converted to definitive
internal fixation at the second procedure when the wound was closed. In some cases, external fixation
may be the definitive form of fixation. This most commonly involved ‘fine-wire’ fixation. However, in
only 1.3% of the NPWT group and 4.7% of the standard dressing group was fine-wire fixation the first
operation. These figrures rose to 8.1% and 14.7%, respectively, at the second operation. This probably
reflects the fact that application of circular frames using fine-wires is technically demanding (not all
surgeons perform this procedure) and can be time-consuming, so surgeons are less likely to perform
fine-wire external fixation in the emergency setting of the first wound debridement. Interestingly, despite
the current NICE guidelines,8 half of the patients in both groups had definitive internal fixation at their first
operation. This may reflect the fact that the WOLLF study started before the guidelines were developed, so
surgeons may have been unaware of the evidence behind this particular NICE guideline. In keeping with the
fact that the most commonly injured bone was the tibia, the most common type of internal fixation was
intramedullary nail (around 22% in both groups), followed by plate and screw fixation (around 15%). It is
important to note that the choice of initial fixation took place before the patient was randomised, so it did
not influence the choice of dressing at the end of the procedure.
As anticipated, there was also considerable variation in the type of procedure used to close the wound
definitively (see Table 11). The most commonly used option was a free flap – this option was used in 40%
of patients in the NPWT group and 35% of the standard dressing group. Free flaps are a technique
whereby tissue is transported from a site away from the zone of injury into the open-fracture wound
together with its own blood vessels. These blood vessels are then ‘anastamosed’ (sewn into) the local
blood vessels to restore blood supply. The formation of free flaps is a technically demanding procedure
and may take several hours to perform but, providing that the local blood vessels are intact, a free flap can
be used to cover essentially any type of wound. Local flaps were used in 15% of NPWT patients and 14%
of the patients in the standard dressing group. Local flaps, as the name would suggest, involve moving
tissue locally using that tissue’s existing blood supply. Although generally less time-consuming, the
surgeon’s ability to use a local flap depends on how much damage there has been to the tissues around
the open-fracture wound. The amount of damage may not always be obvious, so local flaps are
considered less reliable than free flaps in many cases. Approximately 20% of both groups had a simple
split skin graft. A split skin graft involves taking a partial thickness area of skin from a part of the body
outside the zone of injury and transporting it into the area of the open fracture. A split skin graft does not
need its own blood vessels so it is a relatively simple and quick procedure. However, it can be used only if
there is healthy muscle covering the broken bone, as split skin grafts do not heal when applied directly to
the surface of bone. Therefore, split skin grafts are generally used only in less severe open fractures. The
majority of the remaining patients underwent delayed primary closure of their wound (i.e. the surgeons
were able to sew together the edges of the open-fracture wound without the need for a graft). In the
context of the WOLLF study, there was no statistically significant difference in the proportion of patients
having skin grafting or primary closure of the wound.
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In some areas of the world, NPWT is used for prolonged periods of time following an open fracture of
the lower limb, the theory being that NPWT may reduce the size of the wound over time and, therefore,
reduce the need for complex free-tissue transfer surgery. This is particularly the case in the developing
world, where access to the resources and skills needed for flap reconstruction is limited. Since the start
of the WOLLF study, there have been two other reports of the use of NPWT in association with open
fractures. The first trial compared two types of fixation for one particular fracture (heel fracture) rather
than comparing NPWT with another type of dressing and, therefore, is not relevant to this research
question.102 The second trial103 did, however, compare NPWT with standard dressings. This single-centre
trial randomised 90 patients into two groups and followed them for 1 month only. The ‘rate’ of wound
healing (defined by the ‘wound surface area’) was noted to be quicker in the group treated with NPWT,
but there was no difference in the incidence of infection. This trial describes the use of NPWT over a
prolonged period of time, as described in the following text:
Wounds were examined weekly and following, measurements were recorded presence of granulation
tissue, wound bed becomes redder, decrease in wound drainage, and decrease in dimensions
of wound.
Arti et al.103
This trial also describes when the use of NPWT was stopped:
V.A.C Therapy [a trade name for NPWT] was terminated when adequate granulation base was
achieved allowing for change to conventional dressing, split-thickness skin graft, or flap closure.
Arti et al.103
This is a very different use of NPWT from that advocated by the BOAST7 and NICE8 guidelines for the
management of open fractures, in which early definitive wound closure (within 72 hours) is recommended.
It is unlikely that NPWT applied for < 72 hours would have led to a reduction in the size of the open-fracture
wound and hence an increase in the use of simple split skin grafting or primary closure. This is borne out
in the trial results; if anything, fewer patients in the NPWT group (16%) had primary closure of their
open-fracture wound than in the standard dressing group (20%). The length of follow-up in the Arti et al.103
trial was short and no patient-reported outcomes were described. Therefore, although that trial ostensibly
addresses the same question as the WOLLF study, it is not clear whether or not the results are pertinent to
the UK NHS or indeed other health-care systems.
Follow-up rate
Inevitably, some patients did not complete the study. The largest group of participants were men aged
< 40 years, who are not normally considered to be the most reliable demographic for returning study
questionnaires. However, thanks to the efforts of the trial administration team, the number of patients lost
to follow-up in the WOLLF study was actually small. A total of 86 study participants did not provide DRI data
at the 12-month study end point and 33 participants withdrew from the study after consenting but before
the study end point; therefore, based on the available participants, the study is 88% (374/427) complete.
Outcomes
Primary outcome
The primary outcome measure for the WOLLF study was the DRI. The DRI allowed the study participants to
make their own assessment of their disability between 0 and 100 points, where 0 represents no disability
and 100 represents complete disability. The primary end point for the trial was 12 months. Baseline
(retrospective, pre-injury) DRI was also assessed, as was earlier outcome at 3, 6 and 9 months.
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Table 12 shows observed means and SDs for the DRI and Figure 6 shows the full data distributions and
trends in the mean scores. At baseline, pre injury, the majority of patients reported that they had no
disability or only minor disability. However, a few patients had quite significant pre-existing disability and
so the mean DRI before the open fracture was 12 points. This correlates with the fact that, although the
open fractures occurred most commonly in young fit patients, older patients and those with significant
pre-injury disability were also affected. The DRI scores improved in the 12 months following the open
fracture. However, in keeping with the existing literature,1–4 patients still had considerable disability at
1 year after this very significant injury. At 3 months, the mean DRI score was 65 points, improving to
52 points at 6 months, 47 points at 9 months and finally 44 points at 12 months.
The covariates used to adjust the treatment effect estimates generally showed strong statistical
significance, indicating that the inclusion of these terms improved the overall model fit. For example,
a higher pre-injury DRI was associated with a higher 12-month DRI (p < 0.001). Participants aged ≥ 40 years
had a higher 12-month DRI than those aged < 40 years (p < 0.001). As per the existing literature, the
12-month DRI was higher for those participants with a G&A grade of 3, or 3 with vascular involvement,
than for those participants with a G&A grade of 2 (p = 0.047).2
The main results of the WOLLF study is that there was no evidence of a difference in the DRI at 12 months
between those patients treated with NPWT and those treated with standard wound dressings. The mean
DRI in the NPWT group was 45.5 points (SD 28.0 points), compared with 42.4 points (SD 24.2 points) in
the standard dressing group, giving a difference of –3.9 points (95% CI –8.9 to 1.2 points) in favour of
standard dressings (p = 0.132). As the MCID for the DRI is 8 points, we conclude that it is extremely
unlikely that NPWT dressings confer a clinically important difference in DRI scores for patients with an
open fracture of the lower limb. Similarly, there was no evidence of a difference in DRI scores at 3, 6 or
9 months.
A systematic review of the literature before this trial showed only one RCT comparing standard wound
dressing with NPWT for patients with open fractures of the lower limb. Stannard et al.14 did not report a
Disability Rating so there is no existing evidence with which to compare this result.
Pre-planned subgroup and secondary analyses of the Disability Rating Index
The secondary PP (per treatment) analysis did not differ from the primary ITT analysis, and the difference
between groups was –4.0 points (95% CI –9.1 to 1.0 points) in favour of the standard dressings with
p-value of 0.119. This was as expected because the number of patients who crossed over (i.e. did not
receive the treatment allocated) within the trial was small.
As noted above, the number of participants who did not complete the trial was small. However, we
performed a secondary analysis using imputation to account for missing data (see Table 37, Appendix 2).
As expected, the results were very similar to those from the complete-case analysis, indicating that missing
data do not affect the result of the trial.
Secondary outcome measures
Health-related quality of life
Health-related QoL was measured using the EQ-5D-3L utility score, EQ-5D VAS score, physical health score
(PCS from SF-12) and mental health score (MCS from SF-12) in the 12 months post randomisation. Scores
for all outcome measures, other than mental health score, improve significantly in both groups, indicating
improved physical health but participants never recover to pre-injury levels. This is in keeping with the
results of the primary outcome measure of Disability Rating. Mental health score, as measured by MCS,
does not vary much in the 12 months following injury, but is always marginally lower than pre-injury levels.
As per the results of the integrated qualitative research presented in Chapter 3, it may be that physical
recovery following an open fracture of the lower limb proceeds more rapidly than recovery in mental health.
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The analysis of the HRQoL data by treatment group corroborates the analysis of the primary Disability
Rating outcome. There is no evidence to support statistically significant differences between treatment
groups in any of these measures, at any time point in the first year after injury.
A systematic review of the literature identified only one RCT14 comparing standard wound dressing with
NPWT for patients with open fractures of the lower limb. Stannard et al.14 reported HRQoL using the Short
Form questionnaire-36 items at 3-, 6-, 9- and 12-month follow-ups and final follow-up. They found:
There were no significant differences in the mental component score between the 2 groups at any
time point, and there was no significant difference between the groups in PCS for patients who
did not develop an infection.
The authors also found that:
However, there was a significant difference at 3 months (P = 0.013), 6 months (P = 0.049), and
9 months (0.005) after injury in favor of a higher PCS in patients randomized to receive NPWT.
Clearly, the rate of deep infection noted in that trial had a large influence on the physical component of
HRQoL. This is discussed further in Complications and Complications local to the open fracture.
Complications
When interpreting the primary outcome of any trial, it is important to take account of the complication
profile of the two interventions. This is particularly important in the WOLLF study as the interventions
under investigation are specifically designed to improve wound healing and thereby reduce the risk of
deep infection at the site of the open fracture. We have broken these AEs down into ‘complications local
to the open fracture’, most notably infection, ‘systemic complications of the open fracture or its treatment’
and ‘unrelated adverse events’, during the 12 months after the injury.
Complications local to the open fracture
Deep surgical site infection
In total, 35 out of the 460 (7.6%) participants in the WOLLF study had a deep SSI. From any perspective, this
rate of deep infection is high, but it is lower than in most other published series of severe open fractures of
the lower limb.2–4 Although comparisons with other series in the literature should be made with caution,
given the different mechanisms of injury and health-care systems, this relatively low rate of deep infection
could be considered ‘encouraging’. It is tempting to attribute this to the development of multidisciplinary
orthoplastic units and the Major Trauma Network in England. However, longitudinal investigations would be
required to investigate this relationship more thoroughly.
With regard to the rate of deep SSI by treatment group, 16 (7.1%) participants in the NPWT treatment
group and 19 (8.1%) participants in the standard dressing group had a deep infection. Mixed-effects
logistic regression showed no evidence that the rate of deep SSI differed between treatment groups
[estimated OR 1.18 (95% CI 0.59 to 2.37), with p-value from ANOVA F-test 0.638].
As noted earlier, a systematic review of the literature identified only one other RCT14 comparing standard
wound dressing with NPWT for patients with open fractures of the lower limb. Stannard et al.14 demonstrated
a reduction in the rate of deep wound infection in the group of patients treated with NPWT compared
with control [5.4% vs. 20%; RR 0.199 (95% CI 0.05 to 0.87)]. However, this was a small trial (59 patients,
63 fractures) and there were only seven deep infections in the control group and two in the NPWT group. It is
possible that the different rate of deep SSI found in that trial was due to systematic differences in the patients
and/or the treatment pathway in a single centre in the USA; the WOLLF study, in contrast, took place in the
much broader setting of 24 centres in the UK. However, given the relatively small number of cases in the
Stannard et al. trial,14 it is perhaps more likely that the result represents a lack of precision in the estimate of
the incidence of deep infection.
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Other complications local to the open fracture
In keeping with the data for deep SSI, the WOLLF study found no evidence to suggest that numbers of
other local related complications differed between treatment groups (see p-values in Tables 16 and 18).
There was no difference in the numbers of superficial SSIs. As expected, superficial infections were more
common than deep infections. In total, 68 out of the 460 participants (14.8%) had a superficial SSI
according to the CDC criteria: 35 (15.5%) in the NPWT treatment group and 33 (14.1%) in the standard
dressing group. In the WOLLF study, we used photographs of the wound as a supplementary assessment
of infection. The correlation between photographs and other criteria for the diagnosis of infection requires
further investigation. However, it is reassuring that the estimate of the rate of superficial infection on the
photographs was similar to that estimated using the more usual clinical criteria: 27 (15.4%) in the NPWT
group and 31 (17.2%) in the standard dressing group.
In the context of severely injured patients, the number of deep-vein thromboses/pulmonary emboli was
low: six in the NPWT group and four in the standard dressing group. As the wound debridement and
fixation (albeit temporary in some cases) took place before the allocation of treatment, there was no
reason to suspect that the incidence of soft-tissue complications [e.g. nerve or tendon damage, or early
failure of fixation (within 6 weeks)], malunion or non-union would differ between groups and, indeed, no
difference was observed in the trial. Thirty-nine participants had radiographic evidence of non-union at
12 months, 21 in the NPWT group (9.3%) and 18 in the standard dressing group (7.7%).
Patients with an open fracture of the lower limb often require more than one further operation, either
as part of the primary debridement and fixation of the wound and open fracture or in relation to local
related complications such as non-union or infection. This was also the case in the WOLLF study, with some
patients requiring repeat surgery. The most common reasons for reoperation were as expected. Removal
of metalwork (either internal fixation or removal of external fixation under anaesthetic) was required in
44 participants: 18 in the NPWT group and 26 in the standard dressing group. Revision of the wound coverage
was relatively rare, occurring in 33 patients, but only six in each group required a free flap. This may also reflect
increased experience and improved decision-making in the new orthoplastic centres discussed earlier. Ten
patients required amputation of the injured limb: four in the NPWT group and six in the standard dressing
group. This is lower than in other published series,104 but it should be remembered that patients who
underwent primary amputation at the first wound debridement (37 patients in the screening log) were not
eligible for the trial (i.e. patients with unreconstructable leg trauma were excluded from participation).
However, two of the patients who underwent amputation later died of complications that may have been
related to the amputation.
Overall, there was no evidence to suggest that the number of related reoperations differed between
treatment groups (see p-values in Table 19). Mixed-effects logistic regression showed no evidence that
overall revision fixation rates differed between treatment groups [8.0% in the NPWT group and 6.4% in
the standard dressing group (see Table 19); estimated OR 0.78 (95% CI 0.38 to 1.60), with p-value from
ANOVA F-test 0.494].
Systematic complications
As noted previously, open fractures frequently occur in the context of patients suffering multiple injuries. It may
be difficult to separate the systemic effects of an open fracture of the lower limb from the effects of trauma to
other areas of the body. For the purposes of the trial, we took a conservative view and presumed that systemic
complications, including death, were related to the open fracture and its treatment, unless demonstrably
otherwise. Seven participants died of systemic complications during the 12 months after the injury.
Unrelated adverse events
Medical complications included the treatment of chest and urinary infections, etc. These were the most
common systemic complications occurring in 40 patients: 19 in the NPWT group and 21 in the standard
dressing group. There were relatively few psychiatric referrals, which is somewhat surprising given the
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patient experiences documented in Chapter 3. This may reflect the lack of psychiatric/psychological support
services available to trauma patients, rather than a lack of need.
Surgical complications included any return to the operating theatre for treatment other than to the open
fracture. These were common, occurring in 143 participants: 68 in the NPWT group and 75 in the
standard dressing group. Some of these were for the treatment of injuries sustained at the same time as
the open fracture, but most were entirely unrelated, for example elective removal of gallstones. There was
no evidence to suggest that the number of unrelated reoperations differed between treatment groups.
In total, 10 participant deaths were reported during the study: six in the NPWT group and four in the
standard dressing group. As noted previously, two deaths were related to complications following
amputation of the limb with the open fracture and so were deemed related and local and seven were
possibly related but systemic (chest infection, pulmonary embolus, etc.). Only one death was considered
completely unrelated. That patient died in a house fire.
Health economic evaluation
The health economic evaluation shows that costs for individual participants varied greatly across the
WOLLF study. Patients who underwent a successful primary delayed wound closure and definitive fixation
of their fracture with no complications incurred low costs, but patients requiring free-flap surgery or repeat
surgery for complications incurred dramatically increased costs. This is in keeping with previous studies that
reported that complex soft-tissue reconstruction procedures and complications, including amputation,
greatly increased morbidity and cost in the context of open fractures.105
The index hospital admission costs were, to a large degree, determined by the primary operative procedure
associated with that admission, that is, the most resource-intensive procedure. The most common primary
procedure was free flap, which is also the most expensive. In terms of the choice of fixation, the only
statistically significant difference was in the number of participants receiving ‘primary open reduction of
fracture of long bone and extramedullary fixation using plate of hip’ as their primary procedure (p = 0.005).
However, as temporary external fixation is hardly every used in the region of the hip joint, the decision to
use a plate fixation was almost certainly made before the patient was randomised (i.e. any difference is by
chance). With the exception of the cost of the initial inpatient stay (including costs associated with dressings
and dressing changes), there were no statistically significant differences in costs between the trial arms in
any cost category. For the initial patient stay, mean costs were £1223 higher in the NPWT arm (p = 0.030).
However, over the entire follow-up period, there was no evidence of a difference in costs; mean total NHS
and PSS costs were £14,079 in the NPWT group, compared with £14,002 in the standard dressing arm,
generating a mean cost difference of just £77 (bootstrap 95% CI –£2114 to £2925).
Cost-effectiveness
Given that there was very little difference in HRQoL outcomes measured during the 12 months after the
injury and little difference in cost, the cost-effectiveness analysis is very clear. The base-case analysis used
multiply imputed data and produced an ICER of £267,910 per QALY gained, reflecting higher costs on
average and marginally higher QALYs, on average, in the NPWT arm. The probability that NPWT was
cost-effective was low.
The conclusion from the base-case analysis is not altered by the various sensitivity analyses. When broader
social costs are included (e.g. time off work), the ICER increases to £282,858 per QALY gained. With
QALYs calculated using the SF-6D rather than the EQ-5D-3L, NPWT was strictly dominated by standard
dressings, meaning that NPWT resulted in both higher costs and worse outcomes. The only doubt is raised
by the complete-case analysis, for which NPWT generated slightly lower costs and slightly higher QALYs,
on average. The probability that NPWT is cost-effective was estimated as 72% at cost-effectiveness
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thresholds of £20,000 per QALY in the complete-case analysis. However, under the MAR assumption, it is
multiple imputation that produces unbiased estimates of treatment effect.106 Given that complete health
economic data were available in only 31% of cases, it is thus reasonable and unsurprising that the
complete-case analysis produced different results, as this analysis is based only on a subset of the data and
a subset for which missingness could be predicted from the other covariates, rather than being missing
completely at random. Therefore, it is the base-case analysis using multiple imputation that makes use of
all the relevant health economic data and that, under the MAR assumption, provides an unbiased estimate
of the cost-effectiveness of NPWT dressings.
Limitations
There are, of course, some limitations to the trial. A total of 625 potentially eligible participants were
randomised into the trial, but only 460 were eligible and able to provide informed consent. This could
pose a risk to the external validity (generalisability) of the trial. However, the great majority of these
patients were found to be ineligible after randomisation owing to, for example, primary closure of the
wound or permanent cognitive impairment that could not be recognised before surgery/randomisation.
In fact, only 25 potentially eligible patients actually declined to participate in the WOLLF study: 10 in the
NPWT group and 15 in the standard dressing group. The most common reasons for declining were that
the patient ‘did not want to be part of a research project’ or ‘did not want to complete questionnaires’.
Overall, 460 out of the 485 (95%) patients who were randomised and eligible for the trial agreed to
participate in the WOLLF study. Therefore, we can be confident that the patients who took part were
representative of the population with open fractures of the lower limb.
Another possible limitation was post-randomisation crossover of patients from one group to the other.
However, only 23 patients crossed over; therefore, 95% of patients received the treatment to which they
had been allocated. A bigger concern in the early phases of the study was loss to follow-up. The largest
number of participants were men < 40 years, who are not normally considered to be the most reliable
demographic for returning study questionnaires. However, following the pilot stage of the trial we
included e-mail and text message reminders to this group of patients and contacted those who preferred
to do so by telephone. Thanks to the efforts of the trial administration team, the number of patients lost
to follow-up in the WOLLF study was actually small. A total of 86 study participants did not provide DRI
data at the 12-month study end point and 33 participants withdrew from the study after consenting but
before the study end point. Therefore, based on the available participants, the study is 88% (374/427)
complete. This is slightly less than the 90% predicted in the protocol but the 2% difference is highly
unlikely to alter the result.
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Chapter 7 Conclusion
Contrary to the existing literature and current clinical guidelines,7,8,13 NPWT dressings do not provide aclinical or economic benefit for patients with an open fracture of the lower limb. Future work should
investigate alternative strategies to reduce the incidence of infection and improve outcomes for patients
with open fractures of the lower limb. Two specific areas of potentially great benefit are (1) the use of
topical antibiotic preparations in the open-fracture wound and (2) the role of orthopaedic implants with
antimicrobial coatings when fixing the associated fracture.
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
97

Acknowledgements
Trial team
Trial management team
Professor Matthew Costa, chief investigator; Dr Nick R Parsons, trial statistician; Dr Juul Achten, research
manager; Dr Julie Bruce, principal research fellow; Mrs Sonia Davis, trial co-ordinator; Professor Stavros
Petrou, Professor of Health Economics; Ben Parker, health economist; Professor Sarah Lamb, Professor of
Rehabilitation; Mrs Susie Hennings, senior project manager; James Masters, specialist registrar; Rishpal Rai,
trial administrator; and Liz Weaver, data clerk.
Trial applicants
Professor Matthew Costa, chief investigator; Dr Juul Achten, coapplicant; Professor Sarah Lamb,
coapplicant; Professor Keith Willett, coapplicant; Professor Stavros Petrou, coapplicant; Lt.Col.
Steven Jeffery, coapplicant; Professor Damian Griffin, coapplicant; Dr Elizabeth Tutton, coapplicant; and
Dr Julie Bruce, coapplicant.
Trial Steering Committee
Professor Matthew Costa, chief investigator; Professor James Mason, Professor of Health Economics;
Professor Amar Rangan, Professor of Orthopaedic Surgery (independent member); Professor Mike Reed,
consultant orthopaedic surgeon (independent member); Mrs Carole Beamish, lay member, quality
assurance (independent member); Mrs Ceri Jones, manager, research and development, and UHCW
(sponsor representative).
Data Management Committee
Professor Lee Shepstone, Professor of Medical Statistics (chairperson); Professor Simon Donell, consultant
orthopaedic surgeon (independent member); and Mr Phillip Johnston, consultant orthopaedic surgeon
(independent member).
Statistician
Dr Nick Parsons.
Health economists
Professor Stavros Petrou and Mr Ben Parker.
Radiological evaluation
Mr James Masters.
Programming team
Henry Adjei (Programmer, University of Warwick), Chockalingam Muthiah (Programmer, University of
Warwick) and Adrian Willis (Senior Programmer, University of Warwick).
Research team
Principal investigators
Jill Arrowsmith, Gorav Datta, Mick Dennison, Mark Farrar, Peter Giannoudis, Andrew Gray, Philip Henman,
Peter Hull, Umraz Khan, Charlotte Lewis, David Loveday, Jitendra Mangwani, Andrew McAndrew, Damian
McClelland, Mick McNicholas, David Noyes, Ben Ollivere, Ian Pallister, Keith Porter, Manoj Ramachandran,
Rory Rickard, Benedict Rogers, Hemant Sharma, Adel Tavakkolizadeh and Jonathan Young.
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
Research associates
Gokturk Abdulkerim, Shanaz Ahmad, Naheed Akhtar, Manjit Attwal, Sheeba Babu, Steven Barnfield,
Conor Bentley, Jackie Berry, Natalie Blytt-Jordens, Racquel Carpio, Katherine Coates, Louise Clarkson,
Carolyn Colvin, Bernadette Cook, Lauren Cooper, Shirley Cooper, Maria Dibua, Alisen Dube, Julie Foxton,
Christina Haines, Ruth Halliday, Simone Hargreaves, Elizabeth Hawes, Jamila Kassam, Laura Latter,
Maria Letts, Kathryn Lewis, Candice Matthews, Jess Nightingale, Ismail Patel, Sandra Owdziej,
Tracey Potter, Carrie Ridley, Elizabeth Saunders, Karen Smith, Louise Spoors, Rosalyn Squire, Sylvia Turner,
Ylenia Vigo, Maria Vincent and Lisa Wilson.
Contributions of authors
Matthew L Costa was the chief investigator and was responsible for study conception and design, clinical
responsibility and writing and reviewing the report.
Juul Achten was responsible for study conception and design, developing the protocol, writing and
reviewing the report, and was a member of the TMG.
Julie Bruce was responsible for developing the protocol, quality assurance of photographic review, writing
and reviewing the report, and was a member of the TMG.
Sonia Davis was responsible for study management, writing and reviewing the report, and was a member
of the TMG.
Susie Hennings was responsible for study management and was a member of the TMG.
Keith Willett was responsible for developing the protocol and writing and reviewing the report.
Stavros Petrou was responsible for developing the protocol, the health economic analysis, writing and
reviewing the report, and was a member of the TMG.
Steven Jeffery was responsible for developing the protocol and writing and reviewing the report.
Damian Griffin was responsible for developing the protocol and writing and reviewing the report.
Ben Parker was responsible for performing the health economic analysis, writing and reviewing the
report, and was a member of the TMG.
James Masters was responsible for independent clinical review of the outcome data and writing and
reviewing the report.
Sarah E Lamb was responsible for developing the protocol, writing and reviewing the report, and was a
member of the TMG.
Elizabeth Tutton was responsible for developing the protocol, developing the qualitative study design
and conduct and writing and reviewing the report.
Nick Parsons was responsible for developing the protocol, developing the statistical analysis of the trial,
writing and reviewing the report, and was a member of the TMG.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
Publication
Costa ML, Achten J, Bruce J, Tutton E, Petrou S, Lamb SE, et al. Effect of negative pressure wound therapy 
vs standard wound management on 12-month disability among adults with severe open fracture of the 
lower limb: the WOLLF randomized clinical trial. JAMA 2018;319:2280–8.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available 
anonymised data may be granted following review.
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101

References
1. Louie KW. Management of open fractures of the lower limb. BMJ 2009;339:b5092. https://doi.org/
10.1136/bmj.b5092
2. Gustilo RB, Anderson JT. Prevention of infection in the treatment of one thousand and twenty-five
open fractures of long bones: retrospective and prospective analyses. J Bone Joint Surg Am
1976;58:453–8. https://doi.org/10.2106/00004623-197658040-00004
3. Pollak AN, Jones AL, Castillo RC, Bosse MJ, MacKenzie EJ, LEAP Study Group. The relationship
between time to surgical debridement and incidence of infection after open high-energy lower
extremity trauma. J Bone Joint Surg Am 2010;92:7–15. https://doi.org/10.2106/JBJS.H.00984
4. MacKenzie EJ, Jones AS, Bosse MJ, Castillo RC, Pollak AN, Webb LX, et al. Health-care costs
associated with amputation or reconstruction of a limb-threatening injury. J Bone Joint Surg Am
2007;89:1685–92.
5. Court-Brown CM, Rimmer S, Prakash U, McQueen MM. The epidemiology of open long bone
fractures. Injury 1998;29:529–34. https://doi.org/10.1016/S0020-1383(98)00125-9
6. Mody RM, Zapor M, Hartzell JD, Robben PM, Waterman P, Wood-Morris R, et al. Infectious
complications of damage control orthopedics in war trauma. J Trauma 2009;67:758–61.
https://doi.org/10.1097/TA.0b013e3181af6aa6
7. British Orthopaedic Association and British Association of Plastic, Reconstructive and Aesthetic
Surgeons. BOAST 4: The Management of Severe Open Lower Limb Fractures. 2009.
URL: www.boa.ac.uk/wp-content/uploads/2014/12/BOAST-4.pdf (accessed 9 October 2017).
8. National Institute for Health and Care Excellence. Fractures (Complex): Assessment and
Management. NICE guideline NG37. London: NICE; 2016. URL: www.nice.org.uk/guidance/ng37
(accessed 9 October 2017).
9. Pollak AN, Powell ET, Fang R, Cooper EO, Ficke JR, Flaherty SF. Use of negative pressure wound
therapy during aeromedical evacuation of patients with combat-related blast injuries. J Surg
Orthop Adv 2010;19:44–8.
10. Labler L, Rancan M, Mica L, Harter L, Mihic-Probst D, Keel M. Vacuum-assisted closure therapy
increases local interleukin-8 and vascular endothelial growth factor levels in traumatic wounds.
J Trauma 2009;66:749–57. https://doi.org/10.1097/TA.0b013e318171971a
11. Apelqvist J, Armstrong DG, Lavery LA, Boulton AJ. Resource utilization and economic costs of care
based on a randomized trial of vacuum-assisted closure therapy in the treatment of diabetic foot
wounds. Am J Surg 2008;195:782–8. https://doi.org/10.1016/j.amjsurg.2007.06.023
12. Bee TK, Croce MA, Magnotti LJ, Zarzaur BL, Maish GO III, Minard G, et al. Temporary abdominal
closure techniques: a prospective randomized trial comparing polyglactin 910 mesh and
vacuum-assisted closure. J Trauma 2008;65:337–42; discussion 42–4. https://doi.org/10.1097/
TA.0b013e31817fa451
13. Krug E, Berg L, Lee C, Hudson D, Birke-Sorensen H, Depoorter M, et al. Evidence-based
recommendations for the use of negative pressure wound therapy in traumatic wounds and
reconstructive surgery: steps towards an international consensus. Injury 2011;42:S1–12.
https://doi.org/10.1016/S0020-1383(11)00041-6
14. Stannard JP, Volgas DA, Stewart R, McGwin G Jr, Alonso JE. Negative pressure wound therapy
after severe open fractures: a prospective randomized study. J Orthop Trauma 2009;23:552–7.
https://doi.org/10.1097/BOT.0b013e3181a2e2b6
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
15. Great Britain. Mental Capacity Act 2005. London: The Stationery Office; 2005.
16. Salén BA, Spangfort EV, Nygren AL, Nordemar R. The Disability Rating Index: an instrument for
the assessment of disability in clinical settings. J Clin Epidemiol 1994;47:1423–35. https://doi.org/
10.1016/0895-4356(94)90086-8
17. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. https://doi.org/
10.1016/0168-8510(96)00822-6
18. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108.
https://doi.org/10.1097/00005650-199711000-00002
19. Parsons N, Griffin XL, Achten J, Costa ML. Outcome assessment after hip fracture: is EQ-5D the
answer? Bone Joint Res 2014;3:69–75. https://doi.org/10.1302/2046-3758.33.2000250
20. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United
Kingdom. J Epidemiol Community Health 1999;53:46–50. https://doi.org/10.1136/jech.53.1.46
21. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the
SF-36. J Health Econ 2002;21:271–92. https://doi.org/10.1016/S0167-6296(01)00130-8
22. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated
infection and criteria for specific types of infections in the acute care setting. Am J Infect Control
2008;36:309–32. https://doi.org/10.1016/j.ajic.2008.03.002
23. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of nosocomial surgical
site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect
Control Hosp Epidemiol 1992;13:606–8. https://doi.org/10.1017/S0195941700015241
24. Joint Formulary Committee. British National Formulary. 72 ed. London: BMJ Group and
Pharmaceutical Press; 2016.
25. Curtis L. Unit Costs of Health and Social Care 2012. Canterbury: PSSRU, University of Kent; 2012.
26. van den Brink M, van den Hout WB, Stiggelbout AM, et al. (editors). Self Reports of Health Care
Utilisation: Can a Questionnaire Replace a Diary? International Society for Health Technology
Assessment in Health Care, 16th Annual Meeting, The Hague, 2000.
27. Varadhan R, Weiss CO, Segal JB, Wu AW, Scharfstein D, Boyd C. Evaluating health outcomes in
the presence of competing risks: a review of statistical methods and clinical applications. Med Care
2010;48(Suppl. 6):96–105. https://doi.org/10.1097/MLR.0b013e3181d99107
28. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal
2013. PMG9. London: NICE; 2013.
29. Allen C, Beecham J. Costing Services: Ideals and Reality. In Netten A, Beecham J, editors. Costing
Community Care: Theory and Practice. Aldershot: Ashgate Publishing Ltd; 1993. pp. 25–42.
30. Ware JE, Snow KK, Kosinski M, Gandek B, New England Medical Center Hospital Health Institute.
SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New
England Medical Center; 1993.
31. Achten J, Parsons NR, Bruce J, Petrou S, Tutton E, Willett K, et al. Protocol for a randomised
controlled trial of standard wound management versus negative pressure wound therapy in the
treatment of adult patients with an open fracture of the lower limb: UK Wound management of
Open Lower Limb Fractures (UK WOLFF). BMJ Open 2015;5:e009087. https://doi.org/10.1136/
bmjopen-2015-009087
32. Trickett RW, Mudge E, Price P, Pallister I. A qualitative approach to recovery after open tibial
fracture: the road to a novel, patient-derived recovery scale. Injury 2012;43:1071–8. https://doi.org/
10.1016/j.injury.2012.01.027
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
33. Shauver MS, Aravind MS, Chung KC. A qualitative study of recovery from type III-B and III-C tibial
fractures. Ann Plast Surg 2011;66:73–9. https://doi.org/10.1097/SAP.0b013e3181d50eba
34. Griffiths H, Jordan S. Thinking of the future and walking back to normal: an exploratory study of
patients’ experiences during recovery from lower limb fracture. J Adv Nurs 1998;28:1276–88.
https://doi.org/10.1046/j.1365-2648.1998.00847.x
35. Forsberg A, Söderberg S, Engström Å. People’s experiences of suffering a lower limb fracture and
undergoing surgery. J Clin Nurs 2014;23:191–200. https://doi.org/10.1111/jocn.12292
36. McPhail SM, Dunstan J, Canning J, Haines TP. Life impact of ankle fractures: qualitative analysis of
patient and clinician experiences. BMC Musculoskelet Disord 2012;13:224. https://doi.org/10.1186/
1471-2474-13-224
37. Keene DJ, Mistry D, Nam J, Tutton E, Handley R, Morgan L, et al. The Ankle Injury Management
(AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic
evaluation comparing close contact casting with open surgical reduction and internal fixation in
the treatment of unstable ankle fractures in patients aged over 60 years. Health Technol Assess
2016;20(75). https://doi.org/10.3310/hta20750
38. Canvin K, Jacoby A. Duty, desire or indifference? A qualitative study of patient decisions about
recruitment to an epilepsy treatment trial. Trials 2006;7:32. https://doi.org/10.1186/1745-6215-7-32
39. Locock L, Smith L. Personal benefit, or benefiting others? Deciding whether to take part in clinical
trials. Clin Trials 2011;8:85–93. https://doi.org/10.1177/1740774510392257
40. Featherstone K, Donovan JL. ‘Why don’t they just tell me straight, why allocate it?’ The struggle
to make sense of participating in a randomised controlled trial. Soc Sci Med 2002;55:709–19.
https://doi.org/10.1016/S0277-9536(01)00197-6
41. Robinson EJ, Kerr CE, Stevens AJ, Lilford RJ, Braunholtz DA, Edwards SJ, et al. Lay public’s
understanding of equipoise and randomisation in randomised controlled trials. Health Technol
Assess 2005;9(8). https://doi.org/10.3310/hta9080
42. Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks
in clinical trials. Soc Sci Med 2004;58:1689–97. https://doi.org/10.1016/S0277-9536(03)00338-1
43. McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised controlled
trials: conditional altruism and considerations for self. Trials 2010;11:31. https://doi.org/10.1186/
1745-6215-11-31
44. Gobat NH, Gal M, Francis NA, Hood K, Watkins A, Turner J, et al. Key stakeholder perceptions
about consent to participate in acute illness research: a rapid, systematic review to inform epi/
pandemic research preparedness. Trials 2015;16:591. https://doi.org/10.1186/s13063-015-1110-6
45. Heidegger M. Being and Time. Oxford: Blackwell Publishing Ltd; 1962.
46. Madjar I, Walton JA. Nursing and the Experience of Illness: Phenomenology in Practice. London:
Routledge; 1999.
47. van Manen M. Researching Lived Experience: Human Science for an Action Sensitive Pedagogy.
Albany, NY: State University of New York Press; 1990.
48. Gadamer H. Truth and Method. London: Bloomsbury Publications Plc; 1975.
49. Lincoln YS, Guba EG. Naturalistic Inquiry. Newbury Park, CA: Sage Publications Inc.; 1985.
50. Tutton E, Seers K, Langstaff D. Professional nursing culture on a trauma unit: experiences of
patients and staff. J Adv Nurs 2008;61:145–53. https://doi.org/10.1111/j.1365-2648.2007.04471.x
51. Doohan I, Saveman BI. Impact on life after a major bus crash – a qualitative study of survivors’
experiences. Scand J Caring Sci 2014;28:155–63. https://doi.org/10.1111/scs.12040
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
52. Stayt LC, Seers K, Tutton L. Making sense of it: intensive care patients’ phenomenological accounts
of story construction. Nurs Crit Care 2016;21:225–32. https://doi.org/10.1111/nicc.12224
53. Ogilvie R, McCloughen A, Curtis K, Foster K. The experience of surviving life-threatening injury:
a qualitative synthesis. Int Nurs Rev 2012;59:312–20. https://doi.org/10.1111/j.1466-7657.
2012.00993.x
54. Maccallum F, Bryant RA. A Cognitive Attachment Model of prolonged grief: integrating attachments,
memory, and identity. Clin Psychol Rev 2013;33:713–27. https://doi.org/10.1016/j.cpr.2013.05.001
55. Penrod J. Refinement of the concept of uncertainty. J Adv Nurs 2001;34:238–45. https://doi.org/
10.1046/j.1365-2648.2001.01750.x
56. Penrod J. Living with uncertainty: concept advancement. J Adv Nurs 2007;57:658–67.
https://doi.org/10.1111/j.1365-2648.2006.04008.x
57. Morse JM, Penrod J. Linking concepts of enduring, uncertainty, suffering, and hope. Image J Nurs Sch
1999;31:145–50. https://doi.org/10.1111/j.1547-5069.1999.tb00455.x
58. Tutton E, Seers K, Langstaff D, Westwood M. Staff and patient views of the concept of hope
on a stroke unit: a qualitative study. J Adv Nurs 2012;68:2061–9. https://doi.org/10.1111/
j.1365-2648.2011.05899.x
59. Tutton E, Seers K, Langstaff D. Hope in orthopaedic trauma: a qualitative study. Int J Nurs Stud
2012;49:872–9. https://doi.org/10.1016/j.ijnurstu.2012.01.013
60. Wiseman T, Foster K, Curtis K. The experience of emotional wellbeing for patients with
physical injury: a qualitative follow-up study. Injury 2016;47:1983–9. https://doi.org/10.1016/
j.injury.2016.03.021
61. Morse JM, Beres MA, Spiers JA, Mayan M, Olson K. Identifying signals of suffering by linking
verbal and facial cues. Qual Health Res 2003;13:1063–77. https://doi.org/10.1177/
1049732303256401
62. Lawlor D. Test of time: a case study in the functioning of social systems as a defence against
anxiety: rereading 50 years on. Clin Child Psychol Psychiatry 2009;14:523–30. https://doi.org/
10.1177/1359104509339545
63. Gullick JG, Taggart SB, Johnston RA, Ko N. The trauma bubble: patient and family experience
of serious burn injury. J Burn Care Res 2014;35:e413–27. https://doi.org/10.1097/
BCR.0000000000000030
64. Clifton S. Grieving my broken body: an autoethnographic account of spinal cord injury as an experience
of grief. Disabil Rehabil 2014;36:1823–9. https://doi.org/10.3109/09638288.2013.872202
65. Thorpe G, McArthur M, Richardson B. Bodily change following faecal stoma formation:
qualitative interpretive synthesis. J Adv Nurs 2009;65:1778–89. https://doi.org/10.1111/
j.1365-2648.2009.05059.x
66. Morse JM. Using qualitative methods to access the pain experience. Br J Pain 2015;9:26–31.
https://doi.org/10.1177/2049463714550507
67. Morse JM, Mitcham C. The experience of agonizing pain and signals of disembodiment.
J Psychosom Res 1998;44:667–80. https://doi.org/10.1016/S0022-3999(97)00301-2
68. Price B. A model for body-image care. J Adv Nurs 1990;15:585–93. https://doi.org/10.1111/
j.1365-2648.1990.tb01858.x
69. Johnson RA, Taggart SB, Gullick JG. Emerging from the trauma bubble: Redefining ‘normal’ after
burn injury. Burns 2016;42:1223–32. https://doi.org/10.1016/j.burns.2016.03.016
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
70. Kvigne K, Kirkevold M. Living with bodily strangeness: women’s experiences of their changing
and unpredictable body following a stroke. Qual Health Res 2003;13:1291–310. https://doi.org/
10.1177/1049732303257224
71. Stayt LC, Seers K, Tutton E. Patients’ experiences of technology and care in adult intensive care.
J Adv Nurs 2015;71:2051–61. https://doi.org/10.1111/jan.12664
72. Baillie L. Patient dignity in an acute hospital setting: a case study. Int J Nurs Stud 2009;46:23–36.
https://doi.org/10.1016/j.ijnurstu.2008.08.003
73. Richmond TS, Thompson HJ, Deatrick JA, Kauder DR. Journey towards recovery following physical
trauma. J Adv Nurs 2000;32:1341–7. https://doi.org/10.1046/j.1365-2648.2000.01629.x
74. Smith-Young J, Solberg S, Gaudine A. Constant negotiating: managing work-related
musculoskeletal disorders while remaining at the workplace. Qual Health Res 2014;24:217–31.
https://doi.org/10.1177/1049732313519868
75. Closs SJ, Briggs M. Patients’ verbal descriptions of pain and discomfort following orthopaedic
surgery. Int J Nurs Stud 2002;39:563–72. https://doi.org/10.1016/S0020-7489(01)00067-0
76. Toye F, Seers K, Barker K. A meta-ethnography of patients’ experiences of chronic pelvic pain:
struggling to construct chronic pelvic pain as ‘real’. J Adv Nurs 2014;70:2713–27. https://doi.org/
10.1111/jan.12485
77. Abhyankar P, Velikova G, Summers B, Bekker HL. Identifying components in consent information
needed to support informed decision making about trial participation: an interview study with women
managing cancer. Soc Sci Med 2016;161:83–91. https://doi.org/10.1016/j.socscimed.2016.05.040
78. Dewing J. Process consent and research with older persons living with dementia. Research Ethics
2008;4:59–64. https://doi.org/10.1177/174701610800400205
79. Harrop E, Noble S, Edwards M, Sivell S, Moore B, Nelson A, on behalf of the FRAGMATIC Trial
Management Group (TMG). ‘I didn’t really understand it, I just thought it’d help’: exploring the
motivations, understandings and experiences of patients with advanced lung cancer participating in
a non-placebo clinical IMP trial. Trials 2016;17:329. https://doi.org/10.1186/s13063-016-1460-8
80. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: PSSRU, University of
Kent; 2015.
81. Office for National Statistics (ONS). Consumer Price Inflation Time Series Dataset (MM23). London:
ONS; 2016. URL: www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7g7/mm23
(accessed 1 October 2016).
82. Health and Social Care Information Centre. HRG4+ 2015/16 Reference Costs Code to Group User
Manual. Leeds: Health and Social Care Information Centre; 2016.
83. Department of Health. NHS Reference Costs 2014 to 2015. London: Department of Health; 2015.
URL: www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015 (accessed
1 October 2016).
84. NHS Digital. Prescription Costs Analysis, England – 2014. Leeds: NHS Digital; 2014.
URL: http://content.digital.nhs.uk/catalogue/PUB17274 (accessed 1 October 2016).
85. NHS Business Services Authority. NHS Supply Chain Catalogue 2015/16. London; 2015.
86. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic
Evaluation of Health Care Programmes. 3rd edn. New York, NY: Oxford University Press; 2005.
87. Office for National Statistics (ONS). New Earnings Survey Panel Dataset, 1975–2016: Secure Access.
[data collection]. 7th edn. UK Data Service; 2017. URL: https://doi.org/10.5255/UKDA-SN-6706-7
(accessed 1 October 2016).
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
88. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life.
Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9
89. Kharroubi SA, Brazier JE, Roberts J, O’Hagan A. Modelling SF-6D health state preference data
using a nonparametric Bayesian method. J Health Econ 2007;26:597–612. https://doi.org/
10.1016/j.jhealeco.2006.09.002
90. McCabe C, Brazier J, Gilks P, Tsuchiya A, Roberts J, O’Hagan A, Stevens K. Using rank data to
estimate health state utility models. J Health Econ 2006;25:418–31. https://doi.org/10.1016/
j.jhealeco.2005.07.008
91. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and
guidance for practice. Stat Med 2011;30:377–99. https://doi.org/10.1002/sim.4067
92. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness
analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.
https://doi.org/10.1002/hec.944
93. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that
means. PharmacoEconomics 2008;26:733–44.
94. Claxton K, Martin S, Soares M, Rice N, Spackman E, Hinde S, et al. Methods for the estimation of
the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol
Assess 2015;19(14). https://doi.org/10.3310/hta19140
95. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for
good practice in decision-analytic modelling in health technology assessment. Health Technol
Assess 2004;8(36). https://doi.org/10.3310/hta8360
96. National Institute for Health and Care Excellence. The E-Vita Open Plus for Treating Complex
Aneurysms and Dissections of the Thoracic Aorta. Medical Technologies Guidance. MTG16.
London: NICE; 2013. URL: www.nice.org.uk/guidance/mtg16 (accessed 1 October 2016).
97. Curtis L. Unit Costs of Health and Social Care 2014. Canterbury: PSSRU, University of Kent; 2014.
98. British Broadcasting Corporation. Q&A: NHS 111. URL: www.bbc.co.uk/news/health-223706212013
(accessed 1 October 2016).
99. Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: PSSRU, University of Kent; 2010.
100. Elderly Accommodation Counsel. Laundry Service. URL: www.housingcare.org/service/ser-info-
11938-laundry-servic.aspx (accessed 1 October 2016).
101. Complete Care Shop. URL: www.completecareshop.co.uk (accessed 1 October 2016).
102. Zhang T, Yan Y, Xie X, Mu W. Minimally invasive sinus tarsi approach with cannulated screw fixation
combined with vacuum-assisted closure for treatment of severe open calcaneal fractures with medial
wounds. J Foot Ankle Surg 2016;55:112–16. https://doi.org/10.1053/j.jfas.2015.07.023
103. Arti H, Khorami M, Ebrahimi-Nejad V. Comparison of negative pressure wound therapy (NPWT) &
conventional wound dressings in the open fracture wounds. Pak J Med Sci 2016;32:65–9.
https://doi.org/10.12669/pjms.321.8568
104. Saddawi-Konefka D, Kim HM, Chung KC. A systematic review of outcomes and complications of
reconstruction and amputation for type IIIB and IIIC fractures of the tibia. Plast Reconstr Surg
2008;122:1796–805.
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
105. Chung KC, Saddawi-Konefka D, Haase SC, Kaul G. A cost-utility analysis of amputation versus
salvage for Gustilo type IIIB and IIIC open tibial fractures. Plast Reconstr Surg 2009;124:1965–73.
https://doi.org/10.1097/PRS.0b013e3181bcf156
106. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness
analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70.
https://doi.org/10.1007/s40273-014-0193-3
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109

Appendix 1 Study recruitment
T able 33 shows the breakdown of recruited participants (n = 625) by centre and G&A grade. There is agood balance between treatments across and within centres, and between G&A grades.
Table 34 shows the recruitment rate for consented participants (n = 460) by centre (hospital), and the
estimated monthly recruitment rate.
TABLE 33 Recruitment by treatment group, centre and G&A grade
Centre
G&A gradea
All2 3 3C
NPWT Standard NPWT Standard NPWT Standard NPWT Standard Total
RLH 1 3 16 15 4 4 21 22 43
POH 5 5 5 4 0 0 10 9 19
AUH 0 0 1 1 0 0 1 1 2
LGI 0 1 4 5 0 0 4 6 10
ADH 3 4 17 16 0 0 20 20 40
UHS 3 2 5 5 1 0 9 7 16
STH 0 0 2 2 0 0 2 2 4
QAH 2 2 0 0 1 1 3 3 6
RBH 1 1 0 2 0 0 1 3 4
KCH 1 0 12 13 1 0 14 13 27
UNS 2 2 4 5 1 0 7 7 14
PLY 5 5 9 10 1 0 15 15 30
UHC 8 8 26 27 5 4 39 39 78
NNH 1 2 2 2 0 0 3 4 7
UHB 4 2 6 6 8 10 18 18 36
RVI 2 1 10 9 0 0 12 10 22
RDH 2 2 4 4 0 1 6 7 13
JRH 0 3 24 21 2 2 26 26 52
FRH 2 1 48 47 7 10 57 58 115
HRI 0 1 6 6 0 0 6 7 13
UHL 1 2 2 2 0 0 3 4 7
NUH 2 1 13 14 1 2 16 17 33
RSC 2 2 11 10 0 0 13 12 25
MHS 0 0 5 4 0 0 5 4 9
Total 47 50 232 230 32 34 311 314 625
ADH, Addenbrookes Hospital, Cambridge; AUH, Aintree University Hospital; FRH, Frenchay Hospital; HRI, Hull Royal
Infirmary; JRH, John Radcliffe Hospital; KCH, Kings College Hospital; LGI, Leeds General Infirmary; MHS, Morriston Hospital
Swansea; NNH, Norfolk and Norwich University Hospital; NUH, Nottingham University Hospital; PLY, Plymouth Hospitals;
POH, Poole Hospital; QAH, Queen Alexandra Hospital; RBH, Royal Berkshire Hospital; RDH, Royal Derby Hospital; RLH, Royal
London Hospital (RLH); RSC, Royal Sussex County Hospital, Brighton; RVI, Royal Victoria Infirmary; STH, Northern General
Hospital Sheffield; UCH, University Hospital Coventry and Warwickshire; UHB, Queen Elizabeth Hospital, Birmingham;
UHL, University Hospital Leicester; UHS, University Hospital Southampton; UNS, University Hospital of North Staffordshire.
a A G&A grade 3C is any open fracture with accompanying vascular injury requiring repair.
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Figure 16 shows the overall progress of study recruitment for consented participants towards the required
target sample of 460. Shown also is the required recruitment, based on a crude model of centre opening
rates for the 24 recruiting centres to reach the target of 460 participants by September 2015.
Figure 17 shows the recruitment rates for consented participants (n = 460) for individual centres in addition
to the overall data. This is presented on a log-transformed scale to aid visualisation.
TABLE 34 The WOLLF study recruitment and consent by hospital centre
Centre Date opened
Months
open Recruited
Rate per
month
1 FRH Frenchay Hospital 10 September 2012 40 77 1.93
2 UHC UHCW 9 July 2012 42 62 1.48
3 JRH John Radcliffe Hospital 1 December 2012 37 44 1.19
4 RLH Royal London Hospital 13 November 2013 25 28 1.12
5 KCH Kings College Hospital 21 March 2014 21 22 1.05
6 ADH Addenbrookes Hospital Cambridge 13 July 2013 30 29 0.97
7 NUH Nottingham University Hospital 12 June 2013 31 25 0.81
8 HRI Hull Royal Infirmary 25 August 2014 16 12 0.75
9 UHB Queen Elizabeth Hospital Birmingham 4 February 2013 35 25 0.71
10 PLY Plymouth Hospital 13 June 2013 31 21 0.68
11 RSC Royal Sussex County hospital Brighton 12 August 2013 29 18 0.62
12 LGI Leeds General Infirmary 23 September 2014 15 9 0.60
13 POH Poole Hospital 6 August 2013 29 16 0.55
14 RDH Royal Derby Hospital 18 November 2013 25 11 0.44
15 MHS Morriston Hospital Swansea 11 June 2014 18 7 0.39
16 RVI Royal Victoria Infirmary 4 October 2012 39 15 0.38
17 UNS University Hospital of North Staffordshire 28 November 2013 25 8 0.32
18 UHS University Hospital Southampton 5 September 2013 28 8 0.29
19 UHL University Hospital Leicester 23 October 2013 26 7 0.27
20 QAH Queen Alexandra Hospital 5 April 2014 21 5 0.24
21 NNH Norfolk and Norwich University Hospital 17 September 2013 27 5 0.19
22 STH North General Hospital Sheffield 11 August 2014 16 2 0.12
23 RBH Royal Berkshire Hospital 8 May 2013 32 3 0.09
24 AUH Aintree University Hospital 5 August 2014 17 1 0.06
Total 655 460 0.70
ADH, Addenbrookes Hospital, Cambridge; AUH, Aintree University Hospital; FRH, Frenchay Hospital; HRI, Hull Royal
Infirmary; JRH, John Radcliffe Hospital; KCH, Kings College Hospital; LGI, Leeds General Infirmary; MHS, Morriston Hospital
Swansea; NNH, Norfolk and Norwich University Hospital; NUH, Nottingham University Hospital; PLY, Plymouth Hospitals;
POH, Poole Hospital; QAH, Queen Alexandra Hospital; RBH, Royal Berkshire Hospital; RDH, Royal Derby Hospital; RLH, Royal
London Hospital (RLH); RSC, Royal Sussex County Hospital, Brighton; RVI, Royal Victoria Infirmary; STH, Northern General
Hospital Sheffield; UCH, University Hospital Coventry and Warwickshire; UHB, Queen Elizabeth Hospital, Birmingham;
UHL, University Hospital Leicester; UHS, University Hospital Southampton; UNS, University Hospital of North Staffordshire.
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FIGURE 16 Rate of overall recruitment (solid line) and required recruitment (dashed line).
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Appendix 2 Disability Rating Index
T able 35 shows the method of data capture (percentage rates in each category by treatment group andassessment occasion) for DRI.
A summary of missing values, by age group and sex for DRI at 12 months is shown in Table 36. The full
pattern of missing values is shown in Table 37 for NPWT and standard dressing intervention arms.
TABLE 35 Method of DRI collection by time point and treatment group; number and percentage
Occasion
Treatment
group Total, n
Method, n (%)
Face to face Postal Telephone E-mail
Pre injury NPWT 220 217 (99) 2 (1) 1 (0) 0 (0)
Standard 231 230 (100) 1 (0) 0 (0) 0 (0)
3 months NPWT 166 1 (1) 148 (89) 13 (8) 4 (2)
Standard 188 3 (2) 165 (88) 19 (10) 1 (1)
6 months NPWT 154 1 (1) 137 (89) 15 (10) 1 (1)
Standard 175 3 (2) 156 (89) 12 (7) 4 (2)
9 months NPWT 153 1 (1) 127 (83) 20 (13) 5 (3)
Standard 161 1 (1) 139 (86) 20 (12) 1 (1)
12 months NPWT 179 26 (15) 131 (73) 19 (11) 3 (2)
Standard 195 29 (15) 149 (76) 15 (8) 2 (1)
TABLE 36 Data completeness for DRI at 12 months by age group and gender
Age (years) Gender Data available Data missing Total % missing
< 40 Female 21 3 24 12.5
Male 138 39 177 22.0
≥ 40 Female 79 15 94 16.0
Male 136 29 165 17.6
Total 374 86 460 18.7
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TABLE 37 Counts of missing and complete DRI data at baseline (pre injury), 3, 6, 9 and 12 months
Treatment Numbera
Cumulative
(%)b
DRIc
MissingBaseline 3 months 6 months 9 months 12 months
NPWT 111 49 1 1 1 1 1 0
1 50 0 1 1 1 1 1
12 55 1 0 1 1 1 1
13 61 1 1 0 1 1 1
13 66 1 1 1 0 1 1
6 69 1 1 1 1 0 1
5 71 1 0 0 1 1 2
6 74 1 0 1 0 1 2
8 77 1 1 0 0 1 2
1 78 1 0 1 1 0 2
2 79 1 1 0 1 0 2
2 80 1 1 1 0 0 2
1 80 0 0 0 1 1 3
9 84 1 0 0 0 1 3
1 85 1 0 0 1 0 3
2 85 1 0 1 0 0 3
10 90 1 1 0 0 0 3
19 98 1 0 0 0 0 4
4 100 0 0 0 0 0 5
Total 226 – 6 60 72 73 47 258
Standard 138 59 1 1 1 1 1 0
4 61 1 0 1 1 1 1
9 65 1 1 0 1 1 1
16 71 1 1 1 0 1 1
5 74 1 1 1 1 0 1
4 75 1 0 0 1 1 2
5 77 1 0 1 0 1 2
10 82 1 1 0 0 1 2
5 84 1 1 1 0 0 2
9 88 1 0 0 0 1 3
1 88 1 0 0 1 0 3
2 89 1 0 1 0 0 3
5 91 1 1 0 0 0 3
18 99 1 0 0 0 0 4
3 100 0 0 0 0 0 5
Total 234 – 3 46 59 73 39 220
a Number of patients with given pattern of missing DRI data.
b Cumulative percentage of patients with increasing amounts of missing DRI data from 0 to 5.
c Missing data are indicated by 0 and complete data are indicated by 1.
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Appendix 3 Background information
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Appendix 4 Baseline questionnaire
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EQ-5D redacted for copyright reasons.
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Appendix 5 Patient entry form
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Appendix 6 Operation note
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
DOI: 10.3310/hta22730 HEALTH TECHNOLOGY ASSESSMENT 2018 VOL. 22 NO. 73
© Queen’s Printer and Controller of HMSO 2018. This work was produced by Costa et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127

Appendix 7 Six-week follow-up form
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Appendix 8 Three-month questionnaire
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EQ-5D redacted for copyright reasons.
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Appendix 9 Serious adverse event form
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Appendix 10 Surgical site infection diagnosis
algorithm
TABLE 38 Deep SSI: patient has at least one of the following symptoms and are present at the 6-week assessment
Purulent drainage from the deep incision (purulent
drainage)
(d) Is there any fluid leaking from the wound?
(e) If yes, is the fluid pus or cloudy yellow?
Accept if (d) AND (e)= present today OR
Accept if (e) = present today AND (d)= No or missing
A deep incision that spontaneously dehisces and
fever > 38 °C (dehiscence and fever)
(f) Is the wound gaping open (dehisced)?
(h) Any fever of > 38 °C since surgery?
Accept if (f) AND (h) = present today OR
Accept if (f) = present today AND (h) = no or missing
A deep incision that spontaneously dehisces and
localised pain or tenderness (dehiscence and pain)
(f) Is the wound gaping open (dehisced)?
(c) Is the area around the wound painful or tender?
Accept if (f) AND (c) = present today OR
Accept if (f) = present today AND (c) = no or missing
A deep incision that is deliberately opened by
surgeon or attending physician or other designee
and fever > 38 °C (surgery and fever)
(g) Has a surgeon deliberately opened the wound?
(h) Any fever of > 38 °C since surgery?
Accept if (g) AND (h)= present today OR
Accept if (g)= present today AND (h)= no or missing
A deep incision that is deliberately opened by
surgeon or attending physician or other designee
and localised pain or tenderness (surgery and pain)
(g) Has a surgeon deliberately opened the wound?
(c) Is the area around the wound painful or tender?
Accept if (g) AND (c) = present today OR
Accept if (g)= present today AND (c) = no or missing
An abscess or other evidence of infection involving
the deep incision that is detected on gross
examination (abscess)
(i) Is there any sign of abscess or infection on direct examination?
Accept if (i)= present today
Culture swabs and antibiotics (antibiotics) (j) Has a culture swab been obtained?
(k) Have antibiotics been prescribed for a wound infection?
Accept if (j)= present today AND (k) = yes
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Appendix 11 Superficial surgical site infection
TABLE 39 Superficial SSI: patient has at least one of the following previous to the 6-week assessment but not at
the 6-week assessment
Purulent drainage from the superficial incision
(purulent drainage)
(d) Is there any fluid leaking from the wound?
(e) If yes, is the fluid pus or cloudy yellow?
Accept if (d) AND (e)= previous time OR
Accept if (e) = previous time AND (d)= no or missing
Organisms isolated from an aseptically obtained
specimen from the superficial incision or
subcutaneous tissue by a culture or non-culture
based microbiological testing method performed for
the purposes of clinical diagnosis or treatment
(antibiotics)
(j) Has a culture swab been obtained?
(k) Have antibiotics been prescribed for a wound infection?
Accept if (j)= previous time AND (k)= yes
Superficial incision that is deliberately opened by a
surgeon, attending physician or other designee and
has pain or tenderness (surgery and pain)
(g) Has a surgeon deliberately opened the wound?
(c) Is the area around the wound painful or tender?
Accept if (g) AND (c) = previous time OR
Accept if (g)= previous time AND (c)= no or missing
Superficial incision that is deliberately opened by a
surgeon, attending physician or other designee and
has localised swelling (surgery and swelling)
(g) Has a surgeon deliberately opened the wound?
(b) Is the area around the wound swollen?
Accept if (g) AND (b)= previous time OR
Accept if (g)= previous time AND (b)= no or missing
Superficial incision that is deliberately opened by a
surgeon, attending physician or other designee and
has erythema or heat (surgery and inflammation)
(g) Has a surgeon deliberately opened the wound?
(a) Is the wound red or inflamed?
Accept if (g) AND (a)= previous time OR
Accept if (g)= previous time AND (a)= no or missing
An abscess or other evidence of infection involving
the deep incision that is detected on gross
examination (abscess)
(i) Is there any sign of abscess or infection on direct examination?
Accept if (i)= previous time
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Appendix 12 Routinely reported complications
TABLE 40 Wound complications after surgery
Wound complications
Treatment group
Total
Treatment group (%)
NPWT
(n= 226)
Standard
(n= 234) NPWT Standard
Red and inflamed
Any time since surgery 34 28 62 15.0 12.0
No 159 153 312 70.4 65.4
Symptoms present today 13 19 32 5.8 8.1
Missing 20 34 54 8.8 14.5
Chi-squared test: p-value = 0.420 (statistic = 1.733, df = 2). Fisher’s exact test: p-value = 0.439
Swollen
Any time since surgery 26 33 59 11.5 14.1
No 142 119 261 62.8 50.9
Symptoms present today 38 49 87 16.8 20.9
Missing 20 33 53 8.8 14.1
Chi-squared test: p-value = 0.123 (statistic = 4.187, df = 2). Fisher’s exact test: p-value = 0.125
Painful or tender
Any time since surgery 26 35 61 11.5 15
No 147 130 277 65.0 55.6
Symptoms present today 35 33 68 15.5 14.1
Missing 18 36 54 8.0 15.4
Chi-squared test: p-value = 0.335 (statistic = 2.185, df = 2). Fisher’s exact test: p-value = 0.346
Fluid leakage
Any time since surgery 40 42 82 17.7 17.9
No 138 131 269 61.1 56.0
Symptoms present today 28 27 55 12.4 11.5
Missing 20 34 54 8.8 14.5
Chi-squared test: p-value = 0.923 (statistic = 0.160, df = 2). Fisher’s exact test: p-value = 0.912
If yes, fluid pus or cloudy yellow
Any time since surgery 16 15 31 7.1 6.4
No 35 41 76 15.5 17.5
Symptoms present today 11 10 21 4.9 4.3
Missing 164 168 332 72.6 71.8
Chi-squared test: p-value = 0.807 (statistic = 0.429, df = 2). Fisher’s exact test: p-value = 0.800
Gaping open
Any time since surgery 4 8 12 1.8 3.4
No 195 188 383 86.3 80.3
Symptoms present today 6 4 10 2.7 1.7
Missing 21 34 55 9.3 14.5
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TABLE 40 Wound complications after surgery (continued )
Wound complications
Treatment group
Total
Treatment group (%)
NPWT
(n= 226)
Standard
(n= 234) NPWT Standard
Chi-squared test: p-value = 0.407 (statistic = 1.8, df= 2). Fisher’s exact test: p-value = 0.425
Surgeon deliberately opened
Any time since surgery 13 10 23 5.8 4.3
No 194 190 384 85.8 81.2
Symptoms present today 2 0 2 0.9 0.0
Missing 17 34 51 7.5 14.5
Chi-squared test: p-value = 0.327 (statistic = 2.236, df = 2). Fisher’s exact test: p-value = 0.435
Fever
Any time since surgery 22 16 38 9.7 6.8
No 184 186 370 81.4 79.5
Missing 20 32 52 8.8 13.7
Chi-squared test: p-value = 0.431 (statistic = 0.621, df = 1). Fisher’s exact test: p-value = 0.396
Abscess or infection
Any time since surgery 7 8 15 3.1 3.4
No 198 185 383 87.6 79.1
Symptoms present today 3 5 8 1.3 2.1
Missing 18 36 54 8.0 15.4
Chi-squared test: p-value = 0.683 (statistic = 0.762, df = 2). Fisher’s exact test: p-value = 0.710
Culture swab taken
Any time since surgery 40 28 68 17.7 12.0
No 164 164 328 72.6 70.1
Symptoms present today 5 10 15 2.2 4.3
Missing 17 32 49 7.5 13.7
Chi-squared test: p-value = 0.160 (statistic = 3.666, df = 2). Fisher’s exact test: p-value = 0.170
Organism
Bacillus spp. 1 0 1 0.4 0.0
Clostridium 0 1 1 0.0 0.4
Coliform 2 0 2 0.9 0.0
Enterobacter 3 0 3 1.3 0.0
Enterobacter and Pseudomonas spp. 1 0 1 0.4 0.0
Enterococcus spp. 1 1 2 0.4 0.4
Escherichia coli ESB2 1 0 1 0.4 0.0
Faecal flora and Staphylococcus aureus (unknown
sensitivity)
1 0 1 0.4 0.0
Gram-negative rods 0 1 1 0.0 0.4
Mixed growth 1 3 4 0.4 1.3
Nil observed 13 9 22 5.8 3.8
Pseudomonas spp. 2 1 3 0.9 0.4
Skin flora 0 2 2 0.0 0.9
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TABLE 40 Wound complications after surgery (continued )
Wound complications
Treatment group
Total
Treatment group (%)
NPWT
(n= 226)
Standard
(n= 234) NPWT Standard
Skin flora and faecal flora 1 0 1 0.4 0.0
Staphylococcus aureus (meticillin resistant) 1 3 4 0.4 1.3
Staphylococcus aureus (unknown sensitivity) 4 4 8 1.8 1.7
Staphylococcus aureus (unknown sensitivity) and
enterococci
2 0 2 0.9 0.0
Staphylococcus epidermidis (unknown sensitivity) 1 1 2 0.4 0.4
Staphylococcal spp. (mixed) 1 0 1 0.4 0.0
Streptococcal spp. 1 0 1 0.4 0.0
Missing 189 208 397 83.6 88.9
Chi-squared test: p-value = 0.410 (statistic = 19.742, df = 19). Fisher’s exact test: p-value = 0.472
Antibiotics prescribed for trial wound
No 174 163 337 77.0 69.7
Yes 34 37 71 15.0 15.8
Missing 18 34 52 8.0 14.5
Chi-squared test: p-value = 0.658 (statistic = 0.196, df = 1). Fisher’s exact test: p-value = 0.603
Other antibiotics
No 140 135 275 61.9 57.7
Yes 44 38 82 19.5 16.2
Missing 42 61 103 18.6 26.1
Chi-squared test: p-value = 0.756 (statistic = 0.097, df = 1). Fisher’s exact test: p-value = 0.706
Infection diagnosed
No 182 187 369 80.5 79.9
Yes 26 21 47 11.5 9.0
Missing 18 26 44 8 11.1
Chi-squared test: p-value = 0.536 (statistic = 0.384, df = 1). Fisher’s exact test: p-value = 0.536
Fully healed
No 100 101 201 44.2 43.2
Yes 85 80 165 37.6 34.2
Missing 41 53 94 18.1 22.6
Chi-squared test: p-value = 0.817 (statistic = 0.053, df = 1). Fisher’s exact test: p-value = 0.754
Patient thinks fully healed
No 86 109 195 38.1 46.6
Yes 115 89 204 50.9 38.0
Missing 25 36 61 11.1 15.4
Chi-squared test: p-value = 0.019 (statistic = 5.524, df = 1). Fisher’s exact test: p-value = 0.016
df, degrees of freedom.
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TABLE 41 Complications at 6 weeks
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Anaesthesia
No 221 230 451 97.8 98.3
Yes 3 2 5 1.3 0.9
Chi-squared test: p-value = 0.969 (statistic = 0.002, df = 1). Fisher’s exact test: p-value = 0.681
Postoperative bleeding
No 222 230 452 98.2 98.3
Yes 2 2 4 0.9 0.9
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
DVT
No 218 229 447 96.5 97.9
Yes 6 3 9 2.7 1.3
Chi-squared test: p-value = 0.467 (statistic = 0.528, df = 1). Fisher’s exact test: p-value = 0.331
PE
No 222 228 450 98.2 97.4
Yes 2 4 6 0.9 1.7
Chi-squared test: p-value = 0.713 (statistic = 0.135, df = 1). Fisher’s exact test: p-value = 0.686
Nerve damage
No 217 221 438 96.0 94.4
Yes 7 11 18 3.1 4.7
Chi-squared test: p-value = 0.519 (statistic = 0.417, df = 1). Fisher’s exact test: p-value = 0.473
Tendon damage
No 218 230 448 96.5 98.3
Yes 6 2 8 2.7 0.9
Chi-squared test: p-value = 0.263 (statistic = 1.255, df = 1). Fisher’s exact test: p-value = 0.169
Blood vessel damage
No 218 228 446 96.5 97.4
Yes 6 4 10 2.7 1.7
Chi-squared test: p-value = 0.707 (statistic = 0.141, df = 1). Fisher’s exact test: p-value = 0.538
Delayed (non-) union
No 216 229 445 95.6 97.9
Yes 8 3 11 3.5 1.3
Chi-squared test: p-value = 0.201 (statistic = 1.638, df = 1). Fisher’s exact test: p-value = 0.135
Surgery to remove metalwork
No 203 209 412 89.8 89.3
Yes 21 23 44 9.3 9.8
Chi-squared test: p-value = 0.971 (statistic = 0.001, df = 1). Fisher’s exact test: p-value = 0.875
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TABLE 41 Complications at 6 weeks (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Regional pain syndrome
No 224 231 455 99.1 98.7
Yes 0 1 1 0.0 0.4
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Other
No 185 187 372 81.9 79.9
Yes 39 45 84 17.3 19.2
Chi-squared test: p-value = 0.670 (statistic = 0.182, df = 1). Fisher’s exact test: p-value = 0.630
Final wound closure method
Free flap 91 81 172 40.3 34.6
Local flap 22 20 42 9.7 8.5
Other 10 13 23 4.4 5.6
Primarily 37 44 81 16.4 18.8
Skin graft 48 51 99 21.2 21.8
Chi-squared test: p-value = 0.780 (statistic = 1.761, df = 4). Fisher’s exact test: p-value = 0.782
df, degrees of freedom; DVT, deep-vein thrombosis; PE, pulmonary embolism.
Missing: n= 2 in the NPWT group and n= 2 in the standard dressing group for all complications at 6 weeks. For final
wound closure method: missing n= 18 in the NPWT group and n= 25 in the standard dressing group.
TABLE 42 Follow-up complications at 3 months
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Red and inflamed
No 117 123 240 51.8 52.6
Yes 30 48 78 13.3 20.5
Chi-squared test: p-value = 0.146 (statistic = 2.11, df = 1). Fisher’s exact test: p-value = 0.119
Swollen
No 118 133 251 52.2 56.8
Yes 29 38 67 12.8 16.2
Chi-squared test: p-value = 0.685 (statistic = 0.165, df = 1). Fisher’s exact test: p-value = 0.679
Fluid leakage
No 93 102 195 41.2 43.6
Yes 54 69 123 23.9 29.5
Chi-squared test: p-value = 0.586 (statistic = 0.297, df = 1). Fisher’s exact test: p-value = 0.564
Fluid clear or blood stained
No 108 115 223 47.8 49.1
Yes 39 56 95 17.3 23.9
Chi-squared test: p-value = 0.278 (statistic = 1.177, df = 1). Fisher’s exact test: p-value = 0.269
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TABLE 42 Follow-up complications at 3 months (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Fluid yellow or green pus
No 115 142 257 50.9 60.7
Yes 32 29 61 14.2 12.4
Chi-squared test: p-value = 0.346 (statistic = 0.89, df = 1). Fisher’s exact test: p-value = 0.318
Increased pain around wound
No 108 125 233 47.8 53.4
Yes 39 46 85 17.3 19.7
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Edge of wound open
No 121 142 263 53.5 60.7
Yes 26 29 55 11.5 12.4
Chi-squared test: p-value = 0.982 (statistic = 0.001, df = 1). Fisher’s exact test: p-value = 0.883
Sample for laboratory
No 120 136 256 53.1 58.1
Yes 27 35 62 11.9 15.0
Chi-squared test: p-value = 0.742 (statistic = 0.109, df = 1). Fisher’s exact test: p-value = 0.672
Further surgery for fracture
No 132 152 284 58.4 65.0
Yes 15 19 34 6.6 8.1
Chi-squared test: p-value = 0.937 (statistic = 0.006, df = 1). Fisher’s exact test: p-value = 0.857
DVT
No 145 165 310 64.2 70.5
Yes 2 6 8 0.9 2.6
Chi-squared test: p-value = 0.390 (statistic = 0.74, df = 1). Fisher’s exact test: p-value = 0.294
If yes, did you see DVT nurse
No 145 168 313 64.2 71.8
Yes 2 3 5 0.9 1.3
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
DVT medication
No 145 166 311 64.2 70.9
Yes 2 5 7 0.9 2.1
Chi-squared test: p-value = 0.573 (statistic = 0.318, df = 1). Fisher’s exact test: p-value = 0.457
Other complication
No 117 135 252 51.8 57.7
Yes 30 36 66 13.3 15.4
Chi-squared test: p-value = 0.998 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
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TABLE 42 Follow-up complications at 3 months (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Unscheduled hospital appointment
No 130 146 276 57.5 62.4
Yes 17 25 42 7.5 10.7
Chi-squared test: p-value = 0.525 (statistic = 0.405, df = 1). Fisher’s exact test: p-value = 0.507
Any other problems
No 80 85 165 35.4 36.3
Yes 67 86 153 29.6 36.8
Chi-squared test: p-value = 0.468 (statistic = 0.528, df = 1). Fisher’s exact test: p-value = 0.432
df, degrees of freedom; DVT, deep-vein thrombosis.
Missing: n= 79 in the NPWT group and n= 63 in the standard dressing group for all complications at 3 months.
TABLE 43 Complications at 6 months’ follow-up
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Red and inflamed
No 115 120 235 50.9 51.3
Yes 24 35 59 10.6 15.0
Chi-squared test. p-value = 0.322 (statistic = 0.98, df = 1). Fisher’s exact test: p-value = 0.308
Swollen
No 108 123 231 47.8 52.6
Yes 31 32 63 13.7 13.7
Chi-squared test: p-value = 0.839 (statistic = 0.041, df = 1). Fisher’s exact test: p-value = 0.777
Fluid leakage
No 103 109 212 45.6 46.6
Yes 36 46 82 15.9 19.7
Chi-squared test: p-value = 0.555 (statistic = 0.349, df = 1). Fisher’s exact test: p-value = 0.516
Fluid clear or blood stained
No 116 127 243 51.3 54.3
Yes 23 28 51 10.2 12.0
Chi-squared test: p-value = 0.850 (statistic = 0.036, df = 1). Fisher’s exact test: p-value = 0.760
Fluid yellow or green pus
No 118 130 248 52.2 55.6
Yes 21 25 46 9.3 10.7
Chi-squared test: p-value = 0.936 (statistic = 0.006, df = 1). Fisher’s exact test: p-value = 0.873
Increased pain around wound
No 109 118 227 48.2 50.4
Yes 30 37 67 13.3 15.8
Chi-squared test: p-value = 0.743 (statistic = 0.107, df = 1). Fisher’s exact test: p-value = 0.678
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TABLE 43 Complications at 6 months’ follow-up (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Edge of wound open
No 125 138 263 55.3 59.0
Yes 14 17 31 6.2 7.3
Chi-squared test: p-value = 0.953 (statistic = 0.004, df = 1). Fisher’s exact test: p-value = 0.851
Sample for laboratory
No 120 128 248 53.1 54.7
Yes 19 27 46 8.4 11.5
Chi-squared test: p-value = 0.470 (statistic = 0.523, df = 1). Fisher’s exact test: p-value = 0.423
Further surgery for fracture
No 118 128 246 52.2 54.7
Yes 21 27 48 9.3 11.5
Chi-squared test: p-value = 0.706 (statistic = 0.142, df = 1). Fisher’s exact test: p-value = 0.638
DVT
No 135 152 287 59.7 65.0
Yes 4 3 7 1.8 1.3
Chi-squared test: p-value = 0.884 (statistic = 0.021, df = 1). Fisher’s exact test: p-value = 0.711
If yes, did you see DVT nurse
No 136 152 288 60.2 65.0
Yes 3 3 6 1.3 1.3
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
DVT medication
No 135 152 287 59.7 65.0
Yes 4 3 7 1.8 1.3
Chi-squared test: p-value = 0.884 (statistic = 0.021, df = 1). Fisher’s exact test: p-value = 0.711
Other complication
No 114 124 238 50.4 53.0
Yes 25 31 56 11.1 13.2
Chi-squared test: p-value = 0.772 (statistic = 0.084, df = 1). Fisher’s exact test: p-value = 0.766
Unscheduled hospital appointment
No 128 140 268 56.6 59.8
Yes 11 15 26 4.9 6.4
Chi-squared test: p-value = 0.744 (statistic = 0.106, df = 1). Fisher’s exact test: p-value = 0.683
Any other problems
No 79 88 167 35.0 37.6
Yes 60 67 127 26.5 28.6
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
df, degrees of freedom; DVT, deep-vein thrombosis.
Missing, n= 87 in the NPWT group and n= 79 in the standard dressing group for all complications at 6 months.
APPENDIX 12
NIHR Journals Library www.journalslibrary.nihr.ac.uk
158
TABLE 44 Complications at 9 months’ follow-up
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Red and inflamed
No 106 119 225 46.9 50.9
Yes 25 23 48 11.1 9.8
Chi-squared test: p-value = 0.641 (statistic = 0.218, df = 1). Fisher’s exact test: p-value = 0.633
Swollen
No 112 118 230 49.6 50.4
Yes 19 24 43 8.4 10.3
Chi-squared test: p-value = 0.706 (statistic = 0.142, df = 1). Fisher’s exact test: p-value = 0.621
Fluid leakage
No 107 118 225 47.3 50.4
Yes 24 24 48 10.6 10.3
Chi-squared test: p-value = 0.882 (statistic = 0.022, df = 1). Fisher’s exact test: p-value = 0.874
Fluid clear or blood stained
No 115 122 237 50.9 52.1
Yes 16 20 36 7.1 8.5
Chi-squared test: p-value = 0.781 (statistic = 0.077, df = 1). Fisher’s exact test: p-value = 0.722
Fluid yellow or green pus
No 122 128 250 54.0 54.7
Yes 9 14 23 4.0 6.0
Chi-squared test: p-value = 0.503 (statistic = 0.449, df = 1). Fisher’s exact test: p-value = 0.394
Increased pain around wound
No 107 120 227 47.3 51.3
Yes 24 22 46 10.6 9.4
Chi-squared test: p-value = 0.644 (statistic = 0.213, df = 1). Fisher’s exact test: p-value = 0.628
Edge of wound open
No 124 136 260 54.9 58.1
Yes 7 6 13 3.1 2.6
Chi-squared test: p-value = 0.882 (statistic = 0.022, df = 1). Fisher’s exact test: p-value = 0.779
Sample for laboratory
No 122 132 254 54.0 56.4
Yes 9 10 19 4.0 4.3
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Further surgery for fracture
No 111 120 231 49.1 51.3
Yes 20 22 42 8.8 9.4
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
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TABLE 44 Complications at 9 months’ follow-up (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
DVT
No 129 140 269 57.1 59.8
Yes 2 2 4 0.9 0.9
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
If yes, did you see DVT nurse
No 130 140 270 57.5 59.8
Yes 1 2 3 0.4 0.9
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
DVT medication
No 130 141 271 57.5 60.3
Yes 1 1 2 0.4 0.4
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Other complication
No 109 113 222 48.2 48.3
Yes 22 29 51 9.7 12.4
Chi-squared test: p-value = 0.540 (statistic = 0.376, df = 1). Fisher’s exact test: p-value = 0.535
Unscheduled hospital appointment
No 119 135 254 52.7 57.7
Yes 12 7 19 5.3 3.0
Chi-squared test: p-value = 0.257 (statistic = 1.287, df = 1). Fisher’s exact test: p-value = 0.234
Any other problems
No 86 103 189 38.1 44.0
Yes 45 39 84 19.9 16.7
Chi-squared test: p-value = 0.271 (statistic = 1.211, df = 1). Fisher’s exact test: p-value = 0.239
df, degrees of freedom; DVT, deep-vein thrombosis.
Missing: n= 95 in the NPWT group and n= 92 in the standard dressing group for all complications at 9 months.
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TABLE 45 Complications at 12 months’ follow-up
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
Red and inflamed
No 139 155 294 61.5 66.2
Yes 18 25 43 8.0 10.7
Chi-squared test: p-value = 0.616 (statistic = 0.252, df = 1). Fisher’s exact test: p-value = 0.518
Swollen
No 137 156 293 60.6 66.7
Yes 20 24 44 8.8 10.3
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Fluid leakage
No 142 150 292 62.8 64.1
Yes 15 30 45 6.6 12.8
Chi-squared test: p-value = 0.079 (statistic = 3.078, df = 1). Fisher’s exact test: p-value = 0.077
Fluid clear or blood stained
No 143 155 298 63.3 66.2
Yes 14 25 39 6.2 10.7
Chi-squared test: p-value = 0.210 (statistic = 1.569, df = 1). Fisher’s exact test: p-value = 0.174
Fluid yellow or green pus
No 153 169 322 67.7 72.2
Yes 4 11 15 1.8 4.7
Chi-squared test: p-value = 0.188 (statistic = 1.736, df = 1). Fisher’s exact test: p-value = 0.184
Increased pain around wound
No 136 152 288 60.2 65.0
Yes 21 28 49 9.3 12.0
Chi-squared test: p-value = 0.681 (statistic = 0.169, df = 1). Fisher’s exact test: p-value = 0.643
Edge of wound open
No 152 170 322 67.3 72.6
Yes 5 10 15 2.2 4.3
Chi-squared test: p-value = 0.431 (statistic = 0.621, df = 1). Fisher’s exact test: p-value = 0.428
Sample for laboratory
No 146 166 312 64.6 70.9
Yes 11 14 25 4.9 6.0
Chi-squared test: p-value = 0.951 (statistic = 0.004, df = 1). Fisher’s exact test: p-value = 0.837
Further surgery for fracture
No 142 157 299 62.8 67.1
Yes 15 23 38 6.6 9.8
Chi-squared test: p-value = 0.447 (statistic = 0.579, df = 1). Fisher’s exact test: p-value = 0.391
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TABLE 45 Complications at 12 months’ follow-up (continued )
Complications
Treatment group
Total
Treatment group (%)
NPWT (n= 226) Standard (n= 234) NPWT Standard
DVT
No 154 177 331 68.1 75.6
Yes 3 3 6 1.3 1.3
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
If yes, did you see DVT nurse
No 156 177 333 69.0 75.6
Yes 1 3 4 0.4 1.3
Chi-squared test: p-value = 0.714 (statistic = 0.134, df = 1). Fisher’s exact test: p-value = 0.626
DVT medication
No 155 178 333 68.6 76.1
Yes 2 2 4 0.9 0.9
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Other complication
No 134 147 281 59.3 62.8
Yes 23 33 56 10.2 14.1
Chi-squared test: p-value = 0.448 (statistic = 0.577, df = 1). Fisher’s exact test: p-value = 0.383
Unscheduled hospital appointment
No 146 168 314 64.6 71.8
Yes 11 12 23 4.9 5.1
Chi-squared test: p-value = 1 (statistic = 0, df = 1). Fisher’s exact test: p-value = 1
Any other problems
No 121 135 256 53.5 57.7
Yes 36 45 81 15.9 19.2
Chi-squared test: p-value = 0.752 (statistic = 0.1, df= 1). Fisher’s exact test: p-value = 0.702
df, degrees of freedom; DVT, deep-vein thrombosis.
Missing: n= 69 in the NPWT group and n= 54 in the standard dressing group for all complications at 12 months.
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